aromasil has been researched along with Breast Neoplasms in 706 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (2.12) | 18.2507 |
| 2000's | 252 (35.69) | 29.6817 |
| 2010's | 368 (52.12) | 24.3611 |
| 2020's | 71 (10.06) | 2.80 |
| Authors | Studies |
|---|---|
| Amaral, C; Carvalho, RA; Correia-da-Silva, G; Costa, SC; Lopes, A; Roleira, FM; Tavares da Silva, E; Teixeira, N; Varela, CL | 1 |
| Barmade, MA; Murumkar, PR; Tamboli, RS; Yadav, MR | 1 |
| Alcaro, S; Amaral, C; Carvalho, RA; Correia-da-Silva, G; Costa, G; Costa, SC; Roleira, FM; Tavares-da-Silva, EJ; Teixeira, NA; Varela, CL | 1 |
| Barrow, D; Eissa, AG; Foster, PA; Gee, J; Powell, LE; Simons, C | 1 |
| Chen, JZ; Khan, MZI; Nazli, A; Uzair, M | 1 |
| Abdel-Razeq, H; Abdel-Razeq, N; Abdulelah, H; Bater, R; Inserat, B; Salam, M; Sharaf, B | 1 |
| Chen, G; Lazarus, P; Teslenko, I; Watson, CJW; Xia, Z | 1 |
| Abraham, J; Budd, GT; Kruse, ML; LeGrand, SB; Mo, H; Montero, AJ; Moore, HCF; Renna, CE; Wang, L | 1 |
| Iwata, H; Kimura, R; Lee, MJ; Masuda, N; Nishimura, Y; Saji, S; Sawaki, M; Shimomura, A; Tamura, K; Trepel, J; Yasojima, H; Yuno, A | 1 |
| Acikgoz, O; Akin, S; Avci, N; Basaran, G; Beypinar, I; Bilgetekin, I; Bilici, A; Cinkir, HY; Değirmenci, M; Demir, A; Dogan, M; Erdem, D; Kaplan, MA; Menekse, S; Olmez, OF; Paydas, S; Sakalar, T; Sakin, A; Sezgin Goksu, S; Tanriverdi, O; Temiz, S; Tural, D; Turan, M; Turhal, S; Turker, S; Uslu, R; Uysal, M; Yildiz, F | 1 |
| Abramson, VG; Del Valle, L; Ismail-Khan, R; Lush, RM; Majumder, S; Mayer, IA; Means-Powell, JA; Miele, L; Sanders, MS; Sorrentino, C; Tonetti, D | 1 |
| Jing, F; Wang, H; Wang, Y | 1 |
| Goncalves, A; Mezni, E; Sabatier, R; Vicier, C | 1 |
| Laranjeira, MS; Magalhães, AI; Monteiro, FJ; Ribeiro, TP; Santos, JAM; Silva, PC | 1 |
| Abreu, M; Afonso, A; Ferreira, M; Moreira, I; Sousa, S | 1 |
| Chen, G; Lazarus, P; Luo, S; Teslenko, I; Trudeau, J; Truica, CI; Watson, CJW | 1 |
| Joo, YY; Kang, EJ; Lee, K; Moon, SJ; Noh, E; Park, IH; Seo, JH | 1 |
| Aruga, T; Iwasa, T; Iwata, H; Kaneda, A; Kaneko, K; Kawabata, A; Kobayashi, K; Lee, MJ; Masuda, N; Nakamura, R; Nishimura, Y; Saji, S; Seike, T; Tamura, K; Tokunaga, E; Trepel, JB; Tsurutani, J; Yamamoto, Y; Yamashita, T; Yonemori, K; Yuno, A | 1 |
| Boughey, JC; Ellis, MJ; Hunt, KK; Leitch, AM; Meric-Bernstam, F; Olson, J; Suman, VJ; Unzeitig, G; Wingate, HF | 1 |
| Almeida, CF; Amaral, C; Correia-da-Silva, G; Roleira, FMF; Tavares-da-Silva, E; Teixeira, N; Valente, MJ; Varela, C; Vinggaard, AM | 1 |
| Cai, L; Chen, Q; Cui, S; Feng, J; Li, H; Liao, N; Ouyang, Q; Song, Y; Sun, Q; Sun, T; Teng, Y; Tong, Z; Wang, J; Wang, X; Xu, B; Yin, Y | 1 |
| Bedrosian, I; Bertelsen, BE; Bonanni, B; Brown, PH; Castile, T; Crew, KD; D'Amico, M; DeCensi, A; Dimond, E; Gandini, S; Guasone, F; Guerrieri-Gonzaga, A; Heckman-Stoddard, BM; Johansson, H; Kumar, NB; Lazzeroni, M; Lee, JJ; Mellgren, G; Serrano, D; Spinaci, S; Szabo, E; Thomas, P; Veronesi, P; Viale, G; Vornik, LA; Weber, D | 1 |
| Chan, RJ; Fardell, JE; Vardy, JL; Walker, A | 1 |
| Boogerd, W; Kieffer, JM; Lee Meeuw Kjoe, PR; Meershoek-Klein Kranenbarg, E; Schagen, SB; Schilder, CM; Small, BJ; van de Velde, CJH; van der Wall, E | 1 |
| Baktash, N; Biyukov, T; Blau, S; Burris, HA; Cortes, J; Díaz-Redondo, T; García-Sáenz, JÁ; Hart, L; Jañez, NM; Joaquim, A; Lemieux, J; Massey, D; Morales, S; Neven, P; Rugo, HS; Schmid, P | 1 |
| Ahmad, S; Alam, M; Amin, S; Mir, SR; Perwez, A; Rizvi, MMA; Rizwanullah, M | 1 |
| Ferini, G; Strazzanti, A; Zagardo, V | 1 |
| Jia, Y; Liu, Y; Lu, Y; Nong, L; Qin, F; Tan, A; Tang, J; Wang, H; Zhong, W | 1 |
| Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S | 1 |
| Elkodairy, KA; Elzoghby, AO; Gaber, M; Hany, M; Helmy, MW; Mokhtar, S | 1 |
| DiNardo, D; Farkas, A; Merriam, S; Vanderberg, R | 1 |
| Coates, AS; Colleoni, M; Di Leo, A; Fleming, GF; Francis, PA; Gelber, RD; Goldhirsch, A; Gómez, HL; Láng, I; Pagani, O; Pinotti, G; Regan, MM; Tondini, C; Viale, G; Walley, BA | 1 |
| Robert, M; Turner, N | 1 |
| Ahn, HK; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kang, SY; Kim, GM; Kim, HJ; Kim, JH; Kim, JY; Kim, SB; Kim, TY; Koh, SJ; Lee, JI; Lee, KE; Lee, KH; Lee, MH; Park, IH; Park, YH; Sohn, J | 1 |
| Francis, PA | 2 |
| Boven, E; Dercksen, WM; Jager, A; Jansen, MPHM; Konings, IRHM; Kruger, DT; Martens, JWM; Oulad Hadj, J; Sleijfer, S | 1 |
| Chen, J; Fan, Y; He, T; Huang, Q; Li, P; Lv, Q; Wu, Y; Xiang, M; Yang, D; Yang, W; Zhang, X; Zhou, R | 1 |
| Limmer, A; Robare, S; Swali, R | 1 |
| Petit, T | 1 |
| Bartsch, R; Egle, D; Gnant, M; Greil, R; Haslbauer, F; Helfgott, R; Hennebelle, M; Hock, K; Hubalek, M; Lang, A; Marth, C; Mraz, B; Öhler, L; Petru, E; Pfeiler, G; Redl, A; Steger, GG; Tinchon, C | 1 |
| Guillaume, Z; Lillo-Lelouet, A; Marret, G; Medioni, J; Oudard, S; Simonaggio, A | 1 |
| Bahrami, N; Chang, G; Chen, S; Geisler, J; Gravdehaug, B; Kanaya, N; Loeng, M; Park, D; Sauer, T | 1 |
| Fakolade, A; Fan, T | 1 |
| Ciruelos, E; Conte, P; Gavila, J; Generali, D; Jerusalem, G; Lang, I; Martin, M; Martínez-Serrano, MJ; Montemurro, F; Neven, P; Perelló, MF; Tjan-Heijnen, VCG | 1 |
| Chen, PH; Ho, CL; Huang, TC; Kang, YN; Lee, CH; Lin, C; Wu, YY | 1 |
| Chiabudini, M; Decker, T; Falkenstein, J; Hagen, V; Hahn, A; Indorf, M; Klare, P; Kurbacher, CM; Maintz, C; Potthoff, K; Runkel, E; Sent, D; Söling, U; Vehling-Kaiser, U | 1 |
| Bianchi, GV; Capri, G; Corti, F; de Braud, F; Ligorio, F; Manglaviti, S; Nichetti, F; Rea, CG; Vernieri, C; Zattarin, E | 1 |
| Huma, J; Jingxiang, H; May, LM; Xue Ting, O | 1 |
| Amaral, C; Fernandes, PA; Ferreira Almeida, C; João Ramos, M; Oliveira, A; Teixeira, N | 1 |
| Jamal, QMS | 1 |
| Gui, L; Li, Q; Luo, Y; Sun, J; Wang, L; Wang, Q; Zhang, P; Zhang, S | 1 |
| Coudert, B; Goirand, F; Guérard, P; Macaire, P; Schmitt, A; Vaury, C | 1 |
| Ingle, JN; Qin, S; Wang, L; Yu, J; Zayas, J | 1 |
| Beelen, KJ; Boven, E; de Valk, B; Kruger, DT; Linn, SC; Nieuwenhuis, M; Opdam, M; Sanders, J; van der Noort, V | 1 |
| Chen, C; Guan, J; Huang, X; Lin, Y; Mao, F; Shen, S; Sun, Q; Wang, C; Yao, R; Zhang, X; Zhao, J; Zhou, Y; Zhu, H | 1 |
| DiNome, ML; Ganz, PA; Graham, D | 1 |
| Bartlett, JMS; Blok, EJ; Duijm-de Carpentier, M; Hasenburg, A; Hozumi, Y; Kroep, JR; Liefers, GJ; Markopoulos, CJ; Meershoek-Klein Kranenbarg, E; Noordhoek, I; Paridaens, R; Portielje, JEA; Putter, H; Rea, DW; Rutgers, EJT; Seynaeve, C; van de Velde, CJH; Vannetzel, JM | 1 |
| Kohli, K; Mangla, B; Neupane, YR; Shafi, S; Singh, A | 1 |
| Chen, G; Goss, P; Ho, V; Lazarus, P; Luo, S; Pasquet, R; Richardson, H; Tu, D | 1 |
| Barba, M; Barchiesi, G; Krasniqi, E; Mazzotta, M; Pizzuti, L; Vici, P; Villa, A | 1 |
| Cao, Y; Ding, J; Fu, W; Guo, Y; Jiang, X; Li, K | 1 |
| Banda, K; Fritzsche, D; Indorf, A; Miske, A | 1 |
| Abramson, V; Awada, A; Biganzoli, L; Chan, S; Colleoni, M; Garcia-Estevez, L; Gucalp, A; Hart, L; Holmes, F; Kelly, CM; Krop, I; Markova, D; Morris, PG; O'Brien, T; Schwartzberg, L; Sica, L; Steinberg, J; Tarazi, J; Traina, T; Trudeau, M; Winer, E; Yardley, DA; Zamagni, C; Zhu, Z | 1 |
| Al Rabadi, L; Cook, MM; Kaempf, AJ; Mitri, ZI; Saraceni, MM; Savin, MA | 1 |
| Hayashi, Y; Inoue, K; Kai, T; Kurosumi, M; Ninomiya, J; Saito, T; Takei, H | 1 |
| Ahn, HK; Im, SA; Jung, KH; Kang, SY; Kim, GM; Kim, JH; Lee, J; Park, IH; Park, YH | 1 |
| Adachi, M; Amemiya, T; Hata, H; Hayashi, N; Kashiwabara, K; Kikawa, Y; Kondo, N; Mitsunaga, S; Mukai, H; Naito, M; Nakagami, K; Nakatsukasa, K; Niikura, N; Ota, Y; Shibuya, Y; Taniike, N; Umeda, M; Watanabe, KI; Yamanaka, T; Yamashita, T | 1 |
| Adamson, D; Bergh, J; Bogenrieder, T; Cortés, J; Crown, J; Espadero, RM; Gonçalves, A; Huang, DC; Im, SA; Jerusalem, G; Lee, KS; Lu, YS; Martínez, N; Morales, S; Neven, P; Pérez-Fidalgo, JA; Prat, A; Sablin, MP; Schlieker, L; Schmid, P | 1 |
| Chohan, B; Ferguson, A; Lewis, M; Nambi, R; Narang, I; Panthagani, AP | 1 |
| Apostolaki, S; Georgoulia, N; Georgoulias, V; Hatzidaki, D; Kallergi, G; Koinis, F; Kotsakis, A; Nikolaou, C; Politaki, E; Spiliotaki, M; Tsoukalas, N; Xenidis, N | 1 |
| Baak-Pablo, R; Böhringer, S; de Groot, S; Gelderblom, H; Guchelaar, H-; Houtsma, D; Kranenbarg, EM; Kroep, JR; Seynaeve, CM; van de Velde, CJH | 1 |
| Jeon, SY; Lee, KS; Park, IH; Sim, SH; Yang, HN | 1 |
| Abdel-Razeq, H; Adhav, A; Aksoy, S; Bowles, J; Chae, Y; Chang, YC; Cinkir, HY; Im, SA; Im, YH; Jeong, J; Karabulut, B; Kim, SB; Lee, KS; Park, BW; Slimane, K; Xue, H | 1 |
| Barman, P; Cairns, J; Carlson, EE; Ellis, MJ; Gao, H; Goetz, MP; Goodnature, B; Goss, PE; Ingle, JN; Kalari, KR; Shepherd, LE; Wang, L; Weinshilboum, RM | 1 |
| Habibi-Anbouhi, M; Mohammadi, E; Tabatabaei, M; Tafazzoli-Shadpour, M | 1 |
| Accornero, CA; Bonanni, B; Brown, PH; Cagnacci, S; Crew, KD; D'Amico, M; Gandini, S; Guasone, F; Guerrieri-Gonzaga, A; Heckman-Stoddard, B; Kumar, NB; Lee, J; Serrano, D; Spinaci, S; Szabo, E; Thomas, P; Vicini, E; Vornik, LA; Webber, TB | 1 |
| Brown-Glaberman, UA; Budd, GT; Burkard, ME; Connolly, RM; Faller, BA; Kaufman, PA; Lee, MJ; Levine, EG; Miller, KD; Onitilo, AA; Piekarz, RL; Royce, ME; Smith, KL; Sparano, JA; Thomas, A; Trepel, JB; Winn, JS; Wolff, AC; Zhao, F | 1 |
| Almeida, CF; Amaral, C; Augusto, TV; Correia-da-Silva, G; Teixeira, N | 1 |
| Alba, E; Alvarez, E; Antón, A; Bermejo, B; Calvo, L; Carrasco, E; Casas, M; Ciruelos, E; Corsaro, M; Csöszi, T; de la Haba-Rodriguez, J; Gal-Yam, E; Garcia-Palomo, A; Gil-Gil, M; González-Santiago, S; Kahan, Z; Lang, I; López, IÁ; Margeli, M; Martín, M; Morales, S; Muñoz, M; Murillo, L; Ramos, M; Rodrigálvarez, G; Rodríguez, CA; Ruiz-Borrego, M; Servitja, S; Zielinski, C | 1 |
| Beck, JT; Chambers, MS; Dhillon, N; Glaspy, JA; Hwang, LC; Litton, JK; Mayer, IA; Meiller, TF; Nangia, C; Peguero, JA; Pluard, TJ; Rugo, HS; Sabo, JR; Seneviratne, L; Sweetman, RW | 1 |
| Awada, A; Baselga, J; Blum, JL; Ciruelos, EM; Cortes, J; Eaton, L; Ebbinghaus, S; Ewertz, M; Gause, C; Haddad, T; Im, E; Jones, MB; Mauro, D; Morales, SM; Moy, B; Pathiraja, K; Ruddy, KJ; Rugo, HS; Tan, AR; Vuylsteke, P | 1 |
| Cascinu, S; Depenni, R; Filieri, ME; Grizzi, G; Omarini, C; Piacentini, F | 1 |
| Bilancia, D; Cairo, G; Cazzaniga, ME; Chiuri, VE; Ciccarese, M; Cusmai, A; De Matteis, E; Fabi, A; Febbraro, A; Forcignanò, R; Giampaglia, M; Giordano, G; Giotta, F; La Verde, N; Latorre, A; Lorusso, V; Lupo, LI; Maiello, E; Morritti, M; Moscetti, L; Palmiotti, G; Petrucelli, L; Romito, S; Scavelli, C; Surico, G | 1 |
| Chanawong, A; Hu, DG; Mackenzie, PI; McKinnon, RA; Meech, R | 1 |
| Caramia, F; Joshi, S; Loi, S; Moodie, K; Savas, P; Van Geelen, C; Wein, L | 1 |
| Ascione, G; Barone, CA; Bighin, C; Bordonaro, R; Cazzaniga, ME; Cognetti, F; Foglietta, J; Frassoldati, A; Generali, D; Goffredo, F; Ionta, MT; Latini, L; Mafodda, A; Mariani, G; Michelotti, A; Minisini, AM; Molino, A; Montemurro, F; Nolè, F; Nuzzo, F; Piacentini, F; Piovano, P; Portera, G; Riccardi, F; Roila, F; Romito, S; Sartori, D; Schirone, A; Simoncini, EL; Testore, F; Vici, P | 1 |
| Flockhart, DA; Hayes, DF; Henry, NL; Kadakia, KC; Kidwell, KM; Otte, JL; Seewald, NJ; Snyder, CF; Stearns, V; Storniolo, AM | 1 |
| Chirila, C; Colosia, A; Iyer, S; Kaye, JA; Ling, C; Mitra, D; Odom, D | 1 |
| Ali, SM; Budd, GT; Chapman, JW; Elliott, CR; Ellis, MJ; Garg, A; Goss, PE; Han, L; Ingle, JN; Leitzel, K; Lipton, A; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW | 1 |
| Alvarez, I; Andersen, J; Bertelli, G; Bliss, JM; Coates, AS; Coleman, R; Coombes, RC; Del Mastro, L; Dodwell, D; Fallowfield, L; Holmberg, S; Jassem, J; Jones, S; Kilburn, L; Lønning, PE; Morden, JP; Nicholas, H; Ortmann, O; Paridaens, R; Snowdon, C; van de Velde, C | 1 |
| Gourd, E | 1 |
| Baird, CC; Chen, G; Lazarus, P; Leitzel, K; Luo, S; Truica, C | 1 |
| Clark, BL; Kamdem, LK; Murphy, MA | 1 |
| Bellet, M; Bernhard, J; Burstein, HJ; Coates, AS; Colleoni, M; Dane, F; Fleming, GF; Francis, PA; Gelber, RD; Goldhirsch, A; Gómez, HL; Luo, W; Moreira, A; Nottage, M; Pagani, O; Parmar, V; Perelló, A; Price, KN; Regan, MM; Ribi, K; Saha, P; Stewart, J; Torres, R; Vorobiof, D; Walley, BA | 1 |
| Gemignani, ML; Hetzel, DJ | 1 |
| Afonso, N; Baselga, J; Blum, JL; Campone, M; Cortes, J; Denker, A; Eaton, L; Ferreira, M; Gause, CK; Im, E; Jones, MB; Mauro, DJ; Morales, SM; Musolino, A; Park, KH; Ro, J; Rugo, HS; Tan, AR; Trédan, O; Wang, Z | 1 |
| Airoldi, M; Arcangeli, V; Artale, S; Atzori, F; Ballerio, A; Bianchi, GV; Blasi, L; Campidoglio, S; Cazzaniga, ME; Ciccarese, M; Clivio, L; Cursano, MC; Fabi, A; Ferrari, L; Ferzi, A; Ficorella, C; Frassoldati, A; Fumagalli, A; Garrone, O; Gebbia, V; Generali, D; La Verde, N; Maur, M; Michelotti, A; Moretti, G; Musolino, A; Palumbo, R; Piezzo, M; Pistelli, M; Porpiglia, M; Sartori, D; Scavelli, C; Schirone, A; Torri, V; Turletti, A; Valerio, MR; Vici, P; Zambelli, A | 1 |
| Martin, M | 1 |
| Blok, EJ; Derks, MGM; Dirix, LY; Hasenburg, A; Kranenbarg, EM; Kroep, JR; Liefers, GJ; Markopoulos, C; Nortier, JWR; Paridaens, R; Putter, H; Rea, D; Seynaeve, C; Smeets, JBE; van de Velde, CJH | 1 |
| Chlebowski, RT; Lin, EM; Pan, K | 1 |
| He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S | 1 |
| Barba, M; Botti, C; Botticelli, A; Buglioni, S; Catenaro, T; D'Onofrio, L; Di Filippo, S; di Lauro, L; Ferranti, F; Gamucci, T; Giordano, A; Iezzi, L; Marchetti, P; Maugeri-Saccà, M; Mentuccia, L; Moscetti, L; Natoli, C; Pizzuti, L; Sanguineti, G; Santini, D; Scinto, AF; Sergi, D; Sperati, F; Tomao, S; Vici, P | 1 |
| Briceño, CA; Jackson, K; Sulewski, ME | 1 |
| Abu-Serie, MM; El-Lakany, SA; Elgindy, NA; Elzoghby, AO; Helmy, MW | 2 |
| Chamseddine, AN; Mir, O; Paci, A; Ropert, S | 1 |
| Beliera, A; Carabantes, F; Ciruelos, E; Fernández, Y; Fonseca, R; García-Sáenz, JA; Gavilá, J; Martínez de Dueñas, E; Martínez-Jáñez, N; Murillo, L; Vidal, M | 1 |
| Adams, S; Bonakdar, M; Budan, B; Goldberg, JD; Gu, P; Iwano, A; Jhaveri, K; Kozhaya, L; Kwa, M; Li, X; Meyers, M; Muggia, F; Novik, Y; Oratz, R; Raad, R; Speyer, J; Tavukcuoglu, E; Unutmaz, D; Wu, J | 1 |
| Agarwal, SK; Bartlett, J; Bongartz, T; Chapman, JW; Chen, B; Gelmon, K; Goss, PE; Hilsenbeck, SG; Ingle, JN; Kalari, KR; Niravath, P; Osborne, CK; Pritchard, K; Rimawi, MF; Shepherd, LE; Welschhans, RL | 1 |
| Bartlett, JMS; Bliss, JM; Cheang, MCU; Coombes, RC; Jassem, J; Lønning, PE; Morden, J; Palmieri, C; Porta, N; Rasmussen, BB; Shaaban, A; Speirs, V; van De Velde, CJ; Verhoeven, D; Viale, G | 1 |
| Chen, BE; Goss, PE; Liedke, PER; O'Shaughnessy, J; Parulekar, WR; Ramjeesingh, R; Shepherd, LE; Strasser-Weippl, K; Sudan, G | 1 |
| Deng, Y; Tian, W; Wu, M | 1 |
| Kubo, H; Maeda, N; Nagano, H; Nagashima, Y; Sakamoto, K; Sato, Y; Suzuki, N; Takeda, S; Yamamoto, S | 1 |
| Itoh, Y; Makabe, H; Osaki, S; Saeki, T; Sugitani, I; Takahashi, M; Takahashi, T; Todo, M; Ueda, S | 1 |
| Bufill, JA; Cella, D; Chapman, JW; Goss, PE; LaFrancis, IE; Mattar, BI; Nagargoje, GG; Nikcevich, DA; Schultz, WC; Shepherd, LE; Sledge, GW; Vemuri, R; Wagner, LI; Whelan, TJ; Zhao, F | 1 |
| Dirix, LY | 1 |
| Amoroso, D; Arpino, G; Bernardo, A; Bisagni, G; Carlini, P; Cognetti, F; Cogoni, AA; De Laurentiis, M; De Placido, S; Del Mastro, L; Foglietta, J; Frassoldati, A; Gallo, C; Gori, S; Gravina, A; Lai, A; Laudadio, L; Lauria, R; Lorusso, V; Mocerino, C; Montemurro, F; Moretti, G; Moscetti, L; Nuzzo, F; Perrone, F; Riccardi, F; Rizzo, S; Russo, A; Sarobba, MG; Verusio, C | 1 |
| Alunni-Fabbroni, M; Andergassen, U; Beckmann, MW; Fasching, PA; Fehm, T; Friedl, TWP; Gade, J; Janni, W; Lichtenegger, W; Lorenz, R; Mahner, S; Müller, V; Pantel, K; Polasik, A; Rack, B; Rezai, M; Schindlbeck, C; Schneeweiss, A; Schochter, F; Soeling, U; Tesch, H; Trapp, E; Tzschaschel, M | 1 |
| Arakawa, A; Horimoto, Y; Ichikawa, Y; Kobayashi, T; Okazaki, M; Saito, M; Tanabe, M; Tokuda, E | 1 |
| Evans, DG; Howell, A; Howell, SJ | 1 |
| Chaiyakunapruk, N; Imanaka, Y; Kunisawa, S; Lertjanyakun, V | 1 |
| Blau, S; Burris, H; de Boer, RH; Ejlertsen, B; Ewertz, M; Fan, J; Hurvitz, S; Jerusalem, G; Kovalenko, E; Landherr, L; Louveau, AL; Noel-Baron, F; Özgüroglu, M; Taran, T; Yardley, DA | 1 |
| Bellet, M; Bonnefoi, HR; Buchholz, S; Burstein, HJ; Ciruelos, E; Climent, MA; Coates, AS; Coleman, R; Colleoni, M; Davidson, NE; Debled, M; Di Leo, A; Fleming, GF; Francis, PA; Gelber, RD; Geyer, CE; Goetz, MP; Goldhirsch, A; Gómez, HL; Ingle, JN; Láng, I; Maibach, R; Martino, S; Pagani, O; Pavesi, L; Pinotti, G; Puglisi, F; Rabaglio-Poretti, M; Regan, MM; Ruepp, B; Ruhstaller, T; Spazzapan, S; Stearns, V; Tondini, C; Walley, BA; Winer, EP | 1 |
| Bastiaannet, E; de Glas, NA; Derks, MGM; Dirix, LY; Hasenburg, A; Liefers, GJ; Markopoulos, C; Nortier, JWR; Portielje, JEA; Putter, H; Rea, D; Seynaeve, C; van de Velde, CJH; van de Water, W | 1 |
| Bartlett, JMS; Bayani, J; Bennett, L; Cheng, K; Dickson, A; Dirix, LY; Edwards, J; Hasenburg, A; Horgan, PG; Kieback, DG; Mallon, EA; Markopoulos, C; McMillan, DC; Quintayo, MA; Rea, DW; Roseweir, AK; Seynaeve, C; van de Velde, CJH | 1 |
| Hattori, A; Hirano, A; Inoue, H; Kamimura, M; Kodera, A; Matsuoka, A; Naritaka, Y; Ogura, K; Sakaguchi, S; Shimizu, T; Tanaka, N; Yukawa, H | 1 |
| Decker, T; Distelrath, A; Fasching, PA; Hadji, P; Janni, W; Kreuzeder, J; Kurbacher, CM; Lüftner, D; Lux, MP; Marmé, F; Mundhenke, C; Muth, M; Quiering, C; Schneeweiss, A; Stoetzer, O; Taran, FA; Tesch, H | 1 |
| O'Shaughnessy, J; Royce, M; Thaddeus Beck, J | 1 |
| Barbolini, M; Bettelli, S; Caprera, C; Cascinu, S; Conte, PF; Filieri, ME; Guaitoli, G; Kaleci, S; Maiorana, A; Manfredini, S; Moscetti, L; Nasso, C; Omarini, C; Piacentini, F | 1 |
| Baird, CC; Chen, G; Lazarus, P; Luo, S; Truica, CI; Xia, Z | 1 |
| Bruna-Muraille, C; Dejust, S; Eymard, JC; Morland, D; Papathanassiou, D; Savoye, AM; Yazbek, G | 1 |
| Chang, B; Fan, X; Jiang, X; Kariminia, S; Li, L; Li, Q; Li, T; Li, Y; Wu, S; Zhang, J | 1 |
| Amoroso, V; Baldelli, AM; Bari, M; Basso, U; Benedetti, G; Biason, P; Bonura, S; Cecchin, E; Cinausero, M; Clerico, M; Collovà, E; Cretella, E; D'Andrea, MR; Dreussi, E; Fabbri, MA; Foghini, L; Gagno, S; Gasparini, G; Gianni, L; Iacono, D; Innocenti, F; Mansutti, M; Medici, M; Meo, R; Merkabaoui, G; Montico, M; Pellegrino, A; Puglisi, F; Riccardi, F; Rocca, A; Russo, S; Saggia, C; Sandri, P; Saracchini, S; Sartori, D; Serra, P; Spagnoletti, I; Toffoli, G; Vattemi, E; Zanusso, C | 1 |
| Huang, HW; Huang, LS; Li, XY; Lin, JZ; Wang, HB; Xu, QN | 1 |
| Chavez Mac Gregor, M; Esteva, FJ; Griner, RL; Hess, KR; Hodge, S; Hortobagyi, GN; Koenig, KH; Moulder, SL; Patel, MM; Raghavendra, AS; Shroff, GS; Ueno, NT; Valero, V; Yam, C; Yeung, SJ | 1 |
| Croes, S; de Boer, M; de Fallois, AOJ; Dercksen, MW; Geurts, SME; Ibragimova, KIE; Knapen, LM; Lobbezoo, DJA; Pepels, MJAE; Tjan-Heijnen, VCG; van de Wouw, AJ; van den Berkmortel, FWPJ; Vriens, BEPJ | 1 |
| Becherini, C; Bernini, M; Bianchi, S; Cecchini, S; De Feo, ML; Delli Paoli, C; Desideri, I; Francolini, G; Livi, L; Meattini, I; Nori, J; Orzalesi, L; Saieva, C; Salvestrini, V; Sanchez, L; Scotti, V; Visani, L | 1 |
| Adamo, B; Baselga, J; Brase, JC; Cheng, Y; Ciruelos, E; Galván, P; Hortobagyi, GN; Martínez, D; Nuciforo, P; Paré, L; Pascual, T; Prat, A; Vidal, M | 1 |
| Ali, S; Bliss, JM; Cheang, MCU; Coombes, RC; Flach, KD; Linn, SC; Opdam, M; Palmieri, C; Szijgyarto, Z; Wesseling, J; Zwart, W | 1 |
| Chen, Z; Gong, C; Hu, S; Hu, X; Li, Y; Wang, B; Wang, L; Xie, Y; Yuan, P; Zhang, J; Zhang, Y; Zhao, Y | 1 |
| Clark, BL; Gersch, CL; Gregory, BJ; Hayes, DF; Henry, NL; Hertz, DL; Kamdem, LK; Kidwell, KM; Rae, JM; Stearns, V; Storniolo, AM; Xi, J | 1 |
| Eikesdal, HP; Ewertz, M; Fronth, L; Hege Aksnes, L; Ottestad, L; Rajendiran, S; Støre Blix, E | 1 |
| Cao, E; Ge, R; Gong, C; Guan, X; Hu, X; Li, W; Li, Y; Wang, B; Wang, L; Xie, Y; Zhang, J; Zhang, S; Zhang, Y; Zhao, Y | 1 |
| Aristarco, V; Bonanni, B; DeCensi, A; Gandini, S; Gjerde, J; Guerrieri-Gonzaga, A; Johansson, H; Lazzeroni, M; Macis, D; Mellgren, G; Rajasekaran, A; Serrano, D; Williard, CV | 1 |
| Bardia, A; Spring, LM; Wander, SA | 1 |
| Cheng, Y; Cristofanilli, M; Cui, S; Feng, J; Gao, J; Geng, C; Gu, K; Hu, X; Jiang, Z; Li, W; Liu, T; Lu, X; Ning, Z; Ouyang, Q; Ouyang, T; Pan, Y; Sun, T; Sun, Y; Tong, Z; Wang, H; Wang, S; Wang, X; Yin, Y; Zhang, Q | 1 |
| Benelli, M; Bergqvist, M; Biagioni, C; Biganzoli, L; Boccalini, G; Bonechi, M; Chia, S; De Luca, F; Di Leo, A; Galardi, F; Gradishar, WJ; Malorni, L; Mattsson, K; McCartney, A; Migliaccio, I; Pestrin, M; Piccart, M; Romagnoli, D; Schiavon, G | 1 |
| Romero, D | 1 |
| Conforti, F; Pala, L | 1 |
| Bachelot, T; Racadot, S; Visy, A | 1 |
| Dempsey, JM; Desta, Z; Gersch, CL; Hayes, DF; Henry, NL; Hertz, DL; Kidwell, KM; Pesch, AM; Rae, JM; Skaar, TC; Stearns, V; Storniolo, AM | 1 |
| Chen, W; Lin, X; Wei, F | 1 |
| de Boer, M; de Jong, PC; Gerritsen, WR; Grutters, JC; Jonker, MA; Meek, B; Tol, J; van Erp, NP; van Herpen, CML; van Moorsel, C; Willemsen, AECAB | 1 |
| Alviggi, C; Arpino, G; Caputo, R; Conforti, A; De Laurentiis, M; De Placido, G; De Placido, S; De Rosa, P; De Santo, I; Di Rella, F; Giuliano, M; Lauria, R; Locci, M; Nazzaro, G; Schettini, F; Vallone, R | 1 |
| El-Hashimy, M; Horiguchi, J; Inaji, H; Ito, Y; Iwase, H; Iwata, H; Kuroi, K; Masuda, N; Mukai, H; Nakayama, T; Noguchi, S; Noh, WC; Ohno, S; Ohsumi, S; Panneerselvam, A; Park, BW; Puttawibul, P; Rai, Y; Sahmoud, T; Srimuninnimit, V; Taran, T; Tokuda, Y | 1 |
| Chia, SK; Wilson, S | 1 |
| Bourgeois, H; de Boer, RH; Ferrero, JM; Gansert, JL; Jacot, W; Kaufman, PA; Kennecke, H; Loh, E; McCaffery, I; McGreivy, J; Robertson, JF; Suzuki, S; Zhu, M | 1 |
| Baselga, J; Burris, HA; Campone, M; Eakle, J; El-Hashimy, M; Geberth, M; Gnant, M; Hadji, P; Hart, LL; Hortobagyi, GN; Iwata, H; Lebwohl, D; Mukai, H; Noguchi, S; Piccart, M; Pritchard, KI; Rao, S; Rugo, HS; Sahmoud, T; Taran, T | 1 |
| Baselga, J; Bauly, H; Beck, JT; Bennett, L; Burris, HA; Chouinard, E; Gnant, M; Hortobagyi, GN; Komorowski, A; Lebrun, F; Neven, P; Noguchi, S; Petrakova, K; Piccart, M; Pritchard, KI; Ricci, JF; Rugo, HS; Sahmoud, T; Taran, T; Young, R | 1 |
| Chen, D; Hao, T; Li, L; Li, Z; Liu, K; Mei, L; Sun, P; Tang, Z; Tian, Y | 1 |
| Dhillon, S | 1 |
| Cazzaniga, M; DeCensi, A; Dunn, BK | 1 |
| Carpenter, JS; Dantzer, J; Desta, Z; Flockhart, DA; Gersch, C; Hayes, DF; Henry, NL; Kidwell, K; Li, L; Nguyen, AT; Oesterreich, S; Philips, S; Rae, JM; Skaar, TC; Stearns, V; Storniolo, AM | 1 |
| Akiyoshi, T; Asayama, T; Hiura, S; Kato, H; Masuda, S; Ohtani, H; Okamoto, Y; Shimomura, Y | 1 |
| Ando, M; Fujiwara, Y; Hojo, T; Imi, K; Imoto, S; Isaka, H; Ito, H; Kinoshita, T; Shimizu, C; Wada, N | 1 |
| Bartlett, JM; Fontein, DB; Hadji, P; Hasenburg, A; Hille, ET; Hozumi, Y; Jones, SE; Kranenbarg, EM; Markopoulos, C; Nortier, JW; Paridaens, RJ; Putter, H; Rea, DW; Seynaeve, C; van de Velde, CJ; van de Water, W; Vannetzel, JM | 1 |
| Henry, NL; Stearns, V | 1 |
| Ingle, JN | 5 |
| Brauch, H; Precht, JC; Saladores, PH; Schroth, W; Schwab, M | 1 |
| Athanassiadis, I; Nicolatou-Galitis, O; Nikolaidi, A; Papadopoulou, E; Sonis, S | 1 |
| Cruickshank, S; Ismail-Khan, RR; Klein, PM; Lee, MJ; Lichinitser, M; Melichar, B; Miller, KD; Munster, PN; Trepel, JB; Yardley, DA | 1 |
| Chishima, T; Hozumi, Y; Ikeda, M; Ishikawa, T; Iwase, H; Iwata, H; Saji, S; Toyama, T; Yamamoto, Y; Yamamoto-Ibusuki, M; Yamashita, H | 1 |
| Peterson, ME | 1 |
| Hashigaki, S; Hiraoka, M; Iwata, H; Masuda, N; Morimoto, T; Nishizawa, Y; Noguchi, S; Ohno, S; Ohsumi, S; Rai, Y; Saeki, T; Sasano, H; Sato, Y | 1 |
| Kuranishi, F; Ohno, T | 1 |
| Arena, F; Bachelot, T; Baselga, J; Burris, HA; Campone, M; Deleu, I; El-Hashimyt, M; Gnant, M; Hart, L; Héniquez, A; Hortobagyi, GN; Melichar, B; Noguchi, S; Panneerselvam, A; Piccart, M; Pistilli, B; Pritchard, KI; Provencher, L; Rugo, HS; Sahmoud, T; Shtivelband, M; Taran, T | 1 |
| Arteaga, C; Ciruelos, E; Cortes-Funes, H; Ghanem, I; Manso, L | 1 |
| Buzdar, AU | 6 |
| Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D | 1 |
| Bachelot, T; Baselga, J; Beck, JT; Bennett, L; Burris, HA; Cahana, A; Campone, M; Gnant, M; Heng, DY; Horiguchi, J; Hortobagyi, GN; Komorowski, A; Neven, P; Noguchi, S; Nunzi, M; Piccart, M; Pritchard, KI; Provencher, L; Rugo, HS; Sahmoud, T; Taran, T; Zhang, J; Ziemiecki, R | 1 |
| Bastiaannet, E; Hasenburg, A; Hozumi, Y; Jones, SE; Liefers, GJ; Marijnen, CA; Markopoulos, C; Paridaens, R; Putter, H; Rea, D; Scholten, AN; Seynaeve, C; van de Velde, CJ; van Hezewijk, M | 1 |
| Chan, HP; Dantzer, J; Desta, Z; Flockhart, DA; Goswami, CP; Hadjiiski, L; Hayes, DF; Helvie, MA; Henry, NL; Khouri, N; Li, L; Nguyen, AT; Oesterreich, S; Philips, S; Pinsky, R; Rae, JM; Robarge, J; Skaar, TC; Stearns, V; Storniolo, AM; Zhou, C | 1 |
| Bartlett, JM; Brookes, CL; Dirix, LY; Hasenburg, A; Kieback, DG; Kranenbarg, EM; Lyttle, N; Mallon, EA; Markopoulos, C; Piper, T; Putter, H; Quintayo, MA; Rea, DW; Seynaeve, C; Stocken, D; van de Velde, CJ | 1 |
| Coates, AS; Colleoni, M; Fleming, GF; Francis, PA; Gelber, RD; Goldhirsch, A; Maibach, R; Pagani, O; Price, KN; Rabaglio, M; Regan, MM; Ruepp, B; Walley, BA | 1 |
| Andre, F; Dieci, MV; Vicier, C | 1 |
| Aogi, K; Hisamatsu, K; Iwata, H; Kuroi, K; Masuda, N; Ohno, S; Saji, S; Sasano, H; Sato, N; Takei, H; Toi, M; Ueno, T; Yamamoto, Y; Yamanaka, T; Yamashita, H | 1 |
| Arena, FP; Baselga, J; Burris, HA; Cahana, A; Campone, M; Erdkamp, F; Feng, W; Gnant, M; Harb, WA; Hortobagyi, GN; Lebwohl, D; Melichar, B; Noguchi, S; Petrakova, K; Piccart, M; Pistilli, B; Pritchard, KI; Rugo, HS; Taran, T; Yardley, DA | 1 |
| Mehta, A; Tripathy, D | 1 |
| Baselga, J; Bourgeois, H; Burris, HA; Campone, M; Csöszi, T; Dakhil, S; Gnant, M; Gonzalez Martin, A; Heng, D; Hortobagyi, GN; Ito, Y; Noguchi, S; Osborne, K; Panneerselvam, A; Piccart, M; Pritchard, KI; Puttawibul, P; Rugo, HS; Sahmoud, T; Srimuninnimit, V; Taran, T | 1 |
| Bossart, M; Hadji, P; Hasenburg, A; Kieback, DG; Klar, M | 1 |
| Bachelot, T; Duffy, S; Fleetwood, K; Glanville, J; Jerusalem, G; McCool, R; Varley, D; Zhang, J | 1 |
| Boyd, JM; Li, XF; Sawyer, MB; Zhao, Y | 1 |
| Harris, LN; Williams, N | 1 |
| Beck, JT; Brechenmacher, T; Campone, M; Dakhil, S; Deleu, I; Douma, S; El-Hashimy, M; Geberth, M; Hart, L; Heng, DY; Hortobagyi, GN; Lebrun, F; Masuda, N; Melichar, B; Nunzi, M; Piccart, M; Pistilli, B; Ringeisen, F; Rugo, HS | 1 |
| Lintermans, A; Neven, P; Paridaens, R; Van Asten, K; Wildiers, H | 1 |
| Angelucci, D; Ausili Cefaro, G; Cianchetti, E; Cioffi, P; De Tursi, M; Di Nicola, M; Grassadonia, A; Grossi, S; Iacobelli, S; Iezzi, L; Marinelli, C; Natoli, C; Noccioli, P; Politi, R; Tavoletta, S; Tinari, N; Zilli, M | 1 |
| A'Hern, R; Afentakis, M; Arnedos, M; Dowsett, M; Drury, S; Hills, M; Reis-Filho, JS; Salter, J; Smith, IE | 1 |
| Chlebowski, RT | 1 |
| Brufsky, A; Mathew, A | 1 |
| Badovinac-Crnjevic, T; Chalchal, H; Chapman, JA; Cheung, AM; Elliott, CR; Goss, PE; Hershman, DL; Ingle, JN; Khosla, S; Linden, HM; Muss, HB; Pritchard, KI; Rowland, K; Scher, J; Shepherd, LE; St Louis, J; Stearns, V | 1 |
| Bastiaannet, E; de Craen, AJ; Kiderlen, M; Liefers, GJ; Nortier, JW; Seynaeve, C; Siesling, S; van de Velde, CJ; van de Water, W; Westendorp, RG | 1 |
| Bardy-Bouxin, N; Bellet, M; Chow, L; Duvillié, L; Goss, P; Láng, I; Lebrun, F; Leip, E; Moy, B; Neven, P; Sarosiek, T; Turnbull, K; Xu, B; Zacharchuk, C | 1 |
| Gilabert, M; Gonçalves, A; Launay, S | 1 |
| Alés-Martínez, JE; Brundage, M; Cheung, AM; Chlebowski, RT; Cooke, AL; Dubé, P; Ellard, SL; Fabian, CJ; Gelmon, KA; Goss, PE; Hendrix, S; Hiltz, A; Ingle, JN; Johnston, D; Lickley, L; Maunsell, E; Pater, JL; Pruthi, S; Pujol, P; Richardson, H; Rowland, KM; Ruiz, A; Sarto, GE; Spadafora, S; Thayer, DW; Tu, D; Wactawski-Wende, J | 1 |
| Carpenter, J; Clauw, DJ; Flockhart, DA; Harte, SE; Hayes, DF; Henry, NL; Kidwell, KM; Stearns, V; Storniolo, AM; Williams, DA | 1 |
| Bastiaannet, E; De Craen, AJ; de Glas, NA; de Haes, HJ; Fontein, DB; Liefers, GJ; Nortier, HJ; Pijpe, A; van de Velde, CJ; van Leeuwen, FE | 1 |
| Allevi, G; Andreis, D; Bottini, A; Buffa, FM; Byrne, D; Cummings, M; Deb, S; Ferrero, G; Fox, SB; Generali, D; Harris, AL; Lakhani, SR; Martinotti, M; Reid, LE; Taylor, M | 1 |
| Bernhard, J; Bonnefoi, HR; Burstein, HJ; Ciruelos, E; Coates, AS; Colleoni, M; Crivellari, D; Fleming, GF; Francis, PA; Gelber, RD; Geyer, CE; Giobbie-Hurder, A; Goldhirsch, A; Gomez, HL; Láng, I; Luo, W; Maibach, R; Martino, S; Pagani, O; Perez, EA; Pinotti, G; Price, KN; Puglisi, F; Rabaglio-Poretti, M; Regan, MM; Ribi, K; Ruepp, B; Ruhstaller, T; Stearns, V; Tondini, C; Viale, G; Walley, BA; Winer, EP | 1 |
| Aguilar, H; Balart, J; Barril, X; Beijersbergen, RL; Bonifaci, N; Bostner, J; Brunet, J; Burnstein, KL; Bustelo, XR; Caizzi, L; Carlson, KE; Clarke, R; Climent, F; Di Croce, L; Esteller, M; Extremera, AI; Figueras, A; Fornander, T; García, N; Garcia-Mata, R; Gil, M; Gómez-Baldó, L; Halonen, P; Islam, A; Jansen, MP; Karlsson, E; Katzenellenbogen, JA; Kiyotani, K; Martrat, G; Mushiroda, T; Nakamura, Y; Nevedomskaya, E; Pérez Tenorio, G; Pujana, MA; Rodríguez-Peña, AB; Rodríguez-Vida, A; Serra-Musach, J; Sgroi, DC; Soler, MT; Stål, O; Urruticoechea, A; Villanueva, A; Vizoso, M; Zembutsu, H; Zwart, W | 1 |
| Algie, GD; Charehbili, A; de Valk, B; Fontein, DB; Kroep, JR; Liefers, GJ; Linn, S; Meershoek-Klein Kranenbarg, E; Nieuwenhuijzen, GA; Nortier, JW; Putter, H; Terwogt, JM; van de Velde, CJ; van Riet, Y | 1 |
| Rugo, HS | 1 |
| Láng, I; Rubovszky, G | 1 |
| Adunlin, G; Avancha, K; Diaby, V; Gluck, S; Lopes, G; Montero, AJ; Zeichner, SB | 1 |
| Adunlin, G; Ali, AA; Diaby, V; Tawk, R | 1 |
| Bartlett, JM; Brookes, CL; Crozier, C; Dirix, L; Drake, C; Hasenburg, A; Kieback, DG; Markopoulos, C; Piper, T; Rea, DW; Sabine, VS; Seynaeve, C; van de Velde, CJ | 1 |
| Hori, H; Inui, T; Kubo, K; Kuchiike, D; Makita, K; Matsuda, A; Mette, M; Miura, H; Nishikata, T; Sakamoto, N; Uto, Y | 1 |
| Bowman, M; Bruner, D; DeMichele, A; Farrar, JT; Mao, JJ; Seluzicki, C; Xie, SX; Zee, J | 1 |
| de Boer, M; Lobbezoo, DJ; Smeets, RE; Tjan-Heijnen, VC; Vincent, J | 1 |
| Yaqub, F | 1 |
| Olin, JL; St Pierre, M | 1 |
| Campone, M; Faust, E; Gao, H; Kageleiry, A; Signorovitch, JE; Yang, H; Zhang, J | 1 |
| Charalampous, P; Diamandi, M; Gkogkou, P; Ioannidis, G; Ioannou, R | 1 |
| Baselga, J; Burris, HA; Campone, M; Deleu, I; Fan, J; Feng, W; Gnant, M; Hortobagyi, GN; Ito, Y; Lebrun, F; Neven, P; Noguchi, S; Perez, A; Piccart, M; Pritchard, KI; Provencher, L; Rugo, HS; Shtivelband, M; Taran, T; Wu, C | 1 |
| Printz, C | 1 |
| Chalasani, P; Clarke, K; Livingston, R; Stopeck, A | 1 |
| Albertini, S; Kelly, E; Lu, CY; Vitry, A | 1 |
| Beex, LV; Duijm-de Carpentier, M; Lardenoije, S; Nortier, JW; Putter, H; Seynaeve, C; Sramek, A; van de Velde, CJ; van Nes, JG; Van Rongen, I; Zonderland, HM | 1 |
| Abehsera, D; de Santiago, J; Panal, M; Revello, R; Sánchez-Mendez, JI; Zapardiel, I | 1 |
| Donders, F; Kuypers, D; Neven, P; Wolter, P | 1 |
| Hershman, DL | 1 |
| Bellet, M; Bonnefoi, HR; Buchholz, S; Burstein, HJ; Ciruelos, E; Climent, MA; Coates, AS; Coleman, R; Colleoni, M; Da Prada, GA; Davidson, NE; Fleming, GF; Francis, PA; Gelber, RD; Geyer, CE; Giobbie-Hurder, A; Goldhirsch, A; Ingle, JN; Kerbrat, P; Láng, I; Maibach, R; Martino, S; Price, KN; Rabaglio-Poretti, M; Regan, MM; Ruepp, B; Viale, G; Walley, BA; Winer, EP | 1 |
| Ch Yiannakopoulou, E | 1 |
| Budd, GT; Chapman, JA; Ellis, MJ; Goss, PE; Ingle, JN; Kundapur, J; Le Maitre, A; Liedke, PE; Ma, CX; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Stearns, V | 1 |
| Gradishar, WJ | 1 |
| Lanuti, M; Lerwill, MF; Moy, B; Rafferty, EA; Specht, MC | 1 |
| Bachelot, T; Barrios, C; de Boer, R; Di Leo, A; Janni, W; Jerusalem, G; Neven, P | 1 |
| Atkins, L; Barni, S; Deschamp, V; Franquet, A; Gnant, M; Kreienberg, R; Markopoulos, C; Marty, M; Neciosup, S; Neven, P; Tanner, M; Tesarova, P | 1 |
| Horiguchi, J; Ito, Y; Iwata, H; Kuroi, K; Masuda, N; Mori, A; Mukai, H; Noguchi, S; Ohno, N; Tokuda, Y | 1 |
| Liu, J; Zhu, L | 1 |
| Chatziralli, IP; Chrysikos, D; Ladas, I; Moschos, MM; Sergentanis, T; Zagouri, F; Zografos, G | 1 |
| Bartlett, JM; Bastiaannet, E; Charehbili, A; Engels, CC; Kuppen, PJ; Liefers, GJ; Putter, H; Sajet, A; Seynaeve, C; Smit, VT; van de Velde, CJ; van Vlierberghe, RL; van Vliet, EA | 1 |
| Hansen, SK; Hole, S; Lundqvist, J; Lykkesfeldt, AE; Pedersen, AM; Yde, CW | 1 |
| Aktas, B; Hofstatter, EW; Pusztai, L; Sorkin, M | 1 |
| Awada, A; Barthélémy, P; Gombos, A | 1 |
| Piccart, M; Sonnenblick, A | 1 |
| Du, Y; Pan, Y; Shen, Y; Zhang, Y | 1 |
| Akıncı, MB; Aksoy, S; Altundag, K; Dede, DŞ; Ozdemir, N; Şendur, MA; Yalçın, B; Zengin, N | 1 |
| Diener-West, M; Prasad, V | 1 |
| Hortobagyi, GN | 1 |
| Bevers, TB | 1 |
| Biggers, A; Charlson, JA; Kamaraju, S; Laud, PW; Neuner, JM; Pezzin, LE; Smallwood, AJ; Smith, EC; Wozniak, EM | 1 |
| Chang, CH; Chen, SJ; Liu, CY | 1 |
| Brodie, A; Guha, R; Jaiswal, AK; Khatri, R; Rassool, FV; Shah, P; Tomkinson, AE | 1 |
| Bartlett, JMS; Bliss, JM; Cheang, M; Coombes, RC; Jassem, J; Kalaitzaki, E; Lønning, PE; Mousa, K; Nicholas, H; Palmieri, C; Rasmussen, BB; Reed, SN; Shaaban, AM; Speirs, V; van de Velde, CJH; Verhoeven, DM; Viale, G | 1 |
| Bottini, A; Ciani, O; Generali, D; Jerusalem, G; Loi, S; Pusztai, L; Rognoni, C; Tarricone, R; Venturini, S | 1 |
| Hao, Y; Li, N; Lin, PL; Signorovitch, JE; Wu, EQ; Xie, J; Zhong, Y; Zhou, Z | 1 |
| Cai, R; Fan, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Bonneterre, J; Delbeuck, X; Kramar, A; Le Rhun, E; Lefeuvre-Plesse, C; Pasquier, F; Skrobala, E | 1 |
| de la Vega, M; Díaz Cantón, E; Greco, M; Recondo, G; Valsecchi, ME | 1 |
| Alexopoulos, A; Chatzikou, M; Georgoulias, V; Koumakis, G; Kourlaba, G; Maniadakis, N; Rapti, V; Relakis, J | 1 |
| Bozhok, AA; Dashyan, GA; Komyakhov, AV; Lalak, IA; Manikhas, AG; Paltuev, RM; Petrenko, OL; Semiglazov, VF; Semiglazov, VV; Semiglazova, TY | 1 |
| Johnston, SR | 3 |
| Bilal, U; Prasad, V | 1 |
| De Iuliis, F; Lanza, R; Scarpa, S | 1 |
| Abrial, C; Arbre, M; Chollet, P; Devaud, H; Dohou, J; Dubray-Longeras, P; Durando, X; Herviou, P; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Planchat, E; Pouget, M; Van Praagh, I | 1 |
| Kon, M; Sueoka, N; Tsubota, Y; Yamamoto, C; Yamamoto, D | 1 |
| Bondarenko, I; Brain, E; Campone, M; De Porre, P; Griffin, TW; Hayes, D; Johnston, S; Kheoh, T; Martin, J; Neven, P; O'Shaughnessy, J; Peng, W; Yu, MK | 1 |
| Amaral, C; Correia-da-Silva, G; da Silva, ET; Lopes, A; Roleira, FM; Teixeira, N; Varela, CL | 1 |
| Dantzer, J; Desta, Z; Flockhart, DA; Hangartner, TN; Hayes, DF; Henry, NL; Kidwell, KM; Li, L; Nguyen, AT; Oesterreich, S; Peacock, M; Philips, S; Rae, JM; Skaar, TC; Stearns, V; Storniolo, AM; Van Poznak, CH | 1 |
| Ditzel, HJ; Elias, D; Knoop, AS; Lykkesfeldt, AE; Lyng, MB; Lænkholm, AV; Thomsen, KG; Vever, H | 1 |
| Bregni, G; de Braud, F; Di Cosimo, S; Zanardi, E | 1 |
| Cottu, P; Donnadieu, A; Leman-Detours, S; Saltel-Fulero, A | 1 |
| Cui, S; Lü, H; Niu, L; Yan, M; Zeng, H; Zhang, M | 1 |
| Bartlett, JM; Christiansen, J; Dirix, LY; Gustavson, M; Hasenburg, A; Kieback, DG; Markopoulos, CJ; Piper, T; Putter, H; Rea, DW; Rimm, DL; Seynaeve, C; van de Velde, CJ | 1 |
| Avella, A; Azaro, A; Bellet, M; Bohn, U; Catalán, G; Catalán, R; Ciruelos, E; Climent, MA; Ferrer, R; Fleming, GF; Francis, PA; González-Martin, A; Gray, KP; Láng, I; Lluch, A; Morales, J; Price, KN; Rajasekaran, A; Regan, MM; Vázquez, J | 1 |
| Eng-Wong, J; Galbo, CE; Gallagher, A; Gatti-Mays, ME; Heckman-Stoddard, BM; Isaacs, C; Kallakury, B; Korde, L; Makariou, E; Reynolds, J; Singer, A; Venzon, D; Warren, R | 1 |
| Callet, N; Fourme, E; Noguès, C; Reyal, F; Sénéchal, C; Stoppa-Lyonnet, D; This, P | 1 |
| Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M | 1 |
| Bachelot, T; Béal-Ardisson, D; Becuwe, C; Blot, E; Bürki, F; Cropet, C; Dauba, J; Diéras, V; Follana, P; Gouttebel, M; Guardiola, E; Jouannaud, C; Lavau-Denes, S; Moullet, I; Orfeuvre, H; Petit, T; Pujade-Lauraine, E; Stefani, L; Trager-Maury, S; Trédan, O | 1 |
| Aristarco, V; Bonanni, B; Caldarella, P; DeCensi, A; Feroce, I; Gandini, S; Guerrieri-Gonzaga, A; Johansson, H; Lazzeroni, M; Macis, D; Pagani, G; Pruneri, G; Serrano, D; Toesca, A | 1 |
| DeCensi, A; Lazzeroni, M | 1 |
| Batson, S; Jones, N; Livings, C; Telford, C | 1 |
| Martí, S; Viciano, I | 1 |
| Aogi, K; Hisamatsu, K; Imoto, S; Iwata, H; Kuroi, K; Masuda, N; Ohno, S; Saji, S; Sasano, H; Sato, N; Sugimoto, M; Takei, H; Toi, M; Ueno, T; Yamamoto, Y; Yamashita, H | 1 |
| Amaral, C; Correia-da-Silva, G; Sobral, AF; Teixeira, N | 1 |
| Chapman, JA; Elliott, C; Gelmon, KA; Goss, PE; Ingle, JN; Muss, HB; Pritchard, KI; Shepherd, LE; Whelan, TJ | 1 |
| Bellet, M; Bernhard, J; Burstein, HJ; Ciruelos, E; Coates, AS; Colleoni, M; Fleming, GF; Francis, PA; Gelber, RD; Goldhirsch, A; Karlsson, P; Kerbrat, P; Lluch, A; Lombardi, D; Luo, W; Neven, P; Parmar, V; Pavesi, L; Perelló, A; Price, KN; Puglisi, F; Regan, MM; Ribi, K; Ruhstaller, T; Tondini, C; Torres, R; Visini, M | 1 |
| Coates, AS; Colleoni, M; Fleming, GF; Francis, PA; Gelber, RD; Goldhirsch, A; Gómez, HL; Láng, I; Pagani, O; Pinotti, G; Price, KN; Regan, MM; Tondini, C; Viale, G; Walley, BA | 1 |
| Henry, NL; Kadakia, KC | 1 |
| Francis, PA; Pagani, O; Regan, MM | 1 |
| Chen, WG; Chen, XS; Fang, Q; He, JR; Huang, O; Li, YF; Liang, Y; Nie, LJ; Shen, KW; Wu, JY; Zhu, L; Zong, Y | 1 |
| Almajed, MM; Esfahani, K; Panasci, L; Pelmus, M | 1 |
| Bondarenko, I; Brain, E; Campone, M; De Porre, P; Gormley, M; Graas, MP; Griffin, T; Hayes, D; Ivanova, O; Johnston, SR; Kheoh, T; Li, W; Martin, J; Neven, P; O'Shaughnessy, J; Ricci, D; Schaffer, M; Stenina, M; Yu, M; Zbarskaya, I; Zelinsky, K | 1 |
| Andre, F; Bartlett, CH; Beaney, M; Bliss, JM; Cristofanilli, M; Dowsett, M; Fribbens, C; Garcia-Murillas, I; Hrebien, S; Jiang, J; Johnston, SR; Kilburn, L; Koehler, M; Loi, S; Loibl, S; O'Leary, B; Turner, NC | 1 |
| Goto, Y; Kimura, M; Sakiyama, K; Yoshida, T | 1 |
| Gilarranz, YJ; Lopez-Tarruella, S; Martin, M | 1 |
| Arellano, C; Chatelut, E; Dalenc, F; Filleron, T; Iuliano, L; Marquet, P; Poirot, M; Roché, H; Samadi, M; Silvente-Poirot, S; Voisin, M; Zerbinati, C | 1 |
| Bianchetti, S; Camozzi, M; Ciruelos, EM; Conte, P; Gavila, JG; Generali, D; Jerusalem, G; Lang, I; Lorizzo, K; Mardiak, J; Mariani, G; Martin, M; Michelotti, A; Montemurro, F; Naume, B; Neven, P; Simoncini, E; Tjan-Heijnen, VC | 1 |
| Hayashi, N; Kashiwabara, K; Mukai, H; Naito, M; Niikura, N; Ota, Y; Umeda, M; Watanabe, K; Yamashita, T | 1 |
| Cortesi, E; D'Onofrio, L; Fabbri, MA; Gamucci, T; Giuliani, R; Iezzi, L; Magri, V; Mancini, ML; Marchetti, P; Mauri, M; Mentuccia, L; Moscetti, L; Natoli, C; Pizzuti, L; Ramponi, S; Roma, CL; Ruggeri, EM; Santini, D; Sini, V; Sperduti, I; Vaccaro, A; Vici, P | 1 |
| Burns, RB; Libman, H; Schonberg, MA; Tung, NM | 1 |
| Bano, S; Baydoun, S; Choudhary, MI; Imad, R; Wahab, AT | 1 |
| Desta, Z; Flockhart, DA; Gersch, CL; Hayes, DF; Henry, NL; Hertz, DL; Kidwell, KM; Rae, JM; Seewald, NJ; Skaar, TC; Stearns, V; Storniolo, AM | 1 |
| Katzenellenbogen, BS; Piccart, M; Tryfonidis, K; Zardavas, D | 1 |
| Debeljak, Z; Gaudl, A; Horvat, V; Kratzsch, J; Lukic, I; Mandic, D; Mandic, S; Seric, V | 1 |
| Niraula, S; Ocana, A | 1 |
| Desta, Z; Flockhart, DA; Hayes, DF; Henry, NL; Hertz, D; Li, L; Nguyen, AT; Rae, JM; Robarge, JD; Skaar, TC; Stearns, V; Storniolo, AM | 1 |
| Charehbili, A; Fontein, DB; Kranenbarg, EM; Kroep, JR; Linn, SC; Nortier, JW; Putter, H; van de Velde, CJ | 1 |
| Allred, DC; Babiera, G; Barnes, M; Brink, A; Budd, GT; Carey, L; Creighton, CJ; Crouch, E; Dayao, Z; DeSchryver, K; Dowsett, M; Ellis, MJ; Esserman, L; Goncalves, R; Guenther, JM; Hoog, J; Hunt, K; Leitch, M; Luo, J; Ma, CX; Olson, JA; Ota, D; Pluard, T; Sanati, S; Silverman, P; Suman, VJ; Tao, Y; Unzeitig, G; Watson, M; Whitworth, P; Winer, E | 1 |
| Chlebowski, R; Goss, P; Maunsell, E; Meggetto, O; Richardson, H; Tu, D | 1 |
| Baselga, J; Bhatt, T; Chandarlapaty, S; Chen, D; He, W; Hortobagyi, GN; Moynahan, ME; Patel, P; Ringeisen, F; Samoila, A; Sung, P; You, D | 1 |
| Kawaoka, T; Kimura, Y; Kubo, H; Miyahara, M; Nagano, H; Nagashima, Y; Shimizu, R; Yamamoto, S | 1 |
| Giorgadze, E; Khachidze, N; Tsagareli, M | 1 |
| Chow, LW; Lam, CK; Loo, WT; Toi, M; Yip, AY | 1 |
| Boneberg, EM; Fürstenberger, G; Legler, DF; Senn, HJ | 1 |
| Geisler, J; Lønning, PE | 4 |
| Nagykálnai, T | 1 |
| Chen, S; Lui, K; Masri, S; Phung, S; Wang, X; Ye, J; Zhou, D | 1 |
| Dafni, U; Gogas, H; Koukouras, D; Markopoulos, C; Polychronis, A; Tzorakoleftherakis, E; Xepapadakis, G; Zobolas, V | 1 |
| Gibson, K; O'Bryant, CL | 1 |
| McCormack, P; Sapunar, F | 1 |
| Lønning, PE | 7 |
| Dziadziuszko, R; Jassem, J; Orłowska-Kunikowska, E; Senkus-Konefka, E | 1 |
| Beex, LV; Boogerd, W; Eggens, PC; Gundy, CM; Linn, SC; Schagen, SB; Schilder, CM; Seynaeve, C; Van Dam, FS | 1 |
| Karefilakis, CM; Mazokopakis, EE; Milkas, AN; Starakis, IK; Tsartsalis, AN | 1 |
| Beex, LV; Bogaerts, J; Cameron, DA; Cufer, T; Dirix, LY; Nooij, M; Paridaens, RJ; Piccart, MJ; Therasse, P | 1 |
| Bachelot, T; Crétin, J; Debled, M; Delozier, T; Falandry, C; Freyer, G; Mauriac, L; Mille, D; Pujade-Lauraine, E; Romestaing, P; You, B | 1 |
| Bines, J; Mauriac, L; Romieu, G | 1 |
| Cadirni, A; Caffarelli, C; Campagna, MS; Del Santo, K; Gonnelli, S; Montagnani, A; Montomoli, M; Nuti, R; Petrioli, R; Pieropan, C | 1 |
| Asmar, L; Blum, JL; Braun, M; Cantrell, J; Davis, JC; Di Salle, E; Ethirajan, S; Hartung, NL; Holmes, FA; Ilegbodu, D; Jones, S; Kutteh, L; Look, RM; Myron, MC; Patel, M; Paul, D; Pippen, J; Sborov, M; Stokoe, C | 1 |
| Barni, S; Cazzaniga, M; Cozzi, M; Dellach, C; Farris, A; Mansutti, M; Mustacchi, G; Sacco, C | 1 |
| Arcusa, A; Barnadas, A; Gil, M; González, S; Margelí-Vila, M; Moreno, A; Muñoz, M; Prieto, L; Tusquets, I | 1 |
| Dornoff, W; Hadji, P; Hasenburg, A; Kieback, DG; Kuck, J; Melchert, F; Menschik, T; Tessen, HW; Ziller, M | 1 |
| Abreu, P; Cameron, DA; Campos, SM; Guastalla, JP; Subar, M; Winer, EP | 1 |
| Hadji, P; Hasenburg, A; Kalder, M; Kieback, DG; Kuck, J; Menschik, T; Ziller, M | 1 |
| Deeks, ED; Scott, LJ | 1 |
| Al-Sukhun, S; Chollet, P; Durando, X; Ferriere, JP; Mouret-Reynier, MA; Nabholtz, JM; Van Praagh, I | 1 |
| Morohashi, H; Morohashi, S; Odagiri, H; Saito, C | 1 |
| Antonopoulou, Z; Dafni, U; Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Papadiamantis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V | 1 |
| Ando, Y; Fujii, Y; Ito, Y; Iwase, H; Kobayashi, S; Sugiura, H; Takahashi, S; Toyama, T; Yamashita, H; Yamashita, T; Yoshimoto, N | 1 |
| Epstein, RJ | 1 |
| Bertelli, G; Bliss, JM; Coombes, RC; Drosik, K; Hall, E; Ireland, E; Jassem, J; Karnicka-Mlodkowska, H; Snowdon, CF | 1 |
| Glück, S | 1 |
| Amir, E; Clemons, M; Cole, DE; Dowsett, M; Dranitsaris, G; Folkerd, E; Freedman, OC; Hanna, W; Kahn, H; O'Malley, F; Verma, S | 1 |
| Lazarus, P; Sun, D | 1 |
| Auboeuf, D; Bénès, V; Dalenc, F; Gratadou, L; Lacroix-Triki, M; Maillot, G; Millevoi, S; Pierredon, S; Roché, H; Schmidt, S; Vagner, S | 1 |
| Bao, T; Fetting, J; Herlong, F; Jeter, S; Lee, L; Mumford, L; Shahverdi, K; Stearns, V; Zorzi, J | 1 |
| Beex, LV; de Jong, RS; Maartense, E; Meershoek-Klein Kranenbarg, WM; Nortier, JW; Putter, H; Roumen, RM; Seynaeve, C; van de Velde, CJ; van Nes, JG | 1 |
| Chen, S; Masri, S; Phung, S; Wang, X | 2 |
| Aogi, K; Hara, F; Kiyoto, S; Osumi, S; Takabatake, D; Takashima, S | 1 |
| Beex, LV; Boogerd, W; Gundy, CM; Linn, SC; Nortier, JW; Schagen, SB; Schilder, CM; Seynaeve, C; van Dam, FS; van de Velde, CJ | 2 |
| Beex, LV; Boogerd, W; Gundy, CM; Huizenga, HM; Linn, SC; Nortier, JW; Schagen, SB; Schilder, CM; Seynaeve, C; van Dam, FS; van de Velde, CJ | 1 |
| Chan, MS; Chanplakorn, N; Chanplakorn, P; Miki, Y; Ono, K; Saji, S; Sasano, H; Suzuki, T; Toi, M; Ueno, T | 1 |
| Baildam, A; Barr, L; Bundred, NJ; Cheung, KL; Cramer, A; Dixon, JM; Flint, P; Grassby, S; Johnson, R; Landberg, G; Morris, J; Renshaw, L; Turner, L; Young, O | 1 |
| Akahira, J; Hayashi, S; Hirakawa, H; Ishida, T; Kimijima, I; Miki, Y; Nagasaki, S; Onodera, Y; Sasano, H; Suzuki, T; Takagi, K; Watanabe, M | 1 |
| Banerjee, M; Cooksley, T; Younis, N | 1 |
| Dirix, L; Hasenburg, A; Hille, ET; Hozumi, Y; Jones, S; Kerin, MJ; Kieback, DG; Markopoulos, C; Meershoek-Klein Kranenbarg, WM; Nortier, JW; Putter, H; Rea, DW; Seynaeve, C; van de Velde, CJ; van Nes, JG; Vannetzel, JM | 1 |
| Cartei, G; Endri, M; Fassina, A; Serino, FS; Zustovich, F | 1 |
| Domchek, SM; Dorazio, P; Gartner, EM; Khaira, D; Khalil, M; LoRusso, PM; Mariani, GL; Rüter, J; Soulieres, D; Trosko, JA; Usari, T; Vonderheide, RH | 1 |
| Rabaglio, M; Ruepp, B | 1 |
| Devine, S; Sedjo, RL | 1 |
| Amonkar, MM; Forbes, CA; Kessels, A; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R | 1 |
| Bertelli, G; Gangadhara, S | 1 |
| A'Hern, R; Charles, P; Flockhart, DA; Hayes, DF; Henry, NL; Li, L; Nguyen, AT; Pchejetski, D; Stearns, V; Stebbing, J; Storniolo, AM; Waxman, J | 1 |
| Bertolini, E; Letho-Gyselinck, H; Prati, C; Wendling, D | 1 |
| Agrawal, K; Mortimer, JE; Onami, S; Pal, SK | 1 |
| Aguilar, EA; Baena Cañada, JM; Conejo, EA; de la Haba-Rodriguez, J; Mancha, RG; Manga, GP; Rovira, PS | 1 |
| Banks, LM; Bliss, JM; Cawthorn, SJ; Coleman, RE; Coombes, RC; Fox, J; Girgis, SI; Kilburn, LS; Patel, A; Vrdoljak, E | 1 |
| Bauer, W; Hadji, P; Harbeck, N; Hasenburg, A; Kieback, DG; Menschik, T; Weyer, G | 1 |
| Agrawal, A; Cheung, KL; Dowsett, M; Folkerd, E; Robertson, JF; Winterbottom, L | 1 |
| Batzler, A; Chapman, JA; Ellis, MJ; Flockhart, DA; Goetz, MP; Goss, PE; Ingle, JN; Jenkins, GD; Kubo, M; Liu, M; Mushiroda, T; Nakamura, Y; Pater, J; Pritchard, KI; Rohrer, DC; Schaid, DJ; Shepherd, L; Stearns, V; Wang, L; Weinshilboum, RM | 1 |
| Chan, MS; Chanplakorn, N; Chow, LW; Loo, WT; Sasano, H; Toi, M; Yiu, CC | 1 |
| Tang, SC | 1 |
| Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nagase, H; Noguchi, S | 1 |
| Asmar, L; Hadji, P; Hasenburg, A; Jones, SE; Kuck, J; Menschik, T; Nortier, JW; van de Velde, CJ; van Nes, JG; Ziller, M | 1 |
| Brunner, RL; Cigler, T; Fabian, CJ; Goss, PE; Hu, H; Ingle, JN; Johnston, D; Nassif, E; Pater, JL; Qi, S; Richardson, H; Tu, D; Wood, ME; Yaffe, MJ | 1 |
| Amano, S; Enomoto, K; Sakurai, K | 1 |
| Aogi, K; Chanplakorn, N; Hisamatsu, K; Iwata, H; Kuroi, K; Masuda, N; Ohno, S; Saji, S; Sasano, H; Sato, N; Suzuki, T; Takada, M; Takei, H; Toi, M; Ueno, T; Yamamoto, Y; Yamashita, H | 1 |
| Chow, LW; Chu, WP; Loo, WT; Toi, M; Yip, AY | 1 |
| Asmar, L; Bartlett, JM; Hadji, P; Hasenburg, A; Hille, ET; Hozumi, Y; Jones, SE; Kieback, DG; Markopoulos, C; Nortier, JW; Paridaens, R; Putter, H; Rea, D; Seynaeve, C; Smeets, J; van de Velde, CJ; Vannetzel, JM | 1 |
| Coombes, RC; Kilburn, LS | 1 |
| Christiaens, MR; De Smet, L; Dieudonné, AS; Henry, NL; Leunen, K; Lintermans, A; Morales, L; Neven, P; Pans, S; Paridaens, R; Timmerman, D; Van Calster, B; Van Hoydonck, M; Vergote, I; Verhaeghe, J; Verschueren, K; Westhovens, R; Wildiers, H | 1 |
| Aihara, T; Hozumi, Y; Masuda, N; Ohashi, Y; Ohsumi, S; Saito, T; Suemasu, K; Takehara, M; Takei, H | 2 |
| Baldi, A; Biroccio, A; D'Angelo, C; Galati, R; Muti, P; Sacchi, A; Salvatori, L; Stoppoloni, D; Verdina, A; Vincenzi, B | 1 |
| Doughty, JC | 1 |
| Chen, S; Hong, Y; Rashid, R | 1 |
| Bartlett, JM; Billingham, LJ; Brookes, CL; Campbell, FM; Dirix, L; Grant, M; Hasenburg, A; Hille, ET; Kay, C; Kieback, DG; Kranenbarg, EM; Mallon, EA; Markopoulos, C; Putter, H; Rea, D; Robson, T; Seynaeve, C; van de Velde, CJ | 1 |
| Lintermans, A; Neven, P; Paridaens, R | 1 |
| Aogi, K; Hara, F; Kiyoto, S; Ohsumi, S; Takabatake, D; Takahashi, M; Takashima, S | 1 |
| Arun, B; Brown, PH; Castiglione, M; Cuzick, J; DeCensi, A; Dunn, B; Forbes, JF; Glaus, A; Howell, A; Vogel, V; von Minckwitz, G; Zwierzina, H | 1 |
| Cortelazzi, C; De Panfilis, G; Ficarelli, E; Pepe, C; Santini, M; Santoro, S; Tognetti, E | 1 |
| Allred, DC; Babiera, GV; DeSchryver, K; Ellis, MJ; Esserman, LJ; Guenther, JM; Hoog, J; Hunt, K; Leitch, M; Lin, L; Luo, J; Marcom, PK; Margenthaler, J; Olson, JA; Parker, JS; Prat, A; Snider, J; Suman, VJ; Unzeitig, GW; Watson, MA | 1 |
| Landherr, L; Mészáros, E; Nagykálnai, T | 1 |
| Alés-Martínez, JE; Cheung, AM; Chlebowski, RT; Fabian, CJ; Farmer, P; Garber, JE; Gelmon, KA; Goss, PE; Ingle, JN; Johnson, KC; Martin, LW; Maunsell, E; McTiernan, A; Pujol, P; Richardson, H; Robbins, J; Sarto, GE; Tu, D; Wactawski-Wende, J; Winquist, E | 1 |
| Davidson, NE; Kensler, TW | 1 |
| Gallicchio, L; Helzlsouer, KJ; Macdonald, R; Rushovich, E; Wood, B | 1 |
| Ma, CX | 1 |
| Alés-Martínez, JE; Alvarez, I; Andrés, R; Antolín, S; Antón, A; Barnadas, A; Cámara, C; Carrasco, E; Casas, I; García Saenz, JA; Lao, J; Llombart-Cussac, A; Martín, M; Ruiz, A | 1 |
| Brueggemeier, RW; Layman, RM; Lehman, AM; Lustberg, MB; Mrozek, E; Povoski, SP; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shiels, DR; Sugimoto, Y; Zhao, W; Ziegler, RM | 1 |
| Bari, M; Ciruelos, E; De Benedictis, E; Dittrich, C; Gaion, F; Gomez, P; Lluch, A; Luca, G; Mansutti, M; Morandi, P; Pavesi, L; Semiglazov, V; Valagussa, P; Zamagni, C; Zambetti, M | 1 |
| Bartlett, AI; Bartlett, JM; Campbell, FM; Hasenburg, A; Maclellan, A; Markopoulos, C; Rea, D; Robson, T; Seynaeve, C; Starcyznski, J; van de Velde, CJ | 1 |
| Chan, MS; Chanplakorn, N; Chanplakorn, P; Chow, LW; Ono, K; Sasano, H; Suzuki, T; Wang, L; Wing, L; Yiu, CC | 1 |
| Aogi, K; Hisamatsu, K; Iwata, H; Kuroi, K; Masuda, N; Ohno, S; Saji, S; Sasano, H; Sato, N; Takada, M; Takei, H; Toi, M; Ueno, T; Yamamoto, Y; Yamashita, H | 1 |
| Glück, S; Gorouhi, F | 1 |
| Xiao, YP; Xue, M; Zeng, YC | 1 |
| Hanaoka, M; Kawabata, H; Takano, T | 1 |
| Tartarone, A | 1 |
| Cruz Jurado, J; Fernández Martínez, R; Galve Calvo, E; García Mata, J; García Palomo, A; Murillo Jaso, L; Peláez Fernández, I; Polo Marqués, E; Richart Aznar, P; Sampedro Gimeno, T | 1 |
| Alba Conejo, E; Bayo Calero, J; de la Cabeza Lomas Garrido, M; de la Haba Rodríguez, J; de Toro Salas, R; González Mancha, R; Martínez Guisado, A; Ruíz Borrego, M; Sánchez Muñoz, A | 1 |
| Champ, C; Gower-Thomas, K; Jones, M; Osborn, G; Vaughan-Williams, E | 1 |
| Desta, Z; Flockhart, DA; Hayes, DF; Henry, NL; Hoffmann, E; Kamdem, LK; Kreutz, Y; Li, L; Nguyen, AT; Skaar, T; Stearns, V; Storniolo, AM; Tyndale, RF | 1 |
| Enomoto, M; Hirakawa, K; Kawada, N; Kawajiri, H; Morikawa, H; Motoyama, H; Takashima, T; Tamori, A | 1 |
| Schmidt, C | 1 |
| Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K | 1 |
| Andersen, J; Bliss, JM; Cisar, L; Coates, AS; Coleman, RE; Coombes, RC; Delozier, T; Forbes, JF; Jassem, J; Jones, SE; Kilburn, LS; Lønning, PE; Menschik, T; Morden, J; Paridaens, R; Reise, J; van de Velde, CJ | 1 |
| Bachelot, T; Baselga, J; Beck, JT; Burris, HA; Campone, M; Deleu, I; Gnant, M; Hortobagyi, GN; Ito, Y; Lebrun, F; Lebwohl, D; Mukhopadhyay, P; Noguchi, S; Perez, A; Piccart, M; Pritchard, KI; Rugo, HS; Sahmoud, T; Vittori, L; Xu, Z; Yardley, D | 1 |
| Costantino, JP; Goss, PE; Ingle, JN; Jenkins, GD; Kubo, M; McDonnell, SK; Schaid, DJ; Sinnwell, JP; Weinshilboum, RM; Wickerham, DL | 1 |
| Bell, LN; Desta, Z; Flockhart, DA; Hayes, DF; Henry, NL; Li, L; Nguyen, AT; Stearns, V; Storniolo, AM; Wolff, AC | 1 |
| Bastiaannet, E; de Craen, AJ; Hille, ET; Liefers, GJ; Meershoek-Klein Kranenbarg, EM; Paridaens, R; Putter, H; Seynaeve, CM; van de Velde, CJ; van de Water, W; Westendorp, RG | 1 |
| Peeters, PH; van Diest, PJ; Verkooijen, HM | 1 |
| Hozumi, Y; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takehara, M; Takei, H | 1 |
| Goss, PE; Liedke, PE | 1 |
| Bliss, JM; Coombes, RC; Mieog, JS; Morden, JP; van de Velde, CJ | 1 |
| Burstein, HJ; Griggs, JJ | 1 |
| Carro, G; Harper, A; Hui, W; Lawton, J; Menas, P; Merkel, D | 1 |
| Gabriel, EM; Jatoi, I | 1 |
| Cauley, JA | 1 |
| Bordeleau, L; Cardew, S; Cheung, AM; Demaras, A; Elser, C; Erlandson, M; Goss, PE; Hu, H; Ingle, J; Kapral, MK; Khosla, S; Lickley, L; Majumdar, S; Pruthi, S; Richardson, H; Robbins, J; Scher, J; Tile, L; Tomlinson, G | 1 |
| Bastiaannet, E; de Craen, AJ; Hadji, P; Hasenburg, A; Hille, ET; Jones, SE; Liefers, GJ; Markopoulos, C; Nortier, JW; Putter, H; Rea, D; Seynaeve, C; van de Velde, CJ; van de Water, W; Westendorp, RG | 1 |
| Bauer, T; Hadji, P; Hasenburg, A; Kauka, A; Kieback, DG; Tams, J | 1 |
| Azzouz, F; Desta, Z; Flockhart, DA; Hayden, J; Hayes, DF; Henry, NL; Lemler, S; Li, L; Nguyen, AT; Stearns, V; Storniolo, AM; Tarpinian, K; Yakim, E | 1 |
| Bliss, JM; Coombes, RC; Fallowfield, LJ; Kilburn, LS; Langridge, C; Snowdon, CF | 1 |
| Learman, LA | 1 |
| Layman, R; Li, X; Mrózek, E; Ottman, S; Ramaswamy, B; Schaaf, L; Shapiro, CL | 1 |
| de Haes, JC; Fontein, DB; Hille, ET; Nortier, JW; Putter, H; Seynaeve, C; van de Velde, CJ; van Leeuwen, FE; van Nes, JG; Voskuil, DW | 1 |
| Hadji, P; Hasenburg, A; Kieback, DG; Tams, J; Ziller, M | 1 |
| Decensi, A; Dunn, BK; Ford, LG; Gennari, A; Puntoni, M | 1 |
| Kim, SH; Lee, H; Lee, KS; Nam, BH; Park, IH; Ro, J | 1 |
| Allred, DC; Babiera, GV; Ballman, K; Bose, R; Chang, LW; Chen, K; Crowder, R; Demeter, R; DeSchryver, K; Ding, L; Dooling, DJ; Du, F; Elhammali, A; Ellis, MJ; Esserman, L; Fulton, LL; Fulton, RS; Goiffon, RJ; Goldstein, TC; Guenther, JM; Harris, CC; Harrison, M; Hoog, J; Hunt, K; Kandoth, C; Koboldt, DC; Leitch, M; Ley, TJ; Lin, L; Lu, C; Luo, J; Maher, CA; Marcom, PK; Mardis, ER; Margenthaler, J; McDonald, S; McLellan, MD; McMichael, JF; Miller, CA; Ng, S; Oberkfell, B; Olson, J; Ota, D; Piwnica-Worms, D; Piwnica-Worms, H; Schierding, WS; Shen, D; Snider, J; Stuart, JM; Suman, VJ; Tao, Y; Unzeitig, G; Van Tine, BA; Vickery, TL; Wallis, JW; Watson, M; Weber, J; Wendl, MC; Wilson, RK | 1 |
| Beaver, JA; Park, BH | 1 |
| Brooks, JD; Dickler, MN; Goldfarb, SB; Jozefara, JE; King, V; Morris, EA; Nulsen, BF; Pike, MC; Sung, JS | 1 |
| Kolesar, JM; Simondsen, K; Zhang, Y | 1 |
| Bartlett, JMS; Dirix, LY; Fontein, DBY; Gelderblom, H; Guchelaar, HJ; Hille, ETM; Houtsma, D; Meershoek-Klein Kranenbarg, E; Nortier, JWR; Paridaens, R; Putter, H; Seynaeve, C; van de Velde, CJH | 1 |
| Amaral, C; Borges, M; Correia-da-Silva, G; da Silva, ET; Melo, S; Teixeira, N | 1 |
| Bartlett, JM; Dirix, LY; Fontein, DB; Hille, ET; Kranenbarg, EM; Liefers, GJ; Nortier, JW; Paridaens, R; Putter, H; Robson, T; Roumen, RM; Seynaeve, C; van de Velde, CJ; van de Water, W; van Nes, JG | 1 |
| Hammersmith, KM; Nagra, PK; Nottage, JM; Rapuano, CJ; Turaka, K | 1 |
| Becker, M; Bossart, M; Hadji, P; Hasenburg, A; Kieback, DG | 1 |
| Bartlett, JM; Beck, RA; Bloom, KJ; Dirix, L; Hasenburg, A; Kieback, D; Lawton, TJ; Markopoulos, C; Piper, T; Putter, H; Rea, D; Ring, BZ; Ross, DT; Seitz, RS; Seynaeve, C; van de Velde, CJ | 1 |
| Bhargava, R; Brufsky, AM; Davidson, NE | 1 |
| Ensor, J; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Koenig, KB; Lee, MH; Moulder, SL; Murray, JL; Yeung, SC | 1 |
| Climent, MA; Folkerd, E; García, A; Gavilá, J; Guerrero, A; Guillem, V; Martínez, F; Ortiz, B; Ruíz, A | 1 |
| Belli, AK; Buckley, JM; Coopey, SB; Gadd, MA; Garber, JE; Guidi, AJ; Hughes, KS; Kim, EM; Mazzola, E; Parmigiani, G; Polubriaginof, F; Roche, CA; Sharko, J; Smith, BL; Specht, MC | 1 |
| Chen, S; Chu, P; Kanaya, N; Kubo, M; Liu, Z; Nishimura, R; Okido, M; Osako, T; Petrossian, K; Shimada, K; Takahashi, M; Warden, C; Ye, J; Yuan, YC | 1 |
| Bastiaannet, E; de Craen, AJ; Hasenburg, A; Hille, ET; Jones, SE; Liefers, GJ; Markopoulos, C; Paridaens, R; Putter, H; Rea, D; Seynaeve, C; van de Velde, CJ; van de Water, W; Westendorp, RG | 1 |
| Chan, MS; Chow, LW; Felizola, SJ; Loo, W; Sasano, H; Suzuki, T; Toi, M; Ueno, T; Wang, L | 1 |
| Du, YY; Hu, LX; Pan, YY; Zhang, Y | 1 |
| Glück, S; Untch, M; von Minckwitz, G | 1 |
| Ansari, RH; Budd, GT; Chalchal, H; Chapman, JA; D'Souza, DP; Elliott, C; Ellis, MJ; Gelmon, KA; Goss, PE; Ingle, JN; Johnson, DB; Lang, I; Liedke, PE; Perez, EA; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Spadafora, S; Stearns, V; Tozer, R | 1 |
| Tung, N | 1 |
| Goss, PE; Smith, RE | 1 |
| Dixon, JM | 2 |
| Assikis, VJ; Buzdar, A | 1 |
| Koyama, H; Miura, S; Nomura, Y; Tominaga, T; Tsuboi, M | 1 |
| Fujita, Y; Inaji, H; Kanda, K; Miura, S; Nishimura, R; Saeki, H; Saeki, T; Sano, M; Sono, H; Toi, M; Watanabe, T | 1 |
| Abe, R; Andou, J; Aoyama, H; Fujita, Y; Higashi, Y; Hirata, K; Kajiwara, T; Kanda, K; Kashiki, Y; Kimura, M; Kinoshita, H; Kitajima, M; Kobayashi, T; Kobayashi, Z; Koyama, H; Koyanagi, Y; Miura, S; Miyazaki, I; Monden, M; Morishita, Y; Nagao, K; Nomura, Y; Ogita, M; Oka, T; Satomi, S; Sonoo, H; Tabei, T; Takai, S; Takashima, S; Takatsuka, Y; Toge, T; Tominaga, K; Toyama, K; Watanabe, M; Watanabe, T; Yamaguchi, S; Yayoi, E; Yoshino, K | 1 |
| Dank, M | 1 |
| Brueggemeier, RW | 2 |
| Buzdar, AU; Eiermann, W; Nabholtz, JM; Robertson, JF | 1 |
| Higa, GM | 1 |
| Robertson, JF | 1 |
| Bajetta, E; Bombardieri, E; Buzzoni, R; Celio, L; Ferrari, L; Gattinoni, L; La Torre, I; Longarini, R; Martinetti, A; Seregni, E | 1 |
| Chen, SB; Feng, WJ; Hao, XS; Huang, P; Lin, MB; Ren, CC; Wang, HQ; Xiong, YQ; Yan, Z; Zhao, WH | 1 |
| Baum, M; Buzdar, A | 1 |
| Rocchi, A; Verma, S | 1 |
| Brodie, AH; Mouridsen, HT | 1 |
| Rose, C | 1 |
| Beex, L; Biganzoli, L; Cameron, D; Cufer, T; Dirix, L; Duchateau, L; Hamilton, A; Lobelle, JP; Lohrisch, C; Nooij, M; Paridaens, R; Piccart, M | 1 |
| Eckhardt, S | 1 |
| Gershanovich, M; Mouridsen, H | 1 |
| Fan, QX; Liu, JW; Liu, XQ; Qin, FZ; Ren, J; Song, SP; Song, ST; Wang, AL; Wang, TF; Wang, YJ; Xie, GR | 1 |
| Chow, LW; Toi, M; Wong, JL | 1 |
| Bhide, SA; Rea, DW | 1 |
| Atalay, G; Beex, L; Biganzoli, L; Cameron, D; Cufer, T; Dirix, L; Lobelle, JP; Lohrisch, C; Mattiaci, MR; Nooij, M; Paridaens, R; Piccart, M | 1 |
| Domont, J; Khayat, D; Namer, M; Spano, JP | 1 |
| Kawakami, M; Saji, S; Toi, M | 1 |
| Alvarez, I; Andersen, J; Bajetta, E; Bertelli, G; Bliss, JM; Carpentieri, M; Coates, AS; Cocconi, G; Coleman, RE; Coombes, RC; Delozier, T; Dodwell, D; Fallowfield, LJ; Gibson, LJ; Hall, E; Jassem, J; Jones, SE; Lønning, PE; Massimini, G; Mickiewicz, E; Ortmann, O; Paridaens, R; Snowdon, CF; Stewart, A; Stuart, N; van de Velde, C | 1 |
| Piccart-Gebhart, MJ | 1 |
| Asnis, AG; Duncan, B; Francis, D; Hortobagyi, GN; Rivera, E; Schaaf, LJ; Valero, V | 1 |
| Campos, SM | 1 |
| Armeanu, S; Fersis, N; Friedrich, M; Gagulic, E; Pantic, L; Relakis, K; Smyczek-Gargya, B; Wallwiener, D | 1 |
| Arora, A; Potter, JF | 1 |
| Chen, D; Hackl, W; Ortmann, O; Treeck, O | 1 |
| Clemons, M; Coleman, RE; Verma, S | 1 |
| Sainsbury, R | 1 |
| Kunkler, IH | 1 |
| De Neve, W; Vakaet, LA | 1 |
| Tanvetyanon, T | 1 |
| Aebi, S; Baumann, ChK | 1 |
| Chow, LW; Guan, XY; Loo, WT; Toi, M; Zhu, L | 1 |
| Mouridsen, HT | 2 |
| Altundag, K; Buzdar, AU; Hortobagyi, G; Morandi, P; Rouzier, R; Theriault, RL | 1 |
| Abou-Jawde, RM; Alemany, CA; Budd, GT; Choueiri, TK | 1 |
| Aoki, T; Kaise, H; Katsumata, K; Kusama, M; Nakayama, S; Ota, D | 1 |
| Brodie, AM; Goloubeva, OG; Handratta, V; Ingle, JN; Jelovac, D; Long, BJ; Macedo, L | 1 |
| Bessho, T; Hirai, I; Kinoshita, T; Kokawa, Y; Nishida, M; Nishimura, O; Okamura, Y; Oura, S; Sakurai, T; Sasaki, R; Tanino, H; Yokochi, H; Yoshimas, T | 1 |
| de Cremoux, P; Diéras, V; Fourquet, A; Magdelénat, H; Pierga, JY; Poupon, MF; Sigal-Zafrani, B | 1 |
| Fentiman, IS | 1 |
| Beex, L; Come, SE; Jones, SE; Kaufmann, M; Makris, A; Nortier, JW; Possinger, K; Robertson, JF; Rutqvist, LE | 1 |
| Clemons, MJ; Freedman, OC; Verma, S | 2 |
| Michaud, LB | 1 |
| Cleary, JF; Havighurst, TC; Hutson, PR; Love, RR | 1 |
| Ohtake, T; Okayama, H; Sagara, H; Takenoshita, S; Watanabe, K; Yasuda, M | 1 |
| Barash, NIu; Berstein, LM; Bozhok, AA; Dashian, GA; Ivanov, VG; Klemtsel', AA; Mel'nikova, OA; Paltuev, RM; Petrovskiĭ, SG; Semiglazov, VF; Semiglazov, VV; Tonuzov, EE; Zhil'tsova, EK | 1 |
| Suda, T | 1 |
| Jakesz, R | 1 |
| Caraglia, M; Cigolari, S; Colucci, G; Del Prete, S; Fanelli, F; Febbraro, A; Ferrari, E; Formato, R; Gebbia, V; Giotta, G; Iaffaioli, RV; Ianniello, G; Incoronato, P; Manzione, L; Marano, O; Marzano, N; Nasti, G; Pappagallo, G; Pedicini, T; Pezzella, G; Pisano, A; Pisconti, S; Pizza, C; Quattrin, S; Tortoriello, A | 1 |
| Bliss, JM; Coombes, RC; Hall, E | 1 |
| Delozier, T; Khayat, D; Spano, JP | 1 |
| Dodwell, D; Vergote, I | 1 |
| Ingle, JN; Suman, VJ | 1 |
| Bremnes, Y; Erikstein, B; Geisler, J; Hagen, AI; Krag, LE; Lien, EA; Lønning, PE; Massimini, G; Ofjord, ES; Paolini, J; Polli, A; Schlichting, E | 1 |
| Shapiro, CL | 1 |
| Anderson, TJ; Dixon, JM; Evans, D; Krause, A; Larionov, A; Miller, WR; Murray, J; White, S | 1 |
| Bafaloukos, D; Chrissochou, M; Gogas, H; Markopoulos, C; Michailidou, A; Misitzis, J; Papadiamantis, J; Tzoracoleftherakis, E; Xepapadakis, G; Zobolas, V | 1 |
| Chowdhury, S; Ellis, PA | 1 |
| Vogel, V | 1 |
| Gogas, H; Koukouras, D; Lappas, H; Markopoulos, C; Papadiamantis, J; Polychronis, A; Xepapadakis, G; Zobolas, V | 1 |
| Cruz Hernández, JJ; Navarro Martín, LM; Ocaña Fernández, A; Rodríguez Sánchez, CA; Ruiz Martín, I | 1 |
| Jiang, ZF; Song, ST | 1 |
| Pritchard, KI; Wong, NS | 1 |
| Esteva, FJ; Hortobagyi, GN | 1 |
| Bowman, A; Cameron, D; Coleman, R; Dunn, K; Kunkler, I; Leonard, R; Manifold, I; Purohit, O; Steele, N; Zekri, J | 1 |
| Dowsett, M; Johnston, SR; Martin, LA | 1 |
| Abram, P; Vergote, I | 1 |
| Hutchinson, L | 1 |
| Howell, A; Locker, GY | 1 |
| Cleary, JF; Havighurst, TC; Hutson, PR; Love, RR; Rogers, E | 1 |
| Cheung, AM; Goss, PE; Tomlinson, G | 1 |
| Mouridsen, HT; Robert, NJ | 1 |
| Bertelli, G; Bertolotti, L; Castiglione, F; Del Mastro, L; Fusco, O; Garrone, O; Leonard, RC; Merlano, M; Occelli, M; Pepi, F | 1 |
| Shan, ZZ; Shen, KW; Wang, LP | 1 |
| Bliss, JM; Coombes, RC; Fallowfield, LJ; Hall, E; Jones, SE; Porter, LS; Price, MH; Snowdon, CF | 1 |
| Cheng, CW; Chow, LW; Toi, M; Wong, JL | 1 |
| Gltick, S | 1 |
| Come, SE | 1 |
| Abrial, C; Cabrespine, A; Chollet, P; Cure, H; Durando, X; Ferriere, JP; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Penault-Llorca, F | 1 |
| Jones, SE | 2 |
| Grana, G | 1 |
| Geyer, H; Guddat, S; Haenelt, N; Koch, A; Kohler, M; Mareck, U; Opfermann, G; Schänzer, W; Thevis, M | 1 |
| Dowsett, M; Hayes, D; Lønning, PE; Santen, RJ; Smith, IE; Walsh, G; Yap, YS | 1 |
| Canorea, F; Del Castillo, A; Gil, JM; González, P; Rubio-Terrés, C | 1 |
| Brown, MM; Manquez, ME; Shields, CL; Shields, JA | 1 |
| Cadirni, A; Campagna, S; Francini, E; Francini, G; Gonnelli, S; Montagnani, A; Petrioli, R | 1 |
| Fricker, J | 1 |
| Dewar, R; Rayson, D; Skedgel, C; Younis, T | 2 |
| Cadirni, A; Caffarelli, C; Franci, MB; Francini, G; Gonnelli, S; Lucani, B; Montagnani, A; Nuti, R; Petrioli, R | 1 |
| Bundred, N | 1 |
| di Salle, E; Eide, GE; Geisler, J; Hagen, AI; Krag, LE; Lien, EA; Løkkevik, E; Lønning, PE; Ofjord, ES; Paolini, J; Polli, A; Risberg, T; Schlichting, E | 1 |
| Canney, PA; Curto, J; Machin, MA | 1 |
| Holmberg, S; Jönsson, L; Lundkvist, J; Wilking, N | 1 |
| Amant, F; Berteloot, P; Christiaens, MR; De Smet, L; Leunen, K; Morales, L; Neven, P; Pans, S; Paridaens, R; Smeets, A; Timmerman, D; Van den Bogaert, W; Van Limbergen, E; Vergote, I; Verhaeghe, J; Weltens, C; Westhovens, R; Wildiers, H | 1 |
| Chien, AJ; Goss, PE | 1 |
| Chu, QD; Li, BD; McDonald, JC | 1 |
| Suzuki, M | 1 |
| Inoue, K; Nagamoto, N; Ohsako, T; Tanaka, E; Yoshida, Y | 1 |
| Bria, E; Carlini, P; Cognetti, F; Giannarelli, D; Terzoli, E | 1 |
| Ellis, MJ; Rigden, CE | 1 |
| Bundred, NJ | 1 |
| Banks, LM; Bliss, JM; Cawthorn, SJ; Coleman, RE; Coombes, RC; Fox, J; Girgis, SI; Hall, E; Kilburn, LS; Patel, A; Snowdon, CF; Vrdoljak, E | 1 |
| Boccardo, F; Rubagotti, A | 1 |
| Alvarez, I; Andersen, J; Bajetta, E; Bertelli, G; Bliss, JM; Bogle, RG; Carpentieri, M; Castiglione, M; Coates, AS; Cocconi, G; Colajori, E; Coleman, RE; Coombes, RC; Del Mastro, L; Delozier, T; Diedrich, K; Dodwell, D; Fallowfield, LJ; Forbes, J; Hall, E; Holmberg, SB; Ireland, E; Jassem, J; Jones, SE; Kilburn, LS; Lønning, PE; Mickiewicz, E; Ortmann, O; Paridaens, R; Snowdon, CF; Stewart, A; Stuart, N; Subar, M; Van de Velde, CJ | 1 |
| Nortier, JW; Seynaeve, C; van de Velde, CJ; van Nes, JG | 1 |
| Beresford, MJ; Chin, YS; Makris, A; Ravichandran, D | 1 |
| Lian, ZQ; Yang, MT | 1 |
| Hou, KY; Ji, JF; Jia, TZ; Li, HP; Wang, MP; Wang, YF; Xiao, Y; Zhao, HM | 1 |
| Aapro, M; Cannon, H; Georgiou, V; Leto di Priolo, S; Wengström, Y | 1 |
| Alimonti, A; Bria, E; Carlini, P; Cognetti, F; Cresti, N; Di Cosimo, S; Fabi, A; Ferretti, G; Giannarelli, D; Michelotti, A; Milella, M; Papaldo, P; Pellegrini, M; Ricci, S; Ruggeri, EM; Salesi, N | 1 |
| Noda, S; Toji, E; Ueda, M | 1 |
| Atkins, CD | 1 |
| Berstein, LM; Bozhok, AA; Dashyan, GA; Ivanov, VG; Kletzel, A; Melnikova, OA; Paltuev, RM; Semiglazov, VF; Semiglazov, VV; Ziltsova, EK | 1 |
| Mittmann, N; Risebrough, NA; Trudeau, M; Verma, S | 1 |
| Carroll, C; De Nigris, E; Hind, D; Simpson, E; Ward, S; Wyld, L | 1 |
| Gallagher, J; Habin, K; Winters, L | 1 |
| Abreu, P; Banke-Bochita, J; Goss, PE; Hadji, P; Subar, M; Thomsen, T | 1 |
| Kamby, C; Lindberg, H; Nielsen, DL; Tuxen, M | 1 |
| Fabian, CJ | 1 |
| Perez, EA | 1 |
| Jahanzeb, M | 1 |
| Asmar, L; Blum, JL; Bordelon, JH; Brooks, R; Cantrell, J; Chittoor, S; Davis, JC; Hartung, NL; Holmes, FA; Ilegbodu, D; Jones, SE; Ketchel, SJ; Kochis, J; Negron, AG; O'Shaughnessy, J; Pippen, J; Richards, DA; Rivera, R; Vukelja, S; Whittaker, TL | 1 |
| Asnis, A; Borgen, P; Dang, C; Dickler, MN; Duncan, BA; Heerdt, A; Hudis, C; Lake, D; Moasser, M; Norton, L; Panageas, K; Poggesi, I; Robson, M; Traina, TA | 1 |
| Bershteĭn, LM; Bozhok, AA; Damenia, AO; Dashian, GA; Donskikh, RV; Ivanov, VG; Klettsel', AA; Kochetova, IA; Krivorot'ko, PV; Mel'nikova, OA; Paltuev, RM; Semiglazov, VF; Semiglazov, VV; Tonuzov, EE; Voskresenskiĭ, DA; Zernov, KIu; Zhil'tsova, EK | 1 |
| Dutta, U; Pant, K | 1 |
| Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N | 1 |
| Inoue, K; Koh, J; Kurosumi, M; Okubo, K; Saito, T; Sato, K; Suemasu, K; Tabei, T; Takei, H; Tsuda, H | 1 |
| Bundred, NJ; Iddon, J | 1 |
| Fridrik, M; Gnant, M; Greil, R; Jakesz, R; Luschin-Ebengreuth, G; Melbinger, E; Menzel, C; Mlineritsch, B; Ploner, F; Singer, C; Steger, G; Stierer, M; Tausch, C; Urbania, A; Wohlmuth, P | 1 |
| Eisen, A; Messersmith, H; Pritchard, KI; Shelley, W; Trudeau, M | 1 |
| Cuzick, J | 2 |
| Kapoor, S | 1 |
| Alés-Martinez, JE; Chlebowski, R; Goss, PE; Ingle, JN; Johnston, D; Maunsell, E; Richardson, H; Sarto, GE | 1 |
| Blackwell, KL; Herold, CI | 2 |
| Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Shiiki, S; Sonoo, H; Tanaka, K; Yamamoto, Y | 1 |
| Amant, F; Bines, J; Brufsky, A; Buzdar, A; Chia, S; Federico, M; Fein, L; Gradishar, W; Lowe, E; Mauriac, L; Piccart, M; Possinger, K; Rennie, P; Robertson, JF; Romieu, G; Sapunar, F | 1 |
| Burns, R; Come, SE; Farag, N | 1 |
| Abbattista, A; Bapsy, P; Carpentieri, M; Dirix, LY; Falcon, S; Gomez, H; Ignacio, J; Jones, S; Lobelle, JP; Nag, S; Paridaens, R; Raghunadharao, D | 1 |
| Castiglione-Gertsch, M; Coates, AS; Fleming, GF; Francis, P; Gelber, RD; Goldhirsch, A; Maibach, R; Pagani, O; Perez, EA; Price, KN; Regan, MM; Thürlimann, B; Torrisi, R; Walley, B | 1 |
| Bello, A; Buchan, P; Di Salle, E; Jannuzzo, MG; Pirotta, N; Spinelli, R | 1 |
| Atkins, JN; Costantino, JP; Eisen, A; Farrar, WB; Fehrenbacher, L; Ganz, PA; Geyer, CE; Hoehn, JL; Hutchins, LF; Ingle, JN; Jeong, JH; Kroener, JF; Land, SR; Mamounas, EP; Pajon, ER; Robidoux, A; Smith, RE; Vogel, VG; Wickerham, DL; Wolmark, N | 1 |
| Aapro, M | 1 |
| Borges, VF; Elias, AD; Finlayson, C; Harvell, DM; Horwitz, KB; Richer, JK; Singh, M; Spoelstra, N | 1 |
| Jassem, J | 2 |
| Jeong, JH | 1 |
| Chia, S; Gradishar, W | 1 |
| Pennery, E | 1 |
| Marshall, C; Thomas, R; Walker, L; Williams, M | 1 |
| Adrover, E; Barnadas, A; Calvo, L; de la Haba, J; Estevez, LG; Gil, M; Llombart, A; Sánchez-Rovira, P | 1 |
| Fields, MM; Mellington, TE | 1 |
| Gligorov, J; Nabholtz, JM | 1 |
| Chessa, F; Farris, A; Madeddu, G; Manca, A; Pittalis, M; Sanna, D; Spanu, A | 1 |
| Bajetta, E; Buzzoni, R; Di Bartolomeo, M; Di Leo, A; Laffranchi, A; Mariani, L; Martinetti, A; Noberasco, C; Orefice, S; Zilembo, N | 1 |
| Engan, T; Johannessen, DC; Krane, J; Kvinnsland, S; Lønning, PE | 1 |
| Artale, S; Bajetta, E; Bartoli, C; Buzzoni, R; Danesini, GM; Ferrari, L; Greco, M; Mariani, L; Martinetti, A; Noberasco, C; Paolini, J; Spagnoli, I; Zilembo, N | 1 |
| di Salle, E; Lønning, PE; Paridaens, R; Piscitelli, G; Thürlimann, B | 1 |
| Bonneterre, J; di Salle, E; Lanzalone, S; Murray, R; Paridaens, R; Piscitelli, G; Roché, H; Serin, D; Thürlimann, B; Zurlo, MG | 1 |
| Anker, G; Di Salle, E; Dowsett, M; Geisler, J; King, N; Lønning, PE; Ornati, G | 1 |
| Di Salle, E; Engan, T; Johannessen, DC; Kvinnsland, S; Lonning, PE; Ornati, G; Paolini, J; Piscitelli, G; Zurlo, MG | 1 |
| de Belder, K; di Salle, E; Lanzalone, S; Lobelle, JP; Ornati, G; Paridaens, R; Polli, A; Thomas, J; Vermeiren, P; Wildiers, J; Zurlo, MG | 1 |
| Anker, GB; Johannessen, DC; Lien, EA; Lonning, PE; Refsum, H; Ueland, PM | 1 |
| Blijham, GH; de Jong, PC | 1 |
| Arkhipov, A; Consonni, A; Cooper, B; di Salle, E; Eisenberg, P; Fehrenbacher, L; Honig, S; Jones, S; Miller, L; Polli, A; Tiffany, J; Vogel, C; Whaley, F | 1 |
| Scott, LJ; Wiseman, LR | 1 |
| Bonneterre, J; Feutrie, ML | 1 |
| Harvey, HA; Santen, RJ | 1 |
| Arkhipov, A; Bajetta, E; Cervek, J; di Salle, E; Dirix, LY; Dugardyn, JL; Fein, LE; Fowst, C; Jones, SE; Kaufmann, M; Massimini, G; Mennel, RG; Miller, LL; Nasurdi, C; Piscitelli, G; Polli, A; Zilembo, N | 2 |
| Bajetta, E; Bichisao, E; Pozzi, P; Toffolatti, L; Zilembo, N | 1 |
| Aaronson, NK; Arkhipov, A; Bajetta, E; Celio, L; di Salle, E; Eisenberg, PD; Fowst, C; Lønning, PE; Massimini, G; Mickiewicz, E; Mita, M; Murray, R; Pitt, P; Polli, A; Tubiana-Hulin, M | 1 |
| Clemett, D; Lamb, HM | 1 |
| Anker, G; Bonneterre, J; di Salle, E; Dirix, LY; Kvinnsland, S; Lobelle, JP; Mariani, O; Massimini, G; Polli, A; Prove, AM; Wilking, N | 1 |
| Perey, L | 1 |
| Sonoo, H | 1 |
| Attolico, M; Crucitta, E; De Lena, M; Lorusso, V; Mazzei, A; Sambiasi, D | 1 |
| Bajetta, E; Cervek, J; Di Salle, E; Dirix, LY; Fein, LE; Fowst, C; Jones, SE; Kaufmann, M; Massimini, G; Piscitelli, G; Polli, A | 1 |
| Buzdar, A | 1 |
| Cattel, F; Messori, A; Trippoli, S; Vaiani, M | 1 |
| Hillner, BE; Radice, D | 1 |
| Kerbrat, P; Lefeuvre, C | 1 |
| Nabholtz, JM | 1 |
| Mamounas, EP | 1 |
| Hamilton, A; Volm, M | 1 |
| Buzdar, A; Howell, A | 1 |
| Murray, R | 1 |
| Nabholtz, JM; Reese, DM | 1 |
| Bando, H; Saji, S; Toi, M | 1 |
| Dickler, MN; Norton, L | 1 |
| Dixon, JM; Miller, WR | 1 |
| Junker, A; Possinger, K; Wiedemann, GJ | 1 |
| Jönsson, B; Lindgren, P; Radice, D; Redaelli, A | 1 |
| Jones, SA; Jones, SE | 1 |
| Buzdar, A; Johnson, PE | 1 |
| Goss, PE | 1 |
| Beex, L; Biganzoli, L; Cufer, T; Dirix, L; Duchateau, L; Lobelle, JP; Lohrisch, C; Nooij, M; Paridaens, R; Piccart, M; Van Hoorebeeck, I | 1 |
| Soudon, J | 1 |
| Crucitta, E; De Lena, M; Fornier, MN; Locopo, N; Lorusso, V; Silvestris, N | 1 |
| Benedetto, C; De Nicola, B; Ferraris, F; Genta, F; Piccinno, R; Porpiglia, M; Vicelli, R | 1 |
| Lombardi, P | 1 |
175 review(s) available for aromasil and Breast Neoplasms
| Article | Year |
|---|---|
Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Female; Humans; Models, Molecular; Molecular Structure | 2015 |
An overview on Estrogen receptors signaling and its ligands in breast cancer.
Topics: Breast Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Humans; Ligands; Male; Receptors, Estrogen | 2022 |
Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogens; Female; Humans; Postmenopause | 2022 |
[Updates in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in 2021].
Topics: Aged; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Female; Humans; Imidazoles; Immune Checkpoint Inhibitors; Letrozole; Leuprolide; Oxazepines; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Progression-Free Survival; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Selective Estrogen Receptor Modulators | 2022 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Humans; Letrozole; Lipids; Network Meta-Analysis; Research Design; Tamoxifen; Toremifene | 2020 |
[Endocrine adjuvant treatment specific features for young breast cancer women].
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Goserelin; Humans; Luteolytic Agents; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Triptorelin Pamoate | 2019 |
Endocrine therapies in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, pretreated, advanced breast cancer: A network meta-analysis.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Fulvestrant; Humans; Neoplasm Grading; Network Meta-Analysis; Piperazines; Postmenopause; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2020 |
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Everolimus; Female; Humans; Mechanistic Target of Rapamycin Complex 1; Multicenter Studies as Topic; Neoplasm Metastasis; Patient Safety; Phosphatidylinositol 3-Kinases; Prospective Studies; Proto-Oncogene Proteins c-akt; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2020 |
Estrogen receptor-positive (ER
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Fadrozole; Female; Fulvestrant; Gene Expression; Humans; Molecular Targeted Therapy; Tamoxifen | 2020 |
Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Current advances in endocrine therapy options for premenopausal women with hormone receptor positive breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Premenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2017 |
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Network Meta-Analysis; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles | 2017 |
Personalized prevention in high risk individuals: Managing hormones and beyond.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Early Detection of Cancer; Female; Genes, BRCA1; Genes, BRCA2; Humans; Mammography; Middle Aged; Nitriles; Precision Medicine; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Tamoxifen; Triazoles | 2018 |
Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Tamoxifen | 2018 |
CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
Topics: Aminopyridines; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; ErbB Receptors; Everolimus; Female; Fulvestrant; Humans; Network Meta-Analysis; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; TOR Serine-Threonine Kinases | 2019 |
Efficacy and safety of adjuvant endocrine therapy in premenopausal patients with early-stage hormone receptor-positive breast cancer: A meta-analysis of randomized controlled trials.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Glucose Intolerance; Humans; Neoplasm Staging; Pharmacovigilance; Premenopause; Receptors, Estrogen; Tamoxifen; Treatment Outcome | 2019 |
Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Everolimus; Female; Humans; Postmenopause; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Secondary Prevention; Sirolimus; Treatment Outcome | 2013 |
Exemestane: one part of the chemopreventive spectrum for ER-positive breast cancer.
Topics: Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Humans; Receptors, Estrogen | 2013 |
Pharmacogenomics of endocrine therapy in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genome-Wide Association Study; Humans; Japan; Letrozole; Musculoskeletal Physiological Phenomena; Nitriles; Pharmacogenetics; Phenotype; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2013 |
Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Pharmacological; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Humans; Letrozole; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2013 |
Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial.
Topics: Adult; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase III as Topic; Everolimus; Exanthema; Female; Humans; Hyperglycemia; Pneumonia; Sirolimus; Stomatitis; Treatment Outcome | 2013 |
Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer.
Topics: Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Everolimus; Female; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Protein Kinase Inhibitors; Receptor, IGF Type 1; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Estradiol; Everolimus; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Outcome | 2014 |
The renaissance of endocrine therapy in breast cancer.
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Ovariectomy; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome | 2014 |
Aromatase inhibitors in the breast cancer clinic: focus on exemestane.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans | 2014 |
Current concepts in breast cancer chemoprevention.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Estrogen Antagonists; Estrogens; Female; Humans; Incidence; Nitriles; Postmenopause; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2014 |
[Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Randomized Controlled Trials as Topic; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
[Combination of exemestane and everolimus may produce toxic side effects: a new treatment option for metastatic hormone-sensitive breast cancer].
Topics: Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Everolimus; Fatigue; Female; Humans; Sirolimus | 2014 |
Aromatase inhibitors in breast cancer prevention.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Invasiveness; Nitriles; Postmenopause; Risk; Triazoles | 2014 |
Interaction of Salicylates and the Other Nonsteroidal Anti-Inflammatory Agents With Breast Cancer Endocrine Treatment: Systematic Review.
Topics: Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Aspirin; Breast Neoplasms; Celecoxib; Drug Synergism; Female; Humans; Salicylates; Tamoxifen | 2015 |
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Nitriles; Patient Selection; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Failure; Treatment Outcome; Triazoles | 2015 |
Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2015 |
Adjuvant systemic therapy in breast cancer: quo vadis?
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Mastectomy; Paclitaxel; Patient Selection; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Tamoxifen; Trastuzumab; Triple Negative Breast Neoplasms | 2015 |
Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2.
Topics: Age Factors; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Everolimus; Female; Humans; Multicenter Studies as Topic; Neoplasm Staging; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Everolimus; Female; Humans; Kaplan-Meier Estimate; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptors, Estrogen; Retreatment; Treatment Outcome | 2015 |
Anti-Hormonal Therapies for Premenopausal Patients--What did we Learn from the TEXT/SOFT Trials?
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Therapy, Combination; Estrogen Antagonists; Female; Humans; Multicenter Studies as Topic; Ovary; Premenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triptorelin Pamoate | 2015 |
Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Middle Aged; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Research Design; Signal Transduction; Triazoles | 2015 |
Are we ready to change clinical practice after the 'soft and text' results?
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Management; Female; Gonadotropin-Releasing Hormone; Humans; Multicenter Studies as Topic; Practice Patterns, Physicians'; Risk Factors; Treatment Outcome | 2015 |
Better Together: Targeted Combination Therapies in Breast Cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2015 |
[New options in adjuvant endocrine therapy in breast cancer].
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estrogen Antagonists; Estrogens; Female; Humans; Menopause; Receptors, Estrogen; Tamoxifen; Time Factors | 2016 |
[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Genetic Predisposition to Disease; Humans; Mastectomy; Mutation; Nitriles; Prophylactic Surgical Procedures; Raloxifene Hydrochloride; Tamoxifen; Triazoles | 2016 |
Alternate dosing schedules for cancer chemopreventive agents.
Topics: Administration, Oral; Androstadienes; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemoprevention; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Ki-67 Antigen; Preoperative Care; Risk Factors; Tamoxifen | 2016 |
Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Network Meta-Analysis; Nitriles; Postmenopause; Receptors, Estrogen; Treatment Outcome; Triazoles | 2016 |
Unravelling exemestane: From biology to clinical prospects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Autophagy; Biotransformation; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2016 |
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2016 |
Endocrine treatment in breast cancer: Cure, resistance and beyond.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Neoadjuvant Therapy; Piperazines; Pyridines; Receptors, Estrogen; Tamoxifen | 2016 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Trastuzumab; Triazoles | 2016 |
ADJUVANT (HORMONAL) THERAPY AS A CAUSE OF BONE LOSS IN PATIENTS WITH BREAST CANCER (REVIEW OF LITERATURE).
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Osteoporosis; Postmenopause; Premenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2017 |
Experience with exemestane in the treatment of early and advanced breast cancer.
Topics: Androstadienes; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neoplasm Metastasis | 2008 |
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Exemestane: a review of its use in postmenopausal women with breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Postmenopause | 2009 |
Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.
Topics: Anastrozole; Androstadienes; Animals; Breast Neoplasms; Disease Management; Early Detection of Cancer; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2009 |
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Estrogens; Female; Humans; Letrozole; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Pyrazoles; Randomized Controlled Trials as Topic; Recurrence; Salvage Therapy; Sulfonamides; Tamoxifen; Triazoles | 2010 |
Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2010 |
Exemestane in postmenopausal women with early or advanced breast cancer: a review.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Postmenopause | 2010 |
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Colorectal Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; RANK Ligand; Secondary Prevention; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies.
Topics: Androstadienes; Antineoplastic Agents; Belgium; Bone Density; Bone Remodeling; Breast Neoplasms; Female; Germany; Hip; Humans; Lumbar Vertebrae; Middle Aged; Netherlands; Randomized Controlled Trials as Topic; Tamoxifen; United States | 2011 |
When to start an aromatase inhibitor: now or later?
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2011 |
Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2011 |
Drug safety evaluation of exemestane.
Topics: Androstadienes; Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans | 2011 |
Preventive therapy for breast cancer: a consensus statement.
Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Consensus Development Conferences as Topic; Diphosphonates; Estrogen Receptor Modulators; Expert Testimony; Female; Fenretinide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Nitriles; Norpregnenes; Piperidines; Premenopause; Pyrrolidines; Raloxifene Hydrochloride; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Triazoles | 2011 |
Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis.
Topics: Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Retrospective Studies; Vasculitis, Leukocytoclastic, Cutaneous | 2011 |
[Aromatase inhibitors and arthralgia].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Medication Adherence; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Risk Factors; Triazoles | 2011 |
Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Letrozole; Nitriles; Postmenopause; Survival Analysis; Triazoles | 2011 |
Management of patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease Management; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles | 2011 |
Initialization of adjuvant hormonal treatment for breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Early Detection of Cancer; Female; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Premenopause; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Breast cancer chemoprevention.
Topics: Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen | 2012 |
Exemestane for breast cancer prevention: a critical shift?
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Risk Factors | 2012 |
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; Disease Management; Disease Progression; Drug Therapy, Combination; Female; Geriatric Assessment; Health Status; Humans; Letrozole; Life Expectancy; Nitriles; Prognosis; Quality of Life; Treatment Outcome; Triazoles | 2013 |
Letrozole for the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Tolerance; Estrogen Receptor Modulators; Estrogens; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Postmenopause; Progestins; Receptors, Estrogen; Treatment Outcome; Triazoles | 2002 |
Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Tolerance; Female; Humans | 2002 |
Recent advances in aromatase inhibitor therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Premenopause; Triazoles | 2002 |
The role of aromasin in the hormonal therapy of breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans | 2002 |
Overview of the pharmacology of the aromatase inactivator exemestane.
Topics: Adult; Aged; Androstadienes; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Middle Aged; Postmenopause; Receptors, Estrogen | 2002 |
The role of aromatase inactivators in the treatment of breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans | 2002 |
New generation aromatase inhibitors--from the advanced to the adjuvant setting.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2002 |
An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2002 |
Exemestane: treatment of breast cancer with selective inactivation of aromatase.
Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Interactions; Female; Humans | 2002 |
Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Female; Humans; Letrozole; Lipids; Nitriles; Postmenopause; Triazoles | 2003 |
The current status of aromatase inhibitors in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2003 |
Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays | 2003 |
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
[Perspectives for the hormonal therapy of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Toremifene; Triazoles | 2003 |
The role of aromatase inhibitors in the treatment of metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Triazoles | 2003 |
Aromatase inhibitors in breast cancer therapy.
Topics: Anastrozole; Androstadienes; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Triazoles | 2003 |
[Neoadjuvant endocrine therapy for breast cancer: an overview].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Tamoxifen; Triazoles | 2004 |
Exemestane and aromatase inhibitors in the management of advanced breast cancer.
Topics: Administration, Oral; Androstadienes; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; United Kingdom | 2004 |
[Controversies in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogen Replacement Therapy; Female; Humans; Letrozole; Mastectomy, Segmental; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors for breast cancer in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Drug Interactions; Economics, Pharmaceutical; Female; Forecasting; Geriatrics; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Patient Selection; Postmenopause; Practice Patterns, Physicians'; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles; United States; United States Food and Drug Administration | 2004 |
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
[Aromatase inhibitors in the adjuvant therapy of breast carcinomas].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Patient Care Management; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Current developments in hormonal therapy of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2004 |
Role of aromatase inhibitors in the treatment of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2004 |
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Letrozole; Menopause; Neoplasms, Hormone-Dependent; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors and breast cancer: time for a change?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Letrozole; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Nitriles; Postmenopause; Quinazolines; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Exemestane for breast cancer prevention: a feasible strategy?
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Postmenopause; Risk Factors | 2005 |
Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Evidence-Based Medicine; Female; Humans; Letrozole; Mastectomy, Segmental; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
Aromatase inhibitors in advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2004 |
Aromatase inhibition: translation into a successful therapeutic approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogens; Female; Humans; Letrozole; Molecular Structure; Nitriles; Triazoles | 2005 |
[Aromatase inhibitors in adjuvant setting in breast cancer].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Menopause; Nitriles; Triazoles | 2004 |
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
Aromatase inhibitors for therapy of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Evaluation; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Recent advances in the use of aromatase inhibitors for women with postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Triazoles | 2005 |
Chemoprevention in breast cancer.
Topics: Age Factors; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Lobular; Female; Humans; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen | 2005 |
A review of exemestane in the management of breast cancer.
Topics: Administration, Oral; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Megestrol Acetate; Multicenter Studies as Topic; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome | 2005 |
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Lipids; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Risk Factors; Tamoxifen; Triazoles; Triglycerides | 2006 |
Life following aromatase inhibitors--where now for endocrine sequencing?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2005 |
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Joint Diseases; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Neoplasm Staging; Nitriles; Research Design; Tamoxifen; Triazoles | 2005 |
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Triazoles | 2005 |
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Pre-menopausal breast cancer and aromatase inhibitors: Treating a new generation of women.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Therapy; Estrogens; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2006 |
The evolving role of exemestane in the management of breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Female; Humans; Treatment Outcome | 2006 |
Update on the use of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Androstadienes; Animals; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2006 |
Aromatase inhibitors and bone health in women with breast cancer.
Topics: Absorptiometry, Photon; Algorithms; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Remodeling; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Life Style; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Population Surveillance; Risk Factors; Triazoles | 2006 |
Adjuvant therapy for patients who have node-positive breast cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lymphatic Metastasis; Middle Aged; Nitriles; Postmenopause; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
[Advancement in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2007 |
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2007 |
Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Monitoring; Female; Humans; Musculoskeletal Diseases; Nitriles; Nurse's Role; Nursing Assessment; Nursing Research; Oncology Nursing; Pain; Pain Management; Pain Measurement; Patient Care Planning; Patient Education as Topic; Patient Selection; Postmenopause; Quality of Life; Receptors, Estrogen; Treatment Outcome; Triazoles | 2007 |
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Drug Resistance; Female; Humans; Letrozole; Musculoskeletal Diseases; Nitriles; Postmenopause; Premenopause; Tamoxifen; Thromboembolism; Triazoles | 2007 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Causality; Chemotherapy, Adjuvant; Comorbidity; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Incidence; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Osteoporosis; Rats; Survival Analysis; Tamoxifen; Triazoles | 2007 |
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Postmenopause; Practice Guidelines as Topic; Quality of Life; Risk Assessment; Secondary Prevention; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Aromatase inhibitors: past, present and future in breast cancer therapy.
Topics: Aminoglutethimide; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Fadrozole; Female; Humans; Letrozole; Nitriles; Triazoles | 2008 |
To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasms, Hormone-Dependent; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2008 |
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Evidence-Based Medicine; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Statistical analysis in cancer clinical trials.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Data Interpretation, Statistical; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Postmenopause; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Randomized Controlled Trials as Topic; Receptors, Estrogen | 2008 |
Aromatase inhibitors in early breast-cancer treatment: The story so far.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Triazoles | 2008 |
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse Clinicians; Nurse Practitioners; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Receptors, Estrogen; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2008 |
Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Forecasting; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Patient Selection; Postmenopause; Tamoxifen; Triazoles | 2008 |
Targeting breast cancer with hormonal treatment options.
Topics: Aftercare; Ambulatory Care; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor Modulators; Humans; Information Services; Internet; Letrozole; Nitriles; Nurse Practitioners; Patient Selection; Postmenopause; Practice Guidelines as Topic; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Exemestane experience in breast cancer treatment.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Treatment Outcome | 1997 |
Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
Topics: Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Neoplasms, Hormone-Dependent; Postmenopause | 1998 |
New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Triazoles | 1999 |
Exemestane.
Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Postmenopause | 1999 |
[Aromatase inhibitors].
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Estrogen Antagonists; Estrone; Female; Humans; Letrozole; Nitriles; Triazoles | 1999 |
Use of aromatase inhibitors in breast carcinoma.
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Tamoxifen; Triazoles | 1999 |
Steroidal aromatase inhibitors in elderly patients.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2000 |
Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Postmenopause; Quality of Life | 2000 |
[Aromatase inhibitors for treatment of advanced breast cancers].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Fadrozole; Female; Humans; Letrozole; Nitriles; Treatment Outcome; Triazoles | 2000 |
New aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2000 |
Irreversible aromatase inactivation: treatment for breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Randomized Controlled Trials as Topic | 2000 |
Pharmacology and clinical experience with exemestane.
Topics: Androstadienes; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Estrogens; Humans | 2000 |
Exemestane in advanced breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Tolerance; Enzyme Inhibitors; Female; Humans; Postmenopause | 2000 |
Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol; Neoplasm Metastasis; Nitriles; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles | 2000 |
[Aromatase inhibitors: a review of clinical trials].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2000 |
Adjuvant exemestane therapy after 5 years of tamoxifen: rationale for the NSABP B-33 trial.
Topics: Androstadienes; Breast Neoplasms; Female; Humans; Meta-Analysis as Topic; Tamoxifen; Time Factors | 2001 |
Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2001 |
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.
Topics: Anastrozole; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Fadrozole; Female; Headache; Humans; Letrozole; Nausea; Nitriles; Treatment Outcome; Triazoles; Vomiting | 2001 |
Role of anti-aromatase agents in postmenopausal advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2001 |
Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Aromatase and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Survival Analysis; Treatment Outcome; Triazoles | 2001 |
A summary of second-line randomized studies of aromatase inhibitors.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Tolerance; Enzyme Inhibitors; Estrogen Receptor Modulators; Fadrozole; Female; Humans; Letrozole; Megestrol Acetate; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2001 |
Exemestane: a novel aromatase inactivator for breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans | 2000 |
Are differences in the available aromatase inhibitors and inactivators significant?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2001 |
Preliminary data from ongoing adjuvant aromatase inhibitor trials.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 2001 |
Exemestane in breast cancer: current status and future directions.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Survival Analysis | 2000 |
Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review).
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Neoplasm Metastasis | 2002 |
Antiaromatase agents: evolving role in adjuvant therapy.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
[The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile].
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Follow-Up Studies; Forecasting; Humans; Letrozole; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Triazoles | 2002 |
Exemestane, a new steroidal aromatase inhibitor of clinical relevance.
Topics: Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Receptor Modulators; Estrogens; Female; Humans; Neoplasms, Hormone-Dependent | 2002 |
227 trial(s) available for aromasil and Breast Neoplasms
| Article | Year |
|---|---|
Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.
Topics: Acetylation; Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Breast Neoplasms; Female; Histone Deacetylase Inhibitors; Humans; Hypophosphatemia; Japan; Lymphocyte Activation; Middle Aged; Nausea; Platelet Count; Progression-Free Survival; Pyridines | 2021 |
A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC).
Topics: Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorocarbons; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Receptor, Notch3; Receptors, Notch | 2022 |
Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Estrogen Receptor alpha; Female; Humans; Lysine; Neoplasm Recurrence, Local; Receptors, Estrogen | 2023 |
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical
Topics: Anastrozole; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Letrozole; Mastectomy; Neoadjuvant Therapy; Postmenopause; Receptors, Estrogen | 2023 |
Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; East Asian People; Estrogens; Female; Fulvestrant; Humans; Postmenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen | 2023 |
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Topics: Androstadienes; Breast Neoplasms; Everolimus; Female; Humans | 2023 |
Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Receptors, Estrogen; Vascular Endothelial Growth Factor A | 2023 |
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Drug Therapy, Combination; Female; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Middle Aged; Neoplasm Metastasis; Piperazines; Prognosis; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2019 |
Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Estradiol; Estrogens; Female; Humans; Letrozole; MCF-7 Cells; Middle Aged; Neoadjuvant Therapy; Postmenopause | 2020 |
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Everolimus; Female; Humans; Incidence; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen | 2020 |
Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, H
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cross-Over Studies; Estrogen Receptor alpha; Everolimus; Female; Humans; Middle Aged; Patient Preference; Prognosis; Quality of Life; Receptor, ErbB-2; Receptors, Progesterone; Survival Rate; Treatment Outcome | 2020 |
PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Middle Aged; Phosphatidylinositol 3-Kinases; Progression-Free Survival; Signal Transduction | 2020 |
Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
Topics: Acrylamides; Adolescent; Adult; Aged; Aged, 80 and over; Aminoquinolines; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab; Young Adult | 2020 |
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Double-Blind Method; Female; Follow-Up Studies; Humans; Middle Aged; Nitriles; Phenylthiohydantoin; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2020 |
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Everolimus; Female; Follow-Up Studies; Humans; Japan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oral Health; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Stomatitis; Survival Rate | 2021 |
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease Management; Everolimus; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2021 |
The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival.
Topics: Adult; Alleles; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estrogen Receptor alpha; Female; Humans; Middle Aged; Polymorphism, Single Nucleotide; Prognosis | 2021 |
Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circulating Tumor DNA; DNA Mutational Analysis; Everolimus; Female; Humans; Letrozole; Middle Aged; Mutation; Neoplasm Proteins; Piperazines; Pyridines | 2021 |
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer.
Topics: Anastrozole; Androstadienes; Antigens, CD; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Epithelial-Mesenchymal Transition; Female; Humans; Lectins, C-Type; Minor Histocompatibility Antigens; Neoplasm Staging; Patient Selection; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Treatment Outcome | 2021 |
Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Postmenopause | 2021 |
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Breast Neoplasms, Male; Double-Blind Method; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Male; Middle Aged; Progression-Free Survival; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; South Africa; Time Factors; United States | 2021 |
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Topics: Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Disease Progression; Estrogen Receptor Antagonists; Europe; Female; Fulvestrant; Health Status; Humans; Israel; Neoplasm Metastasis; Patient Reported Outcome Measures; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quality of Life; Time Factors | 2021 |
Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
Topics: Administration, Topical; Aged; Androstadienes; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Drug Eruptions; Dyspnea; Everolimus; Female; Humans; Hyperglycemia; Middle Aged; Mouthwashes; Neoplasm Metastasis; Pneumonia; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Severity of Illness Index; Stomatitis | 2017 |
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Receptors, Estrogen; Sirolimus; Stomatitis | 2017 |
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Italy; Middle Aged; Neoplasm Metastasis | 2017 |
Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Estradiol; Female; Humans; Letrozole; Middle Aged; Nitriles; Patient Reported Outcome Measures; Prospective Studies; Random Allocation; Treatment Outcome; Triazoles | 2017 |
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Humans; Male; Mastectomy; Middle Aged; Multivariate Analysis; Nitriles; Osteoporosis, Postmenopausal; Proportional Hazards Models; Radiotherapy, Adjuvant; Receptors, Estrogen; Treatment Outcome; Triazoles | 2017 |
Long-Term Follow-Up of the Intergroup Exemestane Study.
Topics: Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Receptors, Estrogen; Survival Rate; Tamoxifen; Time Factors | 2017 |
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Retreatment; Sirolimus; Treatment Outcome | 2017 |
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mastectomy; Middle Aged; Postmenopause; Tamoxifen; Time Factors; Treatment Outcome | 2017 |
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Glucose; Body Mass Index; Breast Neoplasms; Everolimus; Fasting; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Prognosis; Treatment Outcome | 2017 |
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Safety; Survival Rate | 2018 |
Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast; Breast Neoplasms; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Postmenopause; Progression-Free Survival; Receptors, Estrogen; Receptors, Progesterone; T-Lymphocytes, Regulatory | 2018 |
Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Female; Genetic Predisposition to Disease; Humans; Interleukin-1beta; Mastectomy; Middle Aged; Polymorphism, Single Nucleotide; Receptors, Calcitriol; Vitamin D | 2018 |
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Time Factors | 2018 |
Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease-Free Survival; Female; Humans; Middle Aged; Nitriles; Treatment Outcome; Triazoles | 2018 |
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2018 |
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study.
Topics: Androstadienes; Breast Neoplasms; Female; Humans; Neoplastic Cells, Circulating; Postmenopause; Tamoxifen | 2018 |
Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2018 |
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Premenopause; Receptor, ErbB-2; Tamoxifen; Young Adult | 2018 |
Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial.
Topics: Age Factors; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cause of Death; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen | 2018 |
Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Biomarkers, Pharmacological; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Immunohistochemistry; Middle Aged; Postmenopause; Prognosis; Retrospective Studies; Tamoxifen; Treatment Outcome | 2018 |
Long-term effect of exemestane therapy on bone mineral density supported by bisphosphonates: Results of 5-year adjuvant treatment in postmenopausal women with early-stage breast cancer.
Topics: Aged; Androstadienes; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Middle Aged; Osteoporosis; Postmenopause | 2018 |
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Everolimus; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Overweight; Postmenopause; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2019 |
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
Topics: Absorptiometry, Photon; Adult; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ibandronic Acid; Letrozole; Middle Aged; Single-Blind Method | 2019 |
Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Everolimus; Female; Follow-Up Studies; Humans; International Agencies; Middle Aged; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate | 2019 |
Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.
Topics: Aged; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aromatase; Breast Neoplasms; Celecoxib; Female; Genetic Variation; Glucuronosyltransferase; Humans; Middle Aged; Minor Histocompatibility Antigens; Polymorphism, Single Nucleotide; Postmenopause; Prognosis | 2020 |
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aminopyridines; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Breast Neoplasms; Double-Blind Method; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Salvage Therapy; Survival Rate; Treatment Outcome | 2019 |
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).
Topics: Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Fulvestrant; Humans; Neoplasm Metastasis; Prognosis; Thymidine Kinase | 2019 |
Effects of
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogens; Female; Genotype; Humans; Letrozole; Liver-Specific Organic Anion Transporter 1; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Tamoxifen | 2019 |
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Quality of Life; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.
Topics: Aged; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Postmenopause; Receptor, ErbB-2 | 2013 |
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
Topics: Aged; Alkaline Phosphatase; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Breast Neoplasms; Collagen Type I; Confounding Factors, Epidemiologic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Middle Aged; Odds Ratio; Osteogenesis; Postmenopause; Procollagen; Proportional Hazards Models; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome | 2013 |
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Drug Administration Schedule; Everolimus; Female; Health Status; Humans; Middle Aged; Odds Ratio; Postmenopause; Proportional Hazards Models; Quality of Life; Sirolimus; Surveys and Questionnaires; Treatment Outcome | 2013 |
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Female; Humans; Introns; Letrozole; Middle Aged; Models, Genetic; Multivariate Analysis; Nitriles; Polymorphism, Single Nucleotide; Prospective Studies; Treatment Failure; Triazoles | 2013 |
Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: a randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Postmenopause; Receptors, Estrogen; Time Factors | 2013 |
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromata
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postmenopause; Pyridines; Receptors, Estrogen | 2013 |
Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prognosis; Receptors, Estrogen; Survival Rate; Toremifene | 2013 |
A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone and Bones; Breast Neoplasms; Female; Humans; Japan; Lipids; Middle Aged; Neoplasm Grading; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2013 |
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Everolimus; Female; Health Status; Humans; Immunosuppressive Agents; Middle Aged; Placebos; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Surveys and Questionnaires; Treatment Outcome | 2013 |
Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; International Cooperation; Mastectomy, Segmental; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Postmenopause; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Reference Values; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome | 2013 |
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogens; Female; Humans; Letrozole; Mammography; Middle Aged; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Prospective Studies; Triazoles | 2013 |
Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Middle Aged; Molecular Sequence Data; Prognosis; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Tissue Array Analysis | 2013 |
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ovariectomy; Ovary; Premenopause; Research Design; Statistics as Topic; Tamoxifen; Triptorelin Pamoate | 2013 |
Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.
Topics: Aged; Androstadienes; Breast Neoplasms; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Receptor, ErbB-2; Receptors, Progesterone; Treatment Outcome | 2014 |
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Everolimus; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Outcome | 2013 |
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; International Agencies; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Safety; Sirolimus; Survival Rate | 2013 |
Effect of prior chemotherapy regimens on the efficacy of endocrine therapy within a German cohort of the TEAM trial.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Postmenopause; Retrospective Studies; Survival Rate; Tamoxifen | 2014 |
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Receptors, Progesterone; Sirolimus | 2014 |
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bones of Lower Extremity; Breast Neoplasms; Calcium; Canada; Chemotherapy, Adjuvant; Dietary Supplements; Diphosphonates; Female; Fractures, Bone; Humans; Lumbar Vertebrae; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Radiography; Time Factors; Treatment Outcome; Triazoles; United States; Vitamin D | 2014 |
External validity of a trial comprised of elderly patients with hormone receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Kaplan-Meier Estimate; Netherlands; Odds Ratio; Receptors, Estrogen; Receptors, Progesterone; Registries; Reproducibility of Results; Tamoxifen; Treatment Outcome | 2014 |
Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Topics: Androstadienes; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Nitriles; Postmenopause; Protein Kinase Inhibitors; Quinolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2014 |
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Postmenopause; Quality of Life; Surveys and Questionnaires | 2014 |
Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Prospective Studies; Surveys and Questionnaires; Survival Analysis; Treatment Outcome; Triazoles | 2014 |
Physical activity and survival of postmenopausal, hormone receptor-positive breast cancer patients: results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Exercise; Female; Follow-Up Studies; Humans; Life Style; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen | 2014 |
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Celecoxib; Cohort Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prognosis; Pyrazoles; Sulfonamides; Survival Analysis | 2014 |
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estradiol; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Osteoporosis; Premenopause; Quality of Life; Tamoxifen; Triptorelin Pamoate | 2014 |
Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Postmenopause; Receptors, Estrogen; Sentinel Lymph Node Biopsy | 2014 |
Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Thiocarbamates; Treatment Outcome | 2014 |
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.
Topics: Aged; Anastrozole; Androstadienes; Anxiety; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Depression; Electroacupuncture; Fatigue; Female; Humans; Letrozole; Middle Aged; Nitriles; Quality of Life; Sleep Wake Disorders; Stress, Psychological; Treatment Outcome; Triazoles | 2014 |
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
Topics: Androstadienes; Breast Neoplasms; Double-Blind Method; ErbB Receptors; Everolimus; Female; Humans; Placebos; Sirolimus; Survival Analysis | 2014 |
A pilot study of estradiol followed by exemestane for reversing endocrine resistance in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Pilot Projects; Postmenopause; Receptors, Estrogen; Treatment Outcome | 2014 |
Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Breast Density; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Antagonists; Female; Humans; Mammary Glands, Human; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Radiography; Tamoxifen; Treatment Outcome | 2015 |
Adjuvant ovarian suppression in premenopausal breast cancer.
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Mastectomy; Middle Aged; Premenopause; Tamoxifen | 2015 |
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Hot Flashes; Humans; Kaplan-Meier Estimate; Middle Aged; Musculoskeletal System; Nitriles; Triazoles; Vasomotor System | 2015 |
Does patient education work in breast cancer? Final results from the global CARIATIDE study.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Patient Compliance; Patient Education as Topic; Tamoxifen; Triazoles | 2015 |
[Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2].
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Everolimus; Female; Humans; Middle Aged; Postmenopause; Receptors, Estrogen; Sirolimus | 2015 |
Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Electroretinography; Evoked Potentials, Visual; Female; Humans; Letrozole; Middle Aged; Nerve Fibers; Nitriles; Optic Nerve; Retina; Tomography, Optical Coherence; Triazoles; Visual Acuity | 2016 |
The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Forkhead Transcription Factors; Histocompatibility Antigens Class I; HLA-E Antigens; HLA-G Antigens; Humans; Immunophenotyping; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Prognosis; Receptors, Estrogen; T-Lymphocytes, Regulatory; Tamoxifen | 2015 |
Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.
Topics: Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estrogen Receptor beta; Female; Humans; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Tamoxifen; Treatment Outcome | 2015 |
Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer.
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Goserelin; Humans; Middle Aged; Premenopause; Treatment Outcome | 2015 |
A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition Disorders; Female; Humans; Letrozole; Memory; Middle Aged; Nitriles; Postmenopause; Psychomotor Performance; Quality of Life; Tamoxifen; Triazoles | 2015 |
[BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Doxorubicin; Everolimus; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Nitriles; Paclitaxel; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Triazoles | 2015 |
Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Postmenopause; Proportional Hazards Models; Receptors, Estrogen; Treatment Outcome | 2016 |
Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial.
Topics: Algorithms; Androstadienes; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorescent Antibody Technique; Humans; Image Interpretation, Computer-Assisted; Immunohistochemistry; Kaplan-Meier Estimate; Prognosis; Tamoxifen; Treatment Outcome | 2016 |
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Estradiol; Estrogens; Estrone; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Ovary; Tamoxifen; Triptorelin Pamoate | 2016 |
Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety.
Topics: Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor; Bone Density; Breast Density; Breast Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lipids; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Postmenopause; Prognosis; Quality of Life; Risk Factors | 2016 |
A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Estrogen Receptor alpha; Female; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2 | 2016 |
A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients.
Topics: Aged; Androstadienes; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Celecoxib; Cell Proliferation; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Postmenopause | 2016 |
Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy.
Topics: Aged; Androstadienes; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Microtubule-Associated Proteins; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis | 2016 |
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cause of Death; Chemotherapy, Adjuvant; Comorbidity; Female; Humans; Middle Aged; Nitriles; Postmenopause; Survival Analysis; Treatment Outcome; Triazoles | 2016 |
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lymphatic Metastasis; Ovary; Premenopause; Quality of Life; Self Report; Tamoxifen; Triptorelin Pamoate | 2016 |
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Middle Aged; Neoplastic Cells, Circulating; Postmenopause; Receptors, Androgen; Receptors, Estrogen; Steroid 17-alpha-Hydroxylase | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; DNA, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Piperazines; Prospective Studies; Pyridines; Retrospective Studies; Triazoles | 2016 |
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, e
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Everolimus; Female; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus | 2016 |
Evaluation of oral care to prevent oral mucositis in estrogen receptor-positive metastatic breast cancer patients treated with everolimus (Oral Care-BC): randomized controlled phase III trial.
Topics: Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Everolimus; Female; Humans; Middle Aged; Receptors, Estrogen; Severity of Illness Index; Sodium Chloride; Stomatitis | 2016 |
Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2017 |
Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04).
Topics: Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Arthralgia; Arthritis; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease-Free Survival; Female; Hot Flashes; Humans; Joint Diseases; Logistic Models; Magnetic Resonance Imaging; Mammography; Mastectomy; Middle Aged; Multivariate Analysis; Musculoskeletal Diseases; Myalgia; Neoadjuvant Therapy; Odds Ratio; Osteoporosis; Postmenopause; Prognosis; Receptors, Estrogen; Treatment Outcome; Ultrasonography, Mammary; Vasomotor System | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Decision-Making; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Mitotic Index; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Transcriptome; Triazoles | 2017 |
Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Female; Humans; Menopause; Middle Aged; Patient Compliance; Patient Dropouts; Quality of Life; Surveys and Questionnaires | 2017 |
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell-Free System; Class I Phosphatidylinositol 3-Kinases; DNA Mutational Analysis; DNA, Neoplasm; Everolimus; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Mutation; Neoplasm Metastasis; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2017 |
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Cholesterol; Cyclooxygenase 2 Inhibitors; Female; Humans; Lipids; Middle Aged; Neoadjuvant Therapy; Postmenopause; Pyrazoles; Sulfonamides; Treatment Outcome; Tumor Burden | 2008 |
Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy.
Topics: Adenocarcinoma; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Female; Greece; Humans; Lipid Metabolism; Lipids; Postmenopause; Tamoxifen | 2009 |
Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Receptors, Estrogen | 2008 |
Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Cross-Sectional Studies; Cyclophosphamide; Depression; Doxorubicin; Fatigue; Female; Humans; Middle Aged; Postmenopause; Prospective Studies; Quality of Life; Tamoxifen | 2009 |
Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Humans; Lymphatic Metastasis; Middle Aged; Postmenopause; Soft Tissue Neoplasms; Tamoxifen; Treatment Outcome | 2008 |
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Celecoxib; Chemotherapy, Adjuvant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Postmenopause; Prognosis; Pyrazoles; Soft Tissue Neoplasms; Sulfonamides; Survival Rate; Treatment Outcome | 2009 |
Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Middle Aged; Viscera | 2009 |
The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer.
Topics: Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Body Composition; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Estrogen Receptor Modulators; Female; Humans; Lipids; Middle Aged; Postmenopause; Single-Blind Method; Tamoxifen; Treatment Outcome; Triglycerides | 2008 |
The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Middle Aged; Osteoporosis; Postmenopause; Tamoxifen | 2008 |
Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Treatment Outcome | 2009 |
Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Disease Progression; Female; Humans; Middle Aged; Postmenopause; Receptors, Estrogen; Survival Analysis | 2009 |
Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Postmenopause; Prospective Studies; Tamoxifen; Treatment Outcome | 2009 |
A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Brain Neoplasms; Breast Neoplasms; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nitriles; Pilot Projects; Postmenopause; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Triazoles | 2009 |
The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
Topics: Alkaline Phosphatase; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Collagen Type I; Female; Follow-Up Studies; Humans; Middle Aged; Osteocalcin; Peptides; Tamoxifen; Time Factors; Treatment Outcome | 2009 |
Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy.
Topics: Adult; Aged; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Enzyme Inhibitors; Female; Humans; Lipids; Middle Aged; Postmenopause; Steroids; Tamoxifen | 2009 |
Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Double-Blind Method; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; International Agencies; Middle Aged; Postmenopause; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome; Ultrasonography | 2010 |
A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Drug Administration Schedule; Estradiol; Female; Humans; Ki-67 Antigen; Middle Aged; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2010 |
Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth.
Topics: Androstadienes; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Northern; Blotting, Western; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Proliferation; Estrogen Antagonists; Estrogens; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pilot Projects; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Treatment Outcome | 2009 |
Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; International Agencies; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause; Practice Guidelines as Topic; Practice Patterns, Physicians'; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Treatment Outcome | 2010 |
Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Placebos; Pyrazoles; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sulfonamides | 2010 |
Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.
Topics: Aged; Aged, 80 and over; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CTLA-4 Antigen; Drug Administration Schedule; Female; Humans; Inducible T-Cell Co-Stimulator Protein; Maximum Tolerated Dose; Middle Aged; Neoplasms, Hormone-Dependent; T-Lymphocytes | 2010 |
Exemestane and chemotherapy as first-line treatment of metastatic breast cancer: results of a phase II study.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Postmenopause; Treatment Outcome | 2010 |
Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study.
Topics: Absorptiometry, Photon; Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Australia; Biomarkers; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Estrogen Antagonists; Europe; Female; Fractures, Bone; Humans; Middle Aged; Odds Ratio; Risk Assessment; Risk Factors; Tamoxifen; Time Factors; United States | 2010 |
Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy.
Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrium; Female; Humans; Middle Aged; Postmenopause; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Ultrasonography; Uterine Diseases | 2010 |
Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Female; Gene Expression; Genome-Wide Association Study; Humans; Interleukin-17; Linkage Disequilibrium; Musculoskeletal Diseases; Nitriles; Pharmacogenetics; Polymorphism, Single Nucleotide; Triazoles | 2010 |
A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women.
Topics: Alkaline Phosphatase; Androstadienes; Aromatase Inhibitors; Bone and Bones; Bone Density; Breast; Breast Neoplasms; Collagen Type I; Double-Blind Method; Female; Humans; Lipid Metabolism; Lipids; Mammography; Middle Aged; Peptides; Postmenopause | 2011 |
Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial.
Topics: Androstadienes; Animals; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers; Bone and Bones; Bone Density; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Female; Humans; Neoadjuvant Therapy; Postmenopause; Pyrazoles; Quality of Life; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2011 |
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Early Diagnosis; Female; Humans; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2011 |
The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Japan; Lipids; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles; Triglycerides | 2011 |
Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.
Topics: Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Europe; Female; Humans; Immunohistochemistry; Middle Aged; Patient Selection; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Recurrence; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen; Time Factors; Tissue Array Analysis; Treatment Outcome | 2011 |
Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Resorption; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2010 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptors, Estrogen; Triazoles | 2011 |
Exemestane for breast-cancer prevention in postmenopausal women.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Double-Blind Method; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Neoplasm Invasiveness; Postmenopause; Quality of Life; Risk Factors | 2011 |
Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Dehydroepiandrosterone Sulfate; Female; Humans; Letrozole; Middle Aged; Musculoskeletal Pain; Nitriles; Testosterone; Triazoles | 2011 |
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2012 |
Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Postmenopause; Pyrazoles; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sulfonamides; Survival Rate; Treatment Outcome | 2011 |
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Leukopenia; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Neutropenia; Paclitaxel; Receptors, Estrogen; Treatment Outcome | 2012 |
Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation.
Topics: 17-Hydroxysteroid Dehydrogenases; 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Celecoxib; Cell Proliferation; Female; Humans; Immunohistochemistry; Letrozole; Neoadjuvant Therapy; Nitriles; Pyrazoles; Receptors, Androgen; Sulfonamides; Treatment Outcome; Triazoles | 2011 |
Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; Body Mass Index; Breast Neoplasms; Cross-Over Studies; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP3A; Female; Genetic Variation; Genotype; Humans; Letrozole; Middle Aged; Nitriles; Pharmacogenetics; Postmenopause; Prospective Studies; Triazoles | 2011 |
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Postmenopause; Treatment Outcome | 2012 |
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; ErbB Receptors; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Postmenopause; Recurrence; Sirolimus; Stomatitis; TOR Serine-Threonine Kinases | 2012 |
Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Data Mining; Female; Genome-Wide Association Study; Genome, Human; Humans; Linkage Disequilibrium; Models, Genetic; Nitriles; Polymorphism, Single Nucleotide; Raloxifene Hydrochloride; Software; Tamoxifen; Triazoles | 2012 |
Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Lipids; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2012 |
Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Middle Aged; Postmenopause; Survival Rate; Tamoxifen; Treatment Outcome | 2012 |
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Depression; Female; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Stress, Psychological; Surveys and Questionnaires; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
Topics: Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Carpal Tunnel Syndrome; Disease-Free Survival; Female; Humans; Middle Aged; Musculoskeletal Abnormalities; Postmenopause; Retrospective Studies; Surveys and Questionnaires; Tamoxifen; Treatment Outcome | 2012 |
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
Topics: Absorptiometry, Photon; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Bone and Bones; Bone Density; Breast Neoplasms; Calcium; Canada; Chi-Square Distribution; Dietary Supplements; Double-Blind Method; Female; Femur Neck; Hip Joint; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis; Patient Selection; Placebos; Postmenopause; Primary Prevention; Risk Assessment; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; United States; Vitamin D | 2012 |
Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy.
Topics: Aged; Androstadienes; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Dehydroepiandrosterone Sulfate; Female; Follicle Stimulating Hormone; Germany; Hormones; Humans; Middle Aged; Parathyroid Hormone; Postmenopause; Receptors, Estrogen; Sex Hormone-Binding Globulin; Tamoxifen; Testosterone | 2012 |
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; Female; Follow-Up Studies; Humans; Letrozole; Medication Adherence; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Prospective Studies; Triazoles; Withholding Treatment | 2012 |
Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Substitution; Female; Follow-Up Studies; Humans; Libido; Neoplasms, Unknown Primary; Postmenopause; Quality of Life; Receptors, Estrogen; Surveys and Questionnaires; Tamoxifen; Treatment Outcome; Vaginal Discharge | 2012 |
Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone | 2012 |
Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Postmenopause; Quality of Life; Surveys and Questionnaires; Tamoxifen | 2012 |
Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cohort Studies; Female; Germany; Humans; Middle Aged; Retrospective Studies; Tamoxifen | 2012 |
Exemestane for breast cancer prevention: a critical shift?
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Risk Factors | 2012 |
The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Neoplasm Staging; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Treatment Outcome | 2012 |
Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Humans; Postmenopause; Receptors, Estrogen; Tamoxifen | 2013 |
Compliance, analgesic use and side-effect protection within a German cohort of the TEAM trial.
Topics: Analgesics; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Interactions; Female; Fractures, Bone; Humans; Medication Adherence; Middle Aged; Retrospective Studies; Tamoxifen | 2012 |
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study.
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Immunohistochemistry; Neoplasms, Hormone-Dependent; Recurrence; Retrospective Studies; Risk Factors; Tamoxifen; Tissue Array Analysis | 2012 |
Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Administration, Oral; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Metformin; Middle Aged; Obesity; Overweight; Postmenopause; Rosiglitazone; Thiazolidinediones; Time Factors | 2013 |
Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: a tamoxifen exemestane adjuvant multinational study analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Postmenopause; Recurrence; Tamoxifen; Treatment Outcome | 2013 |
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; History, 18th Century; Hot Flashes; Humans; Hypercholesterolemia; Kaplan-Meier Estimate; Middle Aged; Nitriles; Osteoporosis; Postmenopause; Time Factors; Treatment Outcome; Triazoles | 2013 |
[Phase I single-dose administration study of exemestane in postmenopausal women].
Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Cross-Over Studies; Estrogens; Fasting; Female; Humans; Middle Aged; Postmenopause | 2002 |
[Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents].
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estrogen Antagonists; Estrogens; Female; Hot Flashes; Humans; Hypertension; Middle Aged; Postmenopause; Reproducibility of Results | 2002 |
[Early phase II dose-finding study of exemestane in postmenopausal patients with advanced/recurrent breast cancer].
Topics: Administration, Oral; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Estrogens; Female; Headache; Hot Flashes; Humans; Middle Aged; Nausea; Postmenopause; Receptors, Estrogen | 2002 |
[Treatment of advanced metastatic breast cancer with exemestane, a multicenter randomized controlled study of 195 cases].
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged | 2003 |
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Postmenopause; Tamoxifen; Treatment Outcome | 2003 |
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report.
Topics: Androstadienes; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoembryonic Antigen; Celecoxib; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Pyrazoles; Sulfonamides; Treatment Outcome; Triazoles | 2003 |
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamo
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arteriosclerosis; Breast Neoplasms; Cholesterol; Enzyme Inhibitors; Female; Humans; Lipids; Middle Aged; Neoplasm Metastasis; Postmenopause; Risk Factors; Tamoxifen | 2004 |
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
Topics: Administration, Oral; Aged; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Estrogen Antagonists; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen; Tamoxifen | 2004 |
Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrone; Female; History, 18th Century; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pilot Projects; Tamoxifen | 2004 |
Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Cyclooxygenase Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Prognosis; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Treatment Outcome; Triazoles | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2004 |
Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
Topics: Adult; Aged; Alkaline Phosphatase; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cholesterol, HDL; Estradiol; Estrogen Antagonists; Estrone; Exanthema; Female; Hot Flashes; Humans; Middle Aged; Postmenopause; Tamoxifen; Treatment Outcome | 2005 |
Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2005 |
Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.
Topics: Aged; Androstadienes; Aromatase Inhibitors; Bone Density; Bone Resorption; Breast Neoplasms; Double-Blind Method; Female; Humans; Lipids; Middle Aged; Placebos; Postmenopause | 2005 |
Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cholesterol; Enzyme Inhibitors; Female; Humans; Lipids; Middle Aged; Postmenopause; Risk Factors | 2005 |
The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Greece; Humans; Lipids; Middle Aged; Postmenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triglycerides | 2005 |
Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Interactions; Estradiol; Estrone; Female; Humans; Middle Aged; Postmenopause; Tamoxifen | 2005 |
Serum lipid profiles in patients receiving endocrine treatment for breast cancer--the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial.
Topics: Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cyclooxygenase 2 Inhibitors; Enzyme Inhibitors; Female; Humans; Lipids; Middle Aged; Pyrazoles; Sulfonamides; Triglycerides | 2005 |
Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Disease-Free Survival; Female; Humans; Middle Aged; Postmenopause; Tamoxifen; Treatment Outcome | 2006 |
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Composition; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol, HDL; Cholesterol, LDL; Disease-Free Survival; Female; Humans; Lipid Metabolism; Middle Aged; Obesity; Postmenopause; Quality of Life; Tamoxifen; Treatment Outcome; Triglycerides | 2006 |
Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane.
Topics: Alkaline Phosphatase; Androstadienes; Aromatase Inhibitors; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Collagen Type I; Female; Humans; Middle Aged; Peptides; Radiography; Tamoxifen | 2007 |
Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.
Topics: Androstadienes; Aromatase Inhibitors; Biomarkers; Blood Coagulation Factors; Bone and Bones; Bone Density; Bone Remodeling; Breast Neoplasms; Female; Follow-Up Studies; Gonadal Steroid Hormones; Homocysteine; Humans; Lipids; Middle Aged; Postmenopause; Vitamin D; Withholding Treatment | 2006 |
A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; Feasibility Studies; Female; Humans; Middle Aged; Postmenopause; Pyrazoles; Quality of Life; Sulfonamides; Treatment Outcome | 2006 |
Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Quality of Life; Sweden; Tamoxifen | 2007 |
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
Topics: Androstadienes; Antineoplastic Agents; Biomarkers; Bone Density; Bone Remodeling; Breast Neoplasms; Female; Follow-Up Studies; Fractures, Bone; Hip; Humans; Incidence; Lumbar Vertebrae; Postmenopause; Radiography; Risk Factors; Spine; Tamoxifen; Time Factors; Treatment Outcome | 2007 |
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
Topics: Aged; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Middle Aged; Nitriles; Paclitaxel; Postmenopause; Receptors, Estrogen; Triazoles | 2007 |
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Lipids; Menopause; Middle Aged; Nitriles; Peptide Fragments; Placebos; Procollagen; Single-Blind Method; Tamoxifen; Triazoles | 2007 |
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Follow-Up Studies; Hot Flashes; Humans; Menopause; Middle Aged; Quality of Life; Surveys and Questionnaires; Tamoxifen; Time Factors; Treatment Outcome | 2007 |
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Topics: Aged; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Therapy, Combination; Estradiol; Estrone; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2008 |
[Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Doxorubicin; Female; Humans; Mammography; Middle Aged; Neoadjuvant Therapy; Nitriles; Paclitaxel; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2007 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Paclitaxel; Peripheral Nervous System Diseases; Tamoxifen | 2008 |
Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03).
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Time Factors; Treatment Outcome | 2008 |
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Middle Aged; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2008 |
National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Postmenopause; Quality of Life; Research Design; Risk Assessment | 2007 |
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Placebos; Postmenopause; Quality of Life; Receptors, Estrogen | 2008 |
Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Celecoxib; Disease Progression; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause; Pyrazoles; Sulfonamides; Tissue Distribution; Treatment Outcome | 2008 |
Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone.
Topics: Adult; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Estradiol; Estrone; Female; Gonadotropins; Humans; Ovary; Premenopause; Triptorelin Pamoate; Young Adult | 2009 |
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
Topics: Administration, Oral; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Quality of Life; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome | 2008 |
Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women.
Topics: Affect; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Letrozole; Middle Aged; Nitriles; Patient Participation; Patient Selection; Postmenopause; Prospective Studies; Quality of Life; Research Design; Sample Size; Surveys and Questionnaires; Tamoxifen; Triazoles | 2008 |
The minimal effective exemestane dose for endocrine activity in advanced breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Dehydroepiandrosterone Sulfate; Depression, Chemical; Double-Blind Method; Drug Administration Schedule; Estradiol; Estrogen Antagonists; Estrone; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Middle Aged; Postmenopause; Sex Hormone-Binding Globulin | 1997 |
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Postmenopause; Treatment Outcome | 1997 |
In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.
Topics: Administration, Oral; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carbon Radioisotopes; Estradiol; Estrogens; Estrone; Female; Humans; Postmenopause; Tritium | 1998 |
Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Topics: Aged; Alprostadil; Androgens; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Dinoprostone; Dose-Response Relationship, Drug; Drug Administration Schedule; Estradiol; Estrone; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Postmenopause | 1997 |
Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Dizziness; Dose-Response Relationship, Drug; Estrogen Antagonists; Estrogens; Female; Headache; Humans; Middle Aged; Nausea; Postmenopause | 1998 |
Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogens; Female; Humans; Middle Aged; Postmenopause | 1999 |
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Megestrol Acetate; Middle Aged; Neoplasm Recurrence, Local; Pain; Postmenopause; Quality of Life; Survival Analysis; Tamoxifen; Treatment Outcome | 2000 |
Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chi-Square Distribution; Female; Humans; Middle Aged; Neoplasm Metastasis; Palliative Care; Postmenopause; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2000 |
High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Tamoxifen; Treatment Failure | 2000 |
Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial.
Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Megestrol Acetate; Postmenopause; Survival Analysis; Tamoxifen; Treatment Failure | 2000 |
Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma.
Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Female; Humans; Megestrol | 2001 |
Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study.
Topics: Administration, Oral; Aged; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Humans; Megestrol Acetate; Middle Aged; Neoplasm Metastasis; Postmenopause; Survival Analysis; Treatment Outcome | 2000 |
Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control.
Topics: Administration, Oral; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Female; Humans; Neoplasm Metastasis; Tamoxifen; Treatment Outcome | 2000 |
306 other study(ies) available for aromasil and Breast Neoplasms
| Article | Year |
|---|---|
Exemestane metabolites: Synthesis, stereochemical elucidation, biochemical activity and anti-proliferative effects in a hormone-dependent breast cancer cell line.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Cell Survival; Chemistry Techniques, Synthetic; Dose-Response Relationship, Drug; Estradiol; Humans; MCF-7 Cells; Receptors, Estrogen; Stereoisomerism; Structure-Activity Relationship; Time Factors | 2014 |
Exploring new chemical functionalities to improve aromatase inhibition of steroids.
Topics: Androstanes; Androstenedione; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Molecular Docking Simulation; Steroids; Structure-Activity Relationship | 2016 |
4th generation nonsteroidal aromatase inhibitors: An iterative SAR-guided design, synthesis, and biological evaluation towards picomolar dual binding inhibitors.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Receptors, Estrogen; Triazoles | 2022 |
From clinical trials to clinical practice: the use of everolimus and exemestane in the treatment of hormone receptor-positive metastatic breast cancer: real-world data.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies | 2022 |
Characterization of Cytosolic Glutathione
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chromatography, Liquid; Cysteine; Cytosol; Estrogens; Glutathione Transferase; Hepatobiliary Elimination; Humans; Inactivation, Metabolic; Liver; Protein Isoforms; Receptors, Estrogen | 2021 |
Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors.
Topics: Adolescent; Adult; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Quality of Life; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2022 |
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Treatment Outcome; Turkey | 2022 |
Magnetic mesoporous silica nanoparticles as a theranostic approach for breast cancer: Loading and release of the poorly soluble drug exemestane.
Topics: Androstadienes; Breast Neoplasms; Contrast Media; Drug Carriers; Drug Liberation; Female; Humans; Nanoparticles; Porosity; Precision Medicine; Silicon Dioxide | 2022 |
Everolimus and exemestane in hormone receptor positive advanced breast cancer: A comprehensive cancer center's experience.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Receptor, ErbB-2 | 2022 |
Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane.
Topics: Alleles; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cytosol; Female; Glutathione; Glutathione Transferase; Humans; Liver | 2022 |
Statin use in patients with hormone receptor-positive metastatic breast cancer treated with everolimus and exemestane.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Receptor, ErbB-2; Retrospective Studies | 2023 |
An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER
Topics: Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Humans; MCF-7 Cells; Receptors, Estrogen | 2023 |
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial.
Topics: Aged; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Humans; Ki-67 Antigen; Postmenopause; Receptors, Estrogen; Receptors, Progesterone | 2023 |
Cognitive function among women with breast cancer receiving endocrine therapy: what are the impacts?
Topics: Breast Neoplasms; Cognition; Female; Humans; Postmenopause; Tamoxifen | 2023 |
Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer.
Topics: Breast Neoplasms; Cognition; Female; Follow-Up Studies; Humans; Postmenopause; Prospective Studies; Tamoxifen | 2023 |
Polymer-lipid hybrid nanoparticles of exemestane for improved oral bioavailability and anti-tumor efficacy: An extensive preclinical investigation.
Topics: Androstadienes; Animals; Biological Availability; Breast Neoplasms; Female; Humans; Lipids; Mice; Nanoparticles; Polymers; Rats; Rats, Wistar | 2023 |
Acute generalized exanthematous pustulosis induced by exemestane during adjuvant radiotherapy for breast cancer.
Topics: Acute Generalized Exanthematous Pustulosis; Androstadienes; Breast Neoplasms; Female; Humans; Radiotherapy, Adjuvant | 2023 |
Boronic-targeted albumin-shell oily-core nanocapsules for synergistic aromatase inhibitor/herbal breast cancer therapy.
Topics: Albumins; Androstadienes; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Boron; Breast Neoplasms; Female; Hesperidin; Humans; MCF-7 Cells; Nanocapsules; Phospholipids | 2019 |
Breast Cancer Chemoprevention: A Practical Guide for the Primary Care Provider.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Decision Making, Shared; Female; Humans; Middle Aged; Physician-Patient Relations; Primary Health Care; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen | 2020 |
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Recurrence, Local; Ovariectomy; Ovary; Premenopause; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triptorelin Pamoate | 2020 |
Endocrine-based therapy versus chemotherapy in advanced breast cancer.
Topics: Androstadienes; Breast Neoplasms; Capecitabine; Female; Gonadotropin-Releasing Hormone; Humans; Piperazines; Pyridines | 2019 |
Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration.
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovary; Premenopause; Randomized Controlled Trials as Topic; Risk Assessment; Tamoxifen; Time Factors; Young Adult | 2019 |
High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Everolimus; Female; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation, Missense; Neoplasm Metastasis; Postmenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies | 2020 |
Multiple Pigmented Lesions of the Breast Following Ipsilateral Breast Carcinoma.
Topics: Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Carbamates; Female; Humans; Mastectomy; Mastectomy, Segmental; Melanoma; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Neoplasms, Unknown Primary; Radiotherapy; Skin Neoplasms; Sulfonamides | 2020 |
Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Austria; Breast Neoplasms; Everolimus; Female; Humans; Postmenopause; Practice Patterns, Physicians'; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2020 |
Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Fatal Outcome; Female; Humans; Immunocompromised Host; Lymphocyte Count; Lymphopenia; Piperazines; Pneumocystis; Pneumonia, Pneumocystis; Pyridines; Severity of Illness Index; Trimethoprim, Sulfamethoxazole Drug Combination | 2020 |
Medication Use to Reduce Risk of Breast Cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Medication Adherence; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators | 2020 |
A case of exemestane induced pseudocellulitis.
Topics: Androstadienes; Breast Neoplasms; Erythema; Female; Humans; Middle Aged; Vasculitis, Leukocytoclastic, Cutaneous | 2020 |
Structural Recognition and Binding Pattern Analysis of Human Topoisomerase II Alpha with Steroidal Drugs: In Silico Study to Switchover the Cancer Treatment.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Computer Simulation; DNA Topoisomerases, Type II; Female; Humans; Letrozole; Protein Conformation | 2020 |
[A prospective study of bone loss in early stage postmenopausal breast cancer treated with aromatase inhibitors].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Humans; Letrozole; Postmenopause; Prospective Studies | 2020 |
Lack of everolimus diffusion in pleural fluid during pleural progression of breast cancer: A case report.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Everolimus; Female; Humans; Piperazines; Pyridines | 2021 |
Functional genomics based on germline genome-wide association studies of endocrine therapy for breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Genome-Wide Association Study; Genomics; Germ Cells; Humans; Selective Estrogen Receptor Modulators; Tamoxifen | 2020 |
Breast Cancer Risk-Reducing Medications.
Topics: Adult; Age Factors; Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2020 |
Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cohort Studies; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptors, Estrogen; Reproducibility of Results; Risk Assessment; Tamoxifen | 2020 |
PEGylated Nanoliposomes Potentiated Oral Combination Therapy for Effective Cancer Treatment.
Topics: Administration, Oral; Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biological Availability; Breast Neoplasms; Cell Line, Tumor; Complement Activation; Drug Synergism; Female; Gastrointestinal Absorption; Humans; Liposomes; Lycopene; Mice; Nanoparticles; Polyethylene Glycols; Proof of Concept Study; Tissue Distribution; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial.
Topics: Androstadienes; Breast Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Menopause; Minor Histocompatibility Antigens | 2020 |
Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Everolimus; Female; Humans; Liver Neoplasms; Middle Aged; Premenopause; Progression-Free Survival | 2020 |
Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER+) breast cancer: A case report and narrative review.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Lymphatic Metastasis; Mastectomy, Modified Radical; Middle Aged; Narrative Medicine; Neoplasm Recurrence, Local; Re-Irradiation; Receptors, Estrogen | 2020 |
Exemestane induced cholestatic liver injury - A case report.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Cholestasis; Female; Humans | 2021 |
Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Everolimus; Female; Hormones; Humans; Receptor, ErbB-2; Retrospective Studies; Sirolimus | 2021 |
Optimal Treatment Duration of Neoadjuvant Endocrine Therapy for Women Aged 60 Years or Older with Estrogen Receptor-Positive, HER2-Negative Invasive Breast Cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Duration of Therapy; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen | 2021 |
Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL).
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Female; Humans; Mastectomy; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2021 |
COVID-19-induced toxic epidermal necrolysis.
Topics: Adrenal Cortex Hormones; Androstadienes; Aromatase Inhibitors; Body Surface Area; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; COVID-19; Dexamethasone; Emollients; Female; Hospitalization; Humans; Liver Neoplasms; Middle Aged; Palliative Care; SARS-CoV-2; Stevens-Johnson Syndrome | 2021 |
Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(-) breast cancer receiving salvage treatment with everolimus/exemestane.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; Receptor, ErbB-2; Salvage Therapy; Treatment Outcome | 2021 |
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Asia; Breast Neoplasms; Everolimus; Female; Humans; Neoplasm Recurrence, Local; Postmenopause; Receptor, ErbB-2; Sirolimus | 2021 |
Chemical inhibitor anticancer drugs regulate mechanical properties and cytoskeletal structure of non-invasive and invasive breast cancer cell lines: Study of effects of Letrozole, Exemestane, and Everolimus.
Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Cytoskeleton; Everolimus; Female; Humans; Letrozole; Tumor Cells, Cultured | 2021 |
Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells.
Topics: Anastrozole; Androstadienes; Apoptosis; Aromatase Inhibitors; Autophagy; Biomarkers; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Senescence; Cyclins; Early Growth Response Protein 3; Estrogens; Female; Gene Expression Regulation, Neoplastic; Hormones; Humans; Letrozole; Receptors, Androgen; Receptors, Estrogen; Signal Transduction; Tumor Suppressor Proteins | 2021 |
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid.
Topics: Androstadienes; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cone-Beam Computed Tomography; Diagnosis, Differential; Everolimus; Female; Humans; Jaw Diseases; Mastectomy; Middle Aged; Osteonecrosis | 2017 |
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Italy; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Stomatitis | 2017 |
Exemestane and Its Active Metabolite 17-Hydroexemestane Induce UDP-Glucuronosyltransferase (UGT) 2B17 Expression in Breast Cancer Cells.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; MCF-7 Cells; Minor Histocompatibility Antigens | 2017 |
FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gene Amplification; Goserelin; Humans; Piperazines; Pyridines; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; TOR Serine-Threonine Kinases | 2017 |
Switch to exemestane effective in early breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Drug Substitution; Female; Humans; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2017 |
Role of the UGT2B17 deletion in exemestane pharmacogenetics.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Gene Deletion; Glucuronosyltransferase; Humans; Middle Aged; Minor Histocompatibility Antigens; Pharmacogenetics | 2018 |
COX2 induction: a mechanism of endocrine breast cancer resistance?
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Case-Control Studies; Chromatography, Liquid; Cyclooxygenase 2; Dinoprostone; Drug Monitoring; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Postmenopause; Retrospective Studies; Tandem Mass Spectrometry | 2017 |
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Premenopause; Quality of Life; Receptor, ErbB-2; Tamoxifen; Treatment Outcome | 2017 |
Adjuvant endocrine therapy for premenopausal women: Type and duration.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Premenopause; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Time Factors | 2017 |
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor, ErbB-2 | 2017 |
Tuning up adjuvant endocrine therapy: the TEAM trial.
Topics: Androstadienes; Breast Neoplasms; Female; Follow-Up Studies; Humans; Postmenopause; Tamoxifen | 2017 |
Emerging combination endocrine therapies for advanced breast cancer.
Topics: Adult; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Everolimus; Female; Humans; Lung Neoplasms; Receptor, ErbB-2; Receptors, Estrogen | 2018 |
Progressive Restrictive Strabismus in an Adult Woman.
Topics: Adenocarcinoma; Androstadienes; Antineoplastic Agents; Brachytherapy; Breast Neoplasms; Female; Humans; Middle Aged; Oculomotor Muscles; Orbital Neoplasms; Strabismus | 2017 |
Shell-crosslinked zein nanocapsules for oral codelivery of exemestane and resveratrol in breast cancer therapy.
Topics: Administration, Oral; Androstadienes; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cross-Linking Reagents; Drug Combinations; Drug Liberation; Female; Glutaral; Humans; Hydrophobic and Hydrophilic Interactions; Intestinal Absorption; Male; Mice; Nanocapsules; Particle Size; Rats, Wistar; Resveratrol; Solubility; Stilbenes; Surface Properties; Tissue Distribution; Zein | 2017 |
Curcumin dietary supplements and everolimus-based cancer treatment.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Curcumin; Dietary Supplements; Everolimus; Female; Humans; Middle Aged | 2018 |
Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early-Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Asian People; Breast Neoplasms; China; Female; Humans; Letrozole; Lipid Metabolism; Lipids; Middle Aged; Postmenopause; Retrospective Studies | 2018 |
[Efficacy and Safety of Everolimus plus Exemetane in Postmenopausal Endocrine-Responsive Metastatic Breast Cancer Patients].
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Endocrine System; Everolimus; Female; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause | 2017 |
Improvement of treatment outcomes after implementation of comprehensive pharmaceutical care in breast cancer patients receiving everolimus and exemestane.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Patient Compliance; Pharmaceutical Services; Postmenopause; Quality of Life; Stomatitis; Treatment Failure | 2018 |
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Medication Adherence; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Patient Reported Outcome Measures; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic | 2018 |
Adjuvant aromatase inhibition: more options for patients.
Topics: Anastrozole; Androstadienes; Aromatase; Breast Neoplasms; Humans; Letrozole; Tamoxifen | 2018 |
Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Ki-67 Antigen; Middle Aged; PTEN Phosphohydrolase; Receptor, ErbB-2; Receptors, Estrogen; Ribosomal Protein S6 Kinases | 2018 |
Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Everolimus; Female; Fulvestrant; Health Care Costs; Humans; Japan; Markov Chains; Middle Aged; Models, Economic; Postmenopause; Quality-Adjusted Life Years; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Toremifene | 2018 |
Lactoferrin-decorated vs PEGylated zein nanospheres for combined aromatase inhibitor and herbal therapy of breast cancer.
Topics: Androstadienes; Animals; Aromatase Inhibitors; Breast Neoplasms; Drug Carriers; Female; Humans; Lactoferrin; Luteolin; Mice; Mice, Inbred BALB C; Nanospheres; Particle Size; Phospholipids; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Zein | 2018 |
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; DNA Mutational Analysis; Everolimus; Female; Genes, Neoplasm; Humans; Middle Aged; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Prospective Studies; Retrospective Studies; Sirolimus | 2018 |
Identification and Quantification of Novel Major Metabolites of the Steroidal Aromatase Inhibitor, Exemestane.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chromatography, Liquid; Cysteine; Female; Glucuronides; Humans; Metabolic Detoxication, Phase II; Middle Aged; Tandem Mass Spectrometry | 2018 |
Everolimus-induced pulmonary toxicity: Findings on 18F-FDG PET/CT imaging.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Everolimus; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Diseases, Interstitial; Middle Aged; Positron Emission Tomography Computed Tomography; TOR Serine-Threonine Kinases; Tumor Burden | 2018 |
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
Topics: Age of Onset; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Postmenopause; Prospective Studies; Tamoxifen; Treatment Outcome | 2018 |
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; DNA Repair; Female; Humans; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Receptors, Estrogen; Reproducibility of Results; Risk; Signal Transduction; Survival Analysis | 2019 |
A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Middle Aged; Netherlands; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2019 |
Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Mitogen-Activated Protein Kinases; Neoplasm Grading; Neoplasm Staging; Phosphorylation; Prognosis; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Tamoxifen; Treatment Outcome | 2019 |
Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Capecitabine; Disease Progression; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Receptor, ErbB-2; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2019 |
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
Topics: Androstadienes; Aromatase Inhibitors; Bone and Bones; Bone Density; Bone Remodeling; Breast Neoplasms; Female; Gene Deletion; Genetic Association Studies; Genotype; Glucuronosyltransferase; Humans; Letrozole; Middle Aged; Minor Histocompatibility Antigens; Pharmacogenetics; Postmenopause; Tamoxifen | 2019 |
Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2019 |
Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate | 2019 |
Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer.
Topics: Androstadienes; Breast Neoplasms; Double-Blind Method; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Postmenopause | 2019 |
HDAC inhibitors tested in phase III trial.
Topics: Androstadienes; Breast Neoplasms; Double-Blind Method; Histone Deacetylase Inhibitors; Humans; Postmenopause | 2019 |
Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors.
Topics: Androstadienes; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Premenopause | 2019 |
Radiation recall syndrome in a patient with breast cancer, after introduction of everolimus.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Estrogens; Everolimus; Female; Humans; Lymphatic Irradiation; Lymphocele; Mastectomy; Middle Aged; Neoplasms, Hormone-Dependent; Progesterone; Radiodermatitis; Radiotherapy, Intensity-Modulated; TOR Serine-Threonine Kinases | 2019 |
Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Everolimus; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Prospective Studies; Respiratory Function Tests | 2019 |
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues.
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cancer Survivors; Chemotherapy, Adjuvant; Drug Monitoring; Estradiol; Female; Gonadotropin-Releasing Hormone; Humans; Ovarian Function Tests; Ovary; Premenstrual Syndrome; Tamoxifen; Uterine Hemorrhage | 2019 |
IGF-1R inhibition: right direction, wrong pathway?
Topics: Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent | 2013 |
Poly(D, L-lactide-co-glycolide)/montmorillonite nanoparticles for improved oral delivery of exemestane.
Topics: Androstadienes; Antineoplastic Agents; Bentonite; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Drug Carriers; Female; Humans; Lactic Acid; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2013 |
Effect of aromatase inhibitors on bone mineral density in a Japanese breast cancer population.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Asian People; Bone Density; Breast Neoplasms; Diphosphonates; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Triazoles | 2013 |
Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Follow-Up Studies; Genital Diseases, Female; Humans; International Cooperation; Middle Aged; Multicenter Studies as Topic; Musculoskeletal Diseases; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Tamoxifen; Vasomotor System | 2013 |
Treatment-emergent effects may predict benefit from endocrine therapy.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Mammary Glands, Human; Outcome Assessment, Health Care; Postmenopause; Tamoxifen | 2013 |
Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management.
Topics: Aged; Androstadienes; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Dexamethasone; Everolimus; Female; Follow-Up Studies; Glucocorticoids; Humans; Middle Aged; Oral Ulcer; Prospective Studies; Recurrence; Sirolimus; Stomatitis; Stomatitis, Aphthous; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bone Neoplasms; Breast Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Diphosphonates; Epirubicin; Female; Fixatives; Fluorouracil; Formaldehyde; Humans; Imidazoles; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prognosis; Radiotherapy Dosage; Tomography, Emission-Computed, Single-Photon; Triazoles; Zoledronic Acid | 2013 |
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Everolimus; Exanthema; Fatigue; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Placebos; Postmenopause; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Steroid; Sirolimus; Stomatitis; Treatment Outcome; Viscera | 2013 |
Entinostat plus exemestane has activity in ER+ advanced breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Breast Neoplasms; Disease-Free Survival; Female; Humans; Pyridines; Receptors, Estrogen | 2013 |
Combination endocrine treatments unproven in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2013 |
Liquid chromatography tandem mass spectrometry determination of free and conjugated estrogens in breast cancer patients before and after exemestane treatment.
Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Chromatography, High Pressure Liquid; Estradiol Congeners; Estrogens; Female; Humans; Postmenopause; Solid Phase Extraction; Tandem Mass Spectrometry | 2014 |
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Triazoles | 2014 |
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Insulin Receptor Substrate Proteins; Ki-67 Antigen; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; PTEN Phosphohydrolase; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Stathmin; Tamoxifen; Triazoles | 2014 |
The bone substudy of MA.27: does bone make a difference?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2014 |
VAV3 mediates resistance to breast cancer endocrine therapy.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activators; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genetic Variation; Humans; Indazoles; Letrozole; MCF-7 Cells; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-vav; Quinazolines; RNA Interference; RNA, Small Interfering; Tamoxifen; Toremifene; Triazoles | 2014 |
Hormone therapy in premenopausal women with early-stage breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Tamoxifen; Triptorelin Pamoate | 2014 |
[BOLERO -- another remarkable step in treatment of breast cancer].
Topics: Adult; Aged; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Molecular Targeted Therapy; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Everolimus; Female; Humans; Markov Chains; Neoplasm Metastasis; Sirolimus | 2014 |
Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Tamoxifen | 2014 |
Case report: A breast cancer patient treated with GcMAF, sonodynamic therapy and hormone therapy.
Topics: Androstadienes; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Macrophage-Activating Factors; Middle Aged; Ultrasonic Therapy; Vitamin D-Binding Protein | 2014 |
A new combination therapy for premenopausal breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Premenopause; Tamoxifen | 2014 |
Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Databases, Factual; Europe; Everolimus; Female; Humans; Models, Economic; Sirolimus | 2014 |
Radiation-recall dermatitis with the everolimus/exemestane combination ten years after adjuvant whole-breast radiotherapy.
Topics: Androstadienes; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Everolimus; Female; Humans; Liver Neoplasms; Middle Aged; Neoplasms, Second Primary; Radiodermatitis; Radiotherapy, Adjuvant; Sirolimus | 2014 |
More treatment options for women with hormone receptor-positive breast cancer: guideline update, studies lead to advances in care.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Estrogen Receptor Modulators; Evidence-Based Medicine; Female; Humans; Neoplasm Staging; Ovary; Postmenopause; Practice Guidelines as Topic; Premenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2014 |
Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Australia; Breast Neoplasms; Developed Countries; Drug Utilization Review; England; Female; France; Humans; Internationality; Letrozole; Longitudinal Studies; Netherlands; Nitriles; Scandinavian and Nordic Countries; Tamoxifen; Triazoles | 2015 |
Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Receptors, Estrogen; Retrospective Studies; Spain; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Everolimus in acute kidney injury in a patient with breast cancer: a case report.
Topics: Acute Kidney Injury; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Creatinine; Drug Therapy, Combination; Everolimus; Female; Humans; Sirolimus | 2014 |
Perfecting breast-cancer treatment--incremental gains and musculoskeletal pains.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Tamoxifen; Triptorelin Pamoate | 2015 |
No pain, no gain: a fallacy so far.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Musculoskeletal System; Nitriles; Triazoles; Vasomotor System | 2015 |
Case records of the Massachusetts General Hospital. Case 1-2015. A 66-year-old woman with metastatic breast cancer after endocrine therapy.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Class I Phosphatidylinositol 3-Kinases; Diagnosis, Differential; Female; Humans; Lung Neoplasms; Lymph Nodes; Magnetic Resonance Imaging; Mastectomy, Segmental; Mutation; Nitriles; Phosphatidylinositol 3-Kinases; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Triazoles | 2015 |
Integration of a prognostic gene module with a drug sensitivity module to identify drugs that could be repurposed for breast cancer therapy.
Topics: Androstadienes; Breast Neoplasms; Databases, Genetic; Female; Gene Ontology; Humans; Pharmacogenetics; Prognosis; Tamoxifen | 2015 |
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Culture Techniques; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; Models, Biological; Nitriles; Tamoxifen; Triazoles | 2015 |
Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer.
Topics: Aged; Androstadienes; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Postmenopause; Prognosis; Retrospective Studies; Risk Assessment; Selective Estrogen Receptor Modulators | 2016 |
Synergistic effects of combined treatment with simvastatin and exemestane on MCF-7 human breast cancer cells.
Topics: Androstadienes; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Drug Synergism; Female; Humans; MCF-7 Cells; Simvastatin | 2015 |
Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Obesity; Ovary; Receptors, Estrogen; Treatment Outcome | 2015 |
Primary chemoprevention of breast cancer: Are the adverse effects too burdensome?
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Chemoprevention; Female; Humans; Middle Aged; Risk Assessment; Tamoxifen | 2015 |
Breast cancer risk reduction therapy: the low-hanging fruit.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma in Situ; Female; Humans; Hyperplasia; Nitriles; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2015 |
The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cohort Studies; Drug Costs; Drugs, Generic; Evaluation Studies as Topic; Female; Humans; Letrozole; Medicare; Medication Adherence; Nitriles; Non-Randomized Controlled Trials as Topic; Poverty; Triazoles; United States | 2015 |
Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Depressive Disorder; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Nitriles; Population Surveillance; Proportional Hazards Models; Retrospective Studies; Risk; Taiwan; Tamoxifen; Trastuzumab; Triazoles | 2015 |
Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Letrozole; MCF-7 Cells; Molecular Structure; NF-E2-Related Factor 2; Nitriles; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Triazoles; Ubiquitination | 2015 |
Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Liver Neoplasms; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies | 2015 |
Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.
Topics: Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cost-Benefit Analysis; Everolimus; Female; Greece; Humans; Middle Aged; Quality-Adjusted Life Years | 2015 |
The role of censoring on progression free survival: oncologist discretion advised.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bias; Breast Neoplasms; Data Interpretation, Statistical; Disease-Free Survival; Endpoint Determination; Everolimus; Female; Humans; Kaplan-Meier Estimate; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Time Factors; Treatment Failure | 2015 |
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Estradiol; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Prognosis; Retrospective Studies; Survival Rate; Tamoxifen; Triazoles | 2015 |
[Everolimus plus Exemestane in Postmenopausal Metastatic Breast Cancer Patients].
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Postmenopause; Retrospective Studies; Treatment Outcome | 2015 |
Exemestane metabolites suppress growth of estrogen receptor-positive breast cancer cells by inducing apoptosis and autophagy: A comparative study with Exemestane.
Topics: Androstadienes; Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Proliferation; Cell Shape; Cell Survival; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Membrane Potential, Mitochondrial; Receptors, Estrogen; Testosterone | 2015 |
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Breast Neoplasms; Female; Genetic Association Studies; Genetic Variation; Genotype; Humans; Letrozole; Middle Aged; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Triazoles | 2015 |
Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Topics: Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Eye Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Peptides; Receptors, Estrogen; Retrospective Studies; RGS Proteins; Transcription Factors; Treatment Outcome; Trefoil Factor-3; Triazoles | 2015 |
ESR1 Mutations Prevalent in Some Breast Cancers.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Congresses as Topic; Estrogen Receptor alpha; Everolimus; Female; Humans; Mutation; Treatment Outcome | 2016 |
[Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Hormones; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Postmenopause; Triazoles | 2015 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles | 2016 |
Theoretical Study of the Mechanism of Exemestane Hydroxylation Catalyzed by Human Aromatase Enzyme.
Topics: Androstadienes; Androstenedione; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Hydroxylation; Molecular Docking Simulation; Thermodynamics | 2016 |
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.
Topics: Adult; Aged; Androstadienes; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovary; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen | 2016 |
Adjuvant endocrine therapy in premenopausal women with breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Hormone Replacement Therapy; Humans; Middle Aged; Postmenopause; Quality of Life; Tamoxifen | 2015 |
Are SOFT and TEXT results practice changing and how?
Topics: Adult; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Ovary; Premenopause; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen | 2016 |
[Factors related to adjuvant ovarian function suppression in premenopausal breast cancer patients].
Topics: Adjuvants, Immunologic; Adult; Age Factors; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Middle Aged; Ovary; Premenopause; Tamoxifen | 2016 |
Complete response and long-term survival of leptomeningeal carcinomatosis from breast cancer with maintenance endocrine therapy.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Meningeal Carcinomatosis; Methotrexate; Nitriles; Spinal Neoplasms; Triazoles | 2016 |
[An Elderly Patient with Metastatic Breast Cancer Who Developed Severe Adverse Events such as Stomatitis and Interstitial Pneumonia after Everolimus plus Exemestane Treatment].
Topics: Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Lung Diseases, Interstitial; Neoplasm Metastasis; Stomatitis; Thoracic Wall | 2016 |
Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study.
Topics: Adult; Aged; Androstadienes; Aromatase; Aromatase Inhibitors; Biomarkers; Body Mass Index; Breast Neoplasms; Cholestanes; Cholesterol; Feasibility Studies; Female; Gas Chromatography-Mass Spectrometry; Hormones; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Oxidative Stress; Oxysterols; Pilot Projects; Prognosis; Prospective Studies; Reproducibility of Results; Signal Transduction; Tamoxifen; Triazoles | 2017 |
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Italy; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Receptor, ErbB-2; Regression Analysis; Retrospective Studies; Treatment Outcome | 2016 |
Should We Offer Medication to Reduce Breast Cancer Risk?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Decision-Making; Female; Humans; Middle Aged; Practice Guidelines as Topic; Primary Health Care; Raloxifene Hydrochloride; Risk Assessment; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen | 2016 |
Microbial-catalysed derivatization of anti-cancer drug exemestane and cytotoxicity of resulting metabolites against human breast adenocarcinoma cell line (MCF-7) in vitro.
Topics: Androstadienes; Antineoplastic Agents; Aspergillus niger; Breast Neoplasms; Cell Survival; Cunninghamella; Fermentation; Gibberella; Humans; MCF-7 Cells; Molecular Structure | 2016 |
Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Cytochrome P-450 CYP3A; Female; Genotyping Techniques; Humans; Middle Aged; Pharmacogenomic Testing; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Postmenopause; Precision Medicine; Predictive Value of Tests | 2017 |
Falsely elevated serum oestradiol due to exemestane therapy.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Contraindications; Drug Dosage Calculations; Estradiol; False Positive Reactions; Female; Humans; Immunoassay; Middle Aged; Molecular Mimicry; Monitoring, Physiologic | 2017 |
[A Case of Recurrent Breast Cancer with Bone Metastasis Successfully Treated with Everolimus and Exemestane Therapy].
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Recurrence; Treatment Outcome | 2017 |
Reduced expression of cyclooxygenase-2 in primary breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Down-Regulation; Drug Therapy, Combination; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Treatment Failure | 2008 |
Characterization of the weak estrogen receptor alpha agonistic activity of exemestane.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Profiling; Humans; Microarray Analysis; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triazoles; Tumor Cells, Cultured | 2009 |
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Osteoporosis; Retrospective Studies; Triazoles | 2008 |
Aromatase inhibition versus placebo.
Topics: Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Cholesterol, HDL; Clinical Trials as Topic; Female; Humans | 2008 |
Exacerbation of diabetes related to exemestane treatment.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Blood Glucose; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Middle Aged; Neoplasm Recurrence, Local; Thoracic Wall | 2008 |
Exemestane-induced subclinical hypothyroidism : a case report.
Topics: Aged; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Follow-Up Studies; Humans; Hypothyroidism; Thyroxine | 2008 |
[A case of recurrent breast cancer with liver metastasis responding to exemestane].
Topics: Adult; Androstadienes; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Liver Neoplasms; Recurrence; Tomography, X-Ray Computed | 2009 |
Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Histone Acetyltransferases; Humans; Immunohistochemistry; Ki-67 Antigen; Nuclear Receptor Coactivator 3; Phosphorylation; Receptors, Estrogen; Receptors, Progesterone; Trans-Activators | 2009 |
Visual impairment in myopic patients with breast cancer receiving adjuvant therapy with aromatase inhibitors.
Topics: Adjuvants, Pharmaceutic; Androstadienes; Aromatase Inhibitors; Asian People; Breast Neoplasms; Female; Humans; Middle Aged; Myopia; Vision, Low; Visual Acuity | 2009 |
Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: of relevance to clinical understanding?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Nitriles; Postmenopause; Triazoles | 2010 |
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Letrozole; Nitriles; Pharmacogenetics; Receptors, Estrogen; Tamoxifen; Triazoles | 2010 |
Impact of aromatase inhibitors on bone health in breast cancer patients.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Breast Neoplasms; Calcium; Diphosphonates; Female; Humans; Letrozole; Nitriles; Triazoles; Vitamin D | 2010 |
Severe prolonged cholestatic hepatitis caused by exemestane.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Female; Humans; Middle Aged | 2010 |
Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2010 |
[A case of recurrent breast cancer with extensive liver metastasis successfully treated with endocrine therapy].
Topics: Androstadienes; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Letrozole; Liver Neoplasms; Medroxyprogesterone; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Toremifene; Triazoles | 2009 |
Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Comorbidity; Diabetes Mellitus; Female; Humans; Hypertension; Intelligence Tests; Middle Aged; Multicenter Studies as Topic; Neuropsychological Tests; Postmenopause; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen | 2010 |
Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Cognition Disorders; Female; Humans; Middle Aged; Netherlands; Postmenopause; Prospective Studies; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen | 2010 |
Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Estradiol Dehydrogenases; Estrogens; Female; Humans; Ki-67 Antigen; Mastectomy; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Steroid; Sulfatases | 2010 |
Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment.
Topics: Aged; Androgens; Androstadienes; Aromatase Inhibitors; Blotting, Western; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Chromatography, Liquid; Female; Humans; Immunohistochemistry; Microarray Analysis; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; Tandem Mass Spectrometry | 2010 |
Metastatic breast carcinoma presenting with profound hypocalcemia.
Topics: Adult; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Epilepsy, Tonic-Clonic; Female; Goserelin; Humans; Hypocalcemia; Neoplasm Metastasis | 2010 |
Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast Neoplasms; Clinical Protocols; Combined Modality Therapy; Epidemiologic Methods; Female; Humans; Mastectomy; Middle Aged; Multicenter Studies as Topic; Patient Selection; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen | 2010 |
Differential diagnosis of lung nodules: breast cancer metastases and lung tuberculosis.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Diagnosis, Differential; Estrogens; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasms, Hormone-Dependent; Progesterone; Recurrence; Tamoxifen; Tomography, X-Ray Computed; Tuberculosis, Pulmonary | 2010 |
Death due to liver failure during endocrine therapy for premenopausal breast cancer.
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Diphenhydramine; Drug Synergism; Estrogen Receptor Modulators; Fatal Outcome; Female; Hepatitis, Alcoholic; Humans; Hypnotics and Sedatives; Liver Failure, Acute; Middle Aged; Premenopause; Self Medication; Tamoxifen; Triptorelin Pamoate | 2010 |
Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Databases as Topic; Delivery of Health Care; Drug Costs; Female; Health Knowledge, Attitudes, Practice; Humans; Insurance, Health; Letrozole; Logistic Models; Medication Adherence; Middle Aged; Nitriles; Odds Ratio; Postmenopause; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome; Triazoles; United States | 2011 |
Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.
Topics: Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Case-Control Studies; Cytokines; Estrogens; Female; Humans; Inflammation; Middle Aged; Musculoskeletal Diseases; Postmenopause; Syndrome; Tamoxifen; Taxoids | 2010 |
Rheumatoid arthritis and aromatase inhibitors.
Topics: Adenocarcinoma; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthritis, Rheumatoid; Breast Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Female; Humans; Letrozole; Middle Aged; Nitriles; Triazoles | 2011 |
Cognitive changes associated with endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Female; Humans; Letrozole; Memory; Neoplasms, Hormone-Dependent; Nitriles; Prospective Studies; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; United States; Women's Health | 2010 |
Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Gonadotropin-Releasing Hormone; Goserelin; Hormones; Humans; Middle Aged; Nitriles; Ovary; Premenopause; Tamoxifen; Triazoles | 2010 |
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Chromosome Mapping; Chromosomes, Human, Pair 14; Clinical Trials, Phase III as Topic; Estrogens; Female; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Genotype; Humans; Logistic Models; Middle Aged; Musculoskeletal System; Neoplasm Staging; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Proto-Oncogene Proteins; Randomized Controlled Trials as Topic; Receptors, Interleukin-17; Retrospective Studies; Severity of Illness Index; Triazoles | 2010 |
Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Topics: Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Female; HSP70 Heat-Shock Proteins; Humans; Immunohistochemistry; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2010 |
Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estrogen Receptor alpha; Estrogen Receptor beta; Fadrozole; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Nitriles; Phosphorylation; Predictive Value of Tests; Prognosis; Retrospective Studies; Serine; Tamoxifen; Triazoles | 2010 |
[A successful case of the super elderly breast cancer patient treated with exemestane].
Topics: Adenocarcinoma; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans | 2010 |
Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
Topics: Aged; Androstadienes; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Treatment Outcome | 2011 |
Time to TEAM: exemestane, or tamoxifen then exemestane?
Topics: Adenocarcinoma; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Humans; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Translational Research, Biomedical | 2011 |
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Body Mass Index; Breast Neoplasms; Cohort Studies; Female; Hand Strength; Humans; Letrozole; Middle Aged; Musculoskeletal Diseases; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Syndrome; Tamoxifen; Triazoles | 2011 |
Aromatase inhibitor exemestane has antiproliferative effects on human mesothelioma cells.
Topics: Androstadienes; Aromatase; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Proliferation; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Follow-Up Studies; Humans; Immunoenzyme Techniques; Mesothelioma; Prognosis; Receptors, Estrogen; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured | 2011 |
Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Depression; Female; Humans; Middle Aged; Neuropsychological Tests; Postmenopause; Prospective Studies; Randomized Controlled Trials as Topic; Self Report; Surveys and Questionnaires; Tamoxifen | 2012 |
Binding features of steroidal and nonsteroidal inhibitors.
Topics: Amino Acids; Androgens; Androstadienes; Androstenedione; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Catalytic Domain; Estrogens; Estrone; Female; Humans; Letrozole; Mutagenesis, Site-Directed; NADPH-Ferrihemoprotein Reductase; Neoplasms, Hormone-Dependent; Nitriles; Protein Conformation; Structure-Activity Relationship; Triazoles | 2011 |
Examination of the use of Exemestane in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Liver Neoplasms; Lung Neoplasms; Medroxyprogesterone Acetate; Middle Aged; Retrospective Studies; Tamoxifen | 2011 |
"MAPping" the course of chemoprevention in breast cancer.
Topics: Androstadienes; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Female; Humans; Risk Assessment | 2011 |
Estrogen and progesterone receptors in breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Female; Humans; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen | 2011 |
Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition.
Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Female; Gene Amplification; Genes, erbB-2; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Multicenter Studies as Topic; Practice Guidelines as Topic; Prognosis; Tamoxifen; Treatment Outcome | 2011 |
Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer.
Topics: Aged; Androstadienes; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoadjuvant Therapy; Postmenopause; Preoperative Care; Treatment Outcome | 2012 |
Exemestane for breast-cancer prevention.
Topics: Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Drug Monitoring; Female; Humans; Postmenopause | 2011 |
Exemestane for breast-cancer prevention.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Estrogen Replacement Therapy; Female; Humans; Postmenopause | 2011 |
Exemestane for breast-cancer prevention.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Humans; Mutation; Patient Selection; Postmenopause | 2011 |
Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Could trastuzumab suppress hepatitis C virus in a patient with chronic hepatitis and breast cancer?
Topics: Aged; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Biomarkers; Biomarkers, Tumor; Breast Neoplasms; Drug Combinations; ErbB Receptors; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Neoplasm Staging; Oxonic Acid; Receptor, ErbB-2; Receptors, Estrogen; Tegafur; Trastuzumab | 2011 |
The breast cancer chemoprevention debate.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Female; Humans; Models, Statistical; Nitriles; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2011 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Receptor, ErbB-2; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
[Chemoprevention of breast cancer: exemestane ready to be tested in study setting].
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Cost-Benefit Analysis; Female; Humans; Incidence; Neoplasm Invasiveness; Postmenopause; Risk Factors | 2012 |
Aromatase inhibitors and musculoskeletal adverse events.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Carpal Tunnel Syndrome; Female; Humans; Musculoskeletal Abnormalities; Tamoxifen | 2012 |
Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2012 |
Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Female; Humans; Incidence; Neoplasms, Hormone-Dependent; Nitriles; Outpatients; Retrospective Studies; Triazoles | 2012 |
Bone loss associated with prevention of breast cancer.
Topics: Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Bone and Bones; Bone Density; Breast Neoplasms; Female; Humans; Osteoporosis; Postmenopause; Primary Prevention | 2012 |
Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cause of Death; Female; Follow-Up Studies; Humans; Middle Aged; Postmenopause; Prognosis; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk; Tamoxifen | 2012 |
What is new in primary care? Best articles from the past year.
Topics: Alzheimer Disease; Androstadienes; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Contraception; Dementia, Vascular; Diphosphonates; Estrogens, Conjugated (USP); Female; Femoral Fractures; Humans; Mass Screening; Ovarian Neoplasms; Pregnancy; Pregnancy in Diabetics; Primary Health Care; Randomized Controlled Trials as Topic; Smoking; Stroke | 2012 |
Efficacy of exemestane after nonsteroidal aromatase inhibitor use in metastatic breast cancer patients.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Metastasis; Retrospective Studies | 2012 |
BOLERO-2 - will this change practice in advanced breast cancer?
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Everolimus; Female; Humans; Immunosuppressive Agents; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; DNA Repair; Exome; Exons; Female; Genetic Variation; Genome, Human; Humans; Letrozole; MAP Kinase Kinase 4; MAP Kinase Kinase Kinase 1; Mutation; Nitriles; Receptors, Estrogen; Treatment Outcome; Triazoles | 2012 |
Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Contrast Media; Female; Gadolinium DTPA; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Letrozole; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Retrospective Studies; Subtraction Technique; Triazoles | 2012 |
Exemestane for primary prevention of breast cancer in postmenopausal women.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Estrogen Antagonists; Female; Genetic Predisposition to Disease; Humans; Middle Aged; Postmenopause; Primary Prevention; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen | 2012 |
Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Treatment Outcome | 2012 |
Apoptosis and autophagy in breast cancer cells following exemestane treatment.
Topics: Androstadienes; Antineoplastic Agents; Apoptosis; Aromatase; Autophagy; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Receptors, Estrogen | 2012 |
Dry eye syndrome in aromatase inhibitor users.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Blepharitis; Breast Neoplasms; Conjunctival Diseases; Dry Eye Syndromes; Female; Humans; Keratitis; Letrozole; Middle Aged; Nitriles; Ovarian Neoplasms; Retrospective Studies; Triazoles; Vision Disorders | 2013 |
Prognostic/Predictive immunohistochemistry assays for estrogen receptor-positive breast cancer: back to the future?
Topics: Androstadienes; Breast Neoplasms; Female; Humans; Neoplasms, Hormone-Dependent; Tamoxifen; Tissue Array Analysis | 2012 |
Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane.
Topics: Adult; Amenorrhea; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Substitution; Estradiol; Female; Humans; Incidence; Kaplan-Meier Estimate; Menstruation; Middle Aged; Ovary; Prospective Studies; Recovery of Function; ROC Curve; Tamoxifen; Treatment Outcome | 2013 |
The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoprevention; Female; Humans; Hyperplasia; Mammary Glands, Human; Middle Aged; Precancerous Conditions; Raloxifene Hydrochloride; Tamoxifen | 2012 |
Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
Topics: Aged; Androstadienes; Animals; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Letrozole; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; NF-kappa B p50 Subunit; Nitriles; Panobinostat; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the path
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; CD8-Positive T-Lymphocytes; Clinical Trials as Topic; Female; Forkhead Transcription Factors; Humans; Immunohistochemistry; Lymphocyte Subsets; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Receptors, Estrogen; T-Lymphocytes, Regulatory | 2012 |
Synergistic effects of exemestane and aspirin on MCF-7 human breast cancer cells.
Topics: Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Aspirin; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Proliferation; Dinoprostone; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Tumor Cells, Cultured | 2012 |
What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Practice Guidelines as Topic; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2013 |
Current role of endocrine therapy in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?
Topics: Aged; Androstadienes; Antineoplastic Agents; Body Mass Index; Bone and Bones; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Interleukin-6; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tissue Distribution; Treatment Failure | 2003 |
Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Canada; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol; Middle Aged; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles | 2003 |
[Clinical trial on exemestane in the treatment of postmenopausal women with advanced breast cancer].
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Middle Aged; Postmenopause | 2003 |
Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Female; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen; Tamoxifen | 2004 |
Metastatic breast cancer response after Exemestane withdrawal: a case report.
Topics: Adult; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Remission, Spontaneous | 2004 |
New stars in the sky of treatment for early breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Antagonists; Female; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Tamoxifen | 2004 |
Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer.
Topics: Androstadienes; Angiopoietin-1; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; DNA Primers; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Neovascularization, Pathologic; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tamoxifen; Taxoids; Triazoles; Vascular Endothelial Growth Factor A | 2004 |
Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro.
Topics: Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Endometrial Neoplasms; Enzyme Inhibitors; Female; Humans; Ovarian Neoplasms; Paclitaxel; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Tamoxifen shuffle.
Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Tamoxifen | 2004 |
Adjuvant treatment of breast cancer with exemestane.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Mastectomy; Radiotherapy, Adjuvant; Tamoxifen | 2004 |
Adjuvant treatment of breast cancer with exemestane.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Data Interpretation, Statistical; Female; Humans; Tamoxifen | 2004 |
Adjuvant treatment of breast cancer with exemestane.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fractures, Bone; Humans; Osteoporosis; Tamoxifen | 2004 |
Exemestane following tamoxifen in postmenopausal women with primary breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Density; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Risk Factors; Tamoxifen | 2004 |
[A case of aged advanced breast cancer with multiple lung and pleural metastases responding to exemestane monotherapy].
Topics: Aged; Androstadienes; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoembryonic Antigen; Carcinoma, Ductal, Breast; Female; Humans; Lung Neoplasms; Mucin-1; Pleural Neoplasms | 2004 |
Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Letrozole; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Random Allocation; Tamoxifen; Time Factors; Triazoles | 2004 |
[Anastrozole-resistant breast cancer responsive to exemestane--a case report].
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Resistance, Neoplasm; Female; Humans; Nitriles; Postmenopause; Triazoles | 2004 |
[A patient with metastatic breast cancer associated with retention of pleural effusion with no response to both CMF and exemestane, whose life was saved by high-dose toremifene].
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Methotrexate; Pleural Effusion; Remission Induction; Salvage Therapy; Toremifene | 2005 |
[New results of endocrine therapy of breast cancer (the role of Aromasin)].
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Tamoxifen; Treatment Outcome | 2004 |
[Effective reduction of elevated tumor markers by exemestane--a 12-year follow-up of a case of bone metastatic breast cancer].
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Drug Administration Schedule; Female; Floxuridine; Humans; Medroxyprogesterone Acetate; Mucin-1; Radionuclide Imaging | 2005 |
[New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Time Factors; Triazoles | 2005 |
Safety of exemestane in the Intergroup Exemestane Study.
Topics: Androstadienes; Aromatase Inhibitors; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Research Design; Time Factors | 2005 |
Aromatase inhibitors and bone loss: risks in perspective.
Topics: Androstadienes; Aromatase Inhibitors; Bone Resorption; Breast Neoplasms; Humans; Randomized Controlled Trials as Topic; Risk Factors | 2005 |
Aromatase inhibitors: cellular and molecular effects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Oligonucleotide Array Sequence Analysis; Receptors, Progesterone; Tamoxifen; Triazoles | 2005 |
Durable clinical benefit with exemestane in leptomeningeal metastasis of breast cancer.
Topics: Adult; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Meningeal Neoplasms; Time Factors | 2005 |
[Aromatase inhibitors in the treatment of breast cancer: current status and some problems].
Topics: Adult; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Triazoles | 2005 |
Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Female; Humans; Male; Receptors, Estrogen; Retrospective Studies; Treatment Failure | 2006 |
Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen; Tamoxifen | 2004 |
Bone loss with exemestane: Is the jury still out?
Topics: Androstadienes; Antineoplastic Agents; Bone Density; Breast Neoplasms; Female; Femur; Humans; Postmenopause; Reproducibility of Results | 2005 |
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Confidence Intervals; Disease Progression; Drug Administration Schedule; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2005 |
[Advance and current status of exemestane and androstadienes in the treatment of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Nitriles; Postmenopause; Triazoles | 2005 |
Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Patient Satisfaction; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors; Treatment Outcome | 2006 |
Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2005 |
A 62-year-old woman with a new diagnosis of breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Chemotherapy, Adjuvant; Combined Modality Therapy; Decision Making; Female; Humans; Mastectomy, Segmental; Middle Aged; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2006 |
Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chromatography, High Pressure Liquid; Female; Humans; Male; Nitriles; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Substance Abuse Detection; Tandem Mass Spectrometry; Triazoles | 2006 |
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Follicle Stimulating Hormone; Humans; Letrozole; Luteinizing Hormone; Middle Aged; Neoplasm Staging; Nitriles; Ovariectomy; Practice Guidelines as Topic; Tamoxifen; Triazoles | 2006 |
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Estrogen Antagonists; Estrogens; Fees, Pharmaceutical; Female; Follow-Up Studies; Humans; Letrozole; Markov Chains; Middle Aged; Models, Theoretical; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2006 |
Management of choroidal metastases from breast carcinomas using aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Choroid Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Mastectomy, Radical; Mastectomy, Segmental; Mastectomy, Simple; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Can switching treatments improve breast-cancer outcome?
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Postmenopause; Tamoxifen | 2006 |
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Female; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles; United States | 2007 |
Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging.
Topics: Aged; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Carpal Tunnel Syndrome; Female; Humans; Letrozole; Magnetic Resonance Imaging; Middle Aged; Musculoskeletal Diseases; Nitriles; Pain; Severity of Illness Index; Triazoles; Ultrasonography; Wrist Joint | 2007 |
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Belgium; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Markov Chains; Middle Aged; Nitriles; Postmenopause; Proportional Hazards Models; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2007 |
[A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel].
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Pleural Effusion, Malignant; Pleural Neoplasms; Quality of Life; Remission Induction; Taxoids; Toremifene | 2007 |
[Locally advanced breast cancer with a good response to sequential endocrine monotherapy--a case report].
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Humans; Nitriles; Remission Induction; Tamoxifen; Triazoles | 2007 |
Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Meta-Analysis as Topic; Neoplasms, Hormone-Dependent; Randomized Controlled Trials as Topic; Research Design; Survival Analysis | 2007 |
Optimising bone health in survivors of breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Density; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Female; Humans; Postmenopause; Survivors; Tamoxifen | 2007 |
Cancer: some reasons to be hopeful.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Neoplasm Recurrence, Local; Tamoxifen | 2007 |
Switching to aromatase inhibitors in early breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Randomized Controlled Trials as Topic; Survival Rate; Tamoxifen | 2007 |
Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Postmenopause; Retrospective Studies; Soft Tissue Neoplasms | 2007 |
[Clinical study of aromatase inhibitors in advanced breast cancer].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Middle Aged; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2007 |
Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Communication Barriers; Decision Making; Europe; Female; Health Knowledge, Attitudes, Practice; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen; Triazoles | 2007 |
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2007 |
Exemestane or tamoxifen?
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Postmenopause; Tamoxifen | 2007 |
Exemestane or tamoxifen?
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Survival Analysis; Tamoxifen | 2007 |
Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Costs; Female; Humans; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Quality-Adjusted Life Years; SEER Program; Selective Estrogen Receptor Modulators; Sensitivity and Specificity; Survival Rate; Tamoxifen | 2007 |
Chemoprevention of breast cancer.
Topics: Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Tamoxifen | 2008 |
Exemestane: the dawn of a new era in breast cancer treatment.
Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans | 2008 |
[Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Rate; Triazoles | 2008 |
Update: a 62-year-old woman with a new diagnosis of breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Tamoxifen | 2008 |
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Decision Making; Female; Goserelin; Humans; Premenopause; Randomized Controlled Trials as Topic; Tamoxifen | 2008 |
Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor.
Topics: Androstadienes; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Receptors, Estrogen; Tamoxifen | 2008 |
Exemestane: an alternative treatment option in early breast cancer. Foreward.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Postmenopause | 2008 |
Intergroup Exemestane Study mature analysis: overall survival data.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Survival Rate; Tamoxifen | 2008 |
The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop.
Topics: Amphiregulin; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Receptors, Estrogen; Recombinant Proteins; RNA, Small Interfering | 2008 |
Planar scintimammography and SPECT in neoadjuvant chemo or hormonotherapy response evaluation in locally advanced primary breast cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Humans; Lymph Nodes; Mammography; Mass Screening; Middle Aged; Neoadjuvant Therapy; Organophosphorus Compounds; Organotechnetium Compounds; Prognosis; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon | 2008 |
Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estriol; Female; Humans; Luteinizing Hormone; Middle Aged; Sex Hormone-Binding Globulin | 1995 |
Plasma changes in breast cancer patients during endocrine therapy--lipid measurements and nuclear magnetic resonance (NMR) spectroscopy.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dexamethasone; Enzyme Inhibitors; Female; Humans; Lipids; Magnetic Resonance Spectroscopy; Tamoxifen | 1995 |
Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients.
Topics: Aminoglutethimide; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Creatinine; Enzyme Inhibitors; Estrogen Antagonists; Homocysteine; Humans; Postmenopause; Vitamins | 1999 |
Exemestane for advanced breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Female; Hot Flashes; Humans; Intestinal Absorption; Liver; Middle Aged; Mixed Function Oxygenases; Postmenopause | 2000 |
[Aromatase inhibitors in the treatment of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2000 |
Longer time to tumor progression with exemestane vs tamoxifen in advanced breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Tamoxifen | 2000 |
Steroidal side effects of exemestane.
Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Hyperandrogenism | 2001 |
Aromatase inhibitors and inactivators in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Estrogens; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2001 |
The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.
Topics: Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Incidence; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; White People | 2001 |
Local endocrine effects of aromatase inhibitors within the breast.
Topics: Anastrozole; Androstadienes; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Cells, Cultured; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogens; Estrone; Female; Fibroblasts; Humans; In Vitro Techniques; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2001 |
[Aromatase inhibitors of the 3rd generation. What can the "pill against breast cancer" really do?].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Humans; Letrozole; Nitriles; Triazoles | 2002 |
Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia.
Topics: Aged; Algorithms; Androstadienes; Antineoplastic Agents, Hormonal; Australia; Breast Neoplasms; Cost-Benefit Analysis; Europe; Female; Humans; Megestrol; Middle Aged; Models, Economic | 2002 |
New breast cancer drugs expand treatment options.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
Comparison of in vitro exemestane activity versus other antiaromatase agents.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Choriocarcinoma; Female; Humans; Nitriles; Triazoles; Tumor Cells, Cultured | 2000 |
Estrogen as therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase II as Topic; Diethylstilbestrol; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Letrozole; Megestrol Acetate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Salvage Therapy; Tamoxifen; Treatment Outcome; Triazoles | 2002 |